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A B S T R A C T
Background
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular
endothelial growth factor (anti-VEGF) modalities can reduce oedema and thereby improve vision and prevent further visual loss. These
drugs have replaced laser photocoagulation as the standard of care for people with DMO.
Objectives
The 2014 update of this review found high-quality evidence of benefit with antiangiogenic therapy with anti-VEGF modalities,
compared to laser photocoagulation, for the treatment of DMO.The objective of this updated review is to compare the effectiveness and
safety of the different anti-VEGF drugs in preserving and improving vision and quality of life using network meta-analysis methods.
Search methods
We searched various electronic databases on 26 April 2017.
Selection criteria
We included randomised controlled trials (RCTs) that compared any anti-angiogenic drug with an anti-VEGF mechanism of action
versus another anti-VEGF drug, another treatment, sham or no treatment in people with DMO.
Data collection and analysis
Weused standard Cochrane methods for pair-wise meta-analysis and we augmented this evidence using networkmeta-analysis methods.
We focused on the relative efficacy and safety of the three most commonly used drugs as interventions of direct interest for practice:
aflibercept and ranibizumab, used on-label; and off-label bevacizumab.
We collected data on three efficacy outcomes (gain of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters; mean
change in best-corrected visual acuity (BCVA); mean change in central retinal thickness (CRT)), three safety outcomes (all severe
systemic adverse events (SSAEs); all-cause death; arterial thromboembolic events) and quality of life.
We used Stata ’network’ meta-analysis package for all analyses. We investigated the risk of bias of mixed comparisons based on the
variance contribution of each study, having assigned an overall risk of bias to each study.
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Main results
Twenty-four studies included 6007 participants with DMO and moderate vision loss, of which two studies randomised 265 eyes of
230 participants and one was a cross-over study on 56 participants (62 eyes) that was treated as a parallel-arm trial. Data were collected
on drugs of direct interest from three studies on aflibercept (975 eyes), eight studies on bevacizumab (515 eyes), and 14 studies on
ranibizumab (1518 eyes). As treatments of indirect interest or legacy treatment we included three studies on pegaptanib (541 eyes),
five studies on ranibizumab plus prompt laser (557 eyes), one study on ranibizumab plus deferred laser (188 eyes), 13 studies on laser
photocoagulation (936 eyes) and six studies on sham treatment (793 eyes).
Aflibercept, bevacizumab and ranibizumab were all more effective than laser for improving vision by 3 or more lines after one year (high-
certainty evidence). Approximately one in 10 people improve vision with laser, and about three in 10 people improve with anti-VEGF
treatment: risk ratio (RR) versus laser 3.66 (95% confidence interval (CI) 2.79 to 4.79) for aflibercept; RR 2.47 (95% CI 1.81 to 3.37)
for bevacizumab; RR 2.76 (95% CI 2.12 to 3.59) for ranibizumab. On average there was no change in visual acuity (VA) with laser
after one year, compared with a gain of 1 or 2 lines with anti-VEGF treatment: laser versus aflibercept mean difference (MD) −0.20
(95% CI −0.22 to −0.17) logMAR; versus bevacizumab MD −0.12 (95% CI −0.15 to −0.09) logMAR; versus ranibizumab MD
−0.12 (95% CI −0.14 to−0.10) logMAR. The certainty of the evidence was high for the comparison of aflibercept and ranibizumab
with laser and moderate for bevacizumab comparison with laser due to inconsistency between the indirect and direct evidence.
People receiving ranibizumab were less likely to gain 3 or more lines of VA at one year compared with aflibercept: RR 0.75 (95% CI
0.60 to 0.94), moderate-certainty evidence. For every 1000 people treated with aflibercept, 92 fewer would gain 3 or more lines of VA
at one year if treated with ranibizumab (22 to 148 fewer). On average people receiving ranibizumab had worse VA at one year (MD
0.08 logMAR units, 95% CI 0.05 to 0.11), moderate-certainty evidence; and higher CRT (MD 39 µm, 95% CI 2 µm to 76 µm; low-
certainty evidence). Ranibizumab and bevacizumab were comparable with respect to aflibercept and did not differ in terms of VA: RR
of gain of 3 or more lines of VA at one year 1.11 (95% CI 0.87 to 1.43), moderate-certainty evidence, and difference in change in VA
was 0.00 (95% CI −0.02 to 0.03) logMAR, moderate-certainty evidence. CRT reduction favoured ranibizumab by−29 µm (95% CI
−58 µm to −1 µm, low-certainty evidence). There was no evidence of overall statistical inconsistency in our analyses.
The previous version of this review found moderate-certainty evidence of good safety of antiangiogenic drugs versus control. This
update used data at the longest available follow-up (one or two years) and found that aflibercept, ranibizumab and bevacizumab do not
differ regarding systemic serious adverse events (SSAEs) (moderate- or high-certainty evidence). However, risk of bias was variable, loop
inconsistency could be found and estimates were not precise enough on relative safety regarding less frequent events such as arterial
thromboembolic events or death (low- or very low-certainty evidence).
Two-year data were available and reported in only four RCTs in this review. Most industry-sponsored studies were open-label after one
year. One large publicly-funded study compared the three drugs at two years and found no difference.
Authors’ conclusions
Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience
an improvement of 3 or more lines VA at one year. There is moderate-certainty evidence that aflibercept confers some advantage over
ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms. Relative effects among anti-VEGF drugs
at two years are less well known, since most studies were short term. Evidence from RCTs may not apply to real-world practice, where
people in need of antiangiogenic treatment are often under-treated and under-monitored.
We found no signals of differences in overall safety between the three antiangiogenic drugs that are currently available to treat DMO,
but our estimates are imprecise for cardiovascular events and death.
P L A I N L A N G U A G E S U M M A R Y
Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
What is the aim of this review?
The aim of this Cochrane Review was to find out which is the best type of anti-VEGF drug for diabetic macular oedema (DMO).
Cochrane researchers collected and analysed all relevant studies to answer this question and found 24 studies.
Key messages
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Anti-VEGF drugs given by injection into the eye improve vision in people with diabetic macular oedema as compared to no average
improvement with laser photocoagulation. One of these drugs, aflibercept, probably works slightly better after one year. There did not
appear to be important harms from any of these drugs.
What was studied in the review?
The light-sensitive tissue at the back of the eye is known as the retina. The central area of the retina is called the macula. People with
diabetes can develop problems in the retina, known as retinopathy. Some people with diabetic retinopathy can also develop oedema
(swelling or thickening) at the macula. DMO is a common complication of diabetic retinopathy and can lead to visual loss.
One type of treatment for DMO is anti-VEGF. This drug is given by means of an injection into the eye. It can reduce the swelling at
the back of the eye and prevent visual loss. There are three main types of anti-VEGF drugs in use: aflibercept (EyeleaTM ), bevacizumab
(Avastin) and ranibizumab (LucentisTM ). Only aflibercept and ranibizumab have received marketing authorisation for the treatment
of DMO. All three drugs are used to prevent visual loss and improve vision. They do this by slowing down the growth of new blood
vessels and thereby reducing the swelling at the back of the eye. They may have adverse effects, particularly related to effects on blood
vessels in the rest of the body. These effects may include stroke and heart attack.
What are the main results of the review?
Cochrane researchers found 24 relevant studies. Fourteen of these studies were industry-sponsored studies from USA, Europe or Asia.
Ten studies were independent of industry funding and were from USA, Europe, Middle East and South America.
These studies investigated ranibizumab, bevacizumab and aflibercept. These anti-VEGF drugs were compared with no treatment,
placebo treatment, laser treatment, or each other. The drugs were given every month, every two months, as needed or ’treat and extend’,
which means that the time period between treatments is extended if the condition has stabilised. Decisions about re-treating were based
on visual acuity or by looking at the back of the eye.
The review reveals the following results.
• All three anti-VEGF drugs prevent visual loss and improve vision in people with DMO (high-certainty evidence).
• People receiving ranibizumab were probably slightly less likely to improve vision compared with aflibercept at one year after the start
of treatment (moderate-certainty evidence). Approximately three in 10 people improve vision by 3 or more lines with ranibizumab and
one in 10 additional people can achieve this with aflibercept.
• People receiving ranibizumab and bevacizumab probably have a similar visual outcome at one year after the start of treatment
(moderate-certainty evidence).
• Aflibercept, ranibizumab and bevacizumab are similar for common and serious systemic harms (such as any disease leading to
hospitalisation, disability or death) (moderate- or high-certainty evidence) but is less certain for arterial thromboembolic events (mainly
stroke, myocardial infarction and vascular death) and death of any cause (very low-certainty evidence).
How up to date is this review?
Cochrane researchers searched for studies that had been published up to 26 April 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antiangiogenic therapy versus control
Patient or population: people with diabet ic macular oedema
Settings: ophthalmology clinics
Interventions: laser photocoagulat ion, af libercept, bevacizumab, ranibizumab
Outcomes Assumed risk* Corresponding risk and relative risk* * (95% CI) , mixed evidence Certainty of evidence and
reason for downgrading
Laser photocoagulation Aflibercept Bevacizumab Ranibizumab
Gain 3+ lines of visual acu-
ity at 1 year
100 per 1000 366 per 1000
(279 to 479)
RR: 3.66 (2.79 to 4.79)
247 per 1000
(181 to 337)
RR: 2.47 (1.81 to 3.37)
276 per 1000
(212 to 359)
RR: 2.76 (2.12 to 3.59)
⊕⊕⊕⊕
high
Visual acuity change at 1
year
M easured on the logM AR
scale, range −0.3 to 1.
3. Higher values represent
worse visual acuity.
On average visual acuity im-
proved by −0.01 logM AR
units in the laser group be-
tween the start of treatment
and 1 year (ef fect ively no
change)
Average change in visual
acuity was −0.20 (−0.22 to
−0.17) logM AR units bet-
ter with af libercept com-
pared with laser photocoag-
ulat ion
Average change in visual
acuity was −0.12 (−0.15 to
−0.09) logM AR units bet-
ter with bevacizumab com-
pared with laser photocoag-
ulat ion
Average change in visual
acuity was −0.12 (−0.14 to
−0.10) logM AR units bet-
ter with ranibizumab com-
pared with laser photocoag-
ulat ion
⊕⊕⊕⊕
high for af libercept and
ranibizumab ⊕⊕⊕
moderate for bevacizumab
(−1 for inconsistency of
indirect versus direct evi-
dence)
Central retinal thickness
µm (CRT) change at 1 year
The aim of treatment is
to reduce central retinal
thickness so thinner is bet-
ter.
On average CRT changed by
−64 µm in the laser group
between the start of treat-
ment and 1 year (became
thinner)
Average change in CRT was
−114 (−147 to −81) µm
more (thinner) with afliber-
cept compared with
laser photocoagulat ion
Average change in CRT was
−46 (−78 to −14) µm
more (thinner)with beva-
cizumab
compared with laser photo-
coagulat ion
Average change in CRT
was −75 (−100 to −50)
µm more (thinner) with
ranibizumab compared with
laser photocoagulat ion
⊕⊕⊕⊕
high
Quality of life: NEI-VFQ
composite score at 6 to 12
months
An improvement by 5 units
is clinically significant.
On average the composite
score improved by +2 units
in the laser group between
the start of treatment and 6
to 12 months
Average change in compos-
ite score was 5.14 (2.96
to 7.32) with ranibizumab
compared with laser photo-
coagulat ion
⊕⊕⊕
moderate (−1 for risk of
bias)
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All serious systemic ad-
verse events at 1 to 2 years
200 per 1000 196 per 1000
(166 to 232)
RR: 0.98 (0.83 to 1.16)
186 per 1000
(146 to 238)
RR: 0.93 (0.73 to 1.19)
194 per 1000
(160 to 234)
RR: 0.97 (0.80 to 1.17)
⊕⊕⊕⊕
high
Arterial thromboembolic
events at 1 to 2 years
45 per 1000 38 per 1000
(16 to 94)
RR: 0.88 (0.37 to 2.13)
41 per 1000
(15 to 117)
RR: 0.94 (0.33 to 2.66)
48 per 1000
(23 to 101)
RR: 1.09 (0.52 to 2.29)
⊕⊕
low
(−2 for imprecise est i-
mates)
Death at 1 to 2 years 20 per 1000 20 per 1000
(7 to 61)
RR: 1.01 (0.34 to 3.03) a
32 per 1000
(9 to 114)
RR: 1.61 (0.45 to 5.69)
18 per 1000
(8 to 40)
RR: 0.90 (0.40 to 2.01)
⊕⊕
low for bevacizumab and
af libercept
(−2 for imprecise est i-
mates)
⊕
very low for af libercept (ad-
dit ional −1 direct evidence
inconsistent, higher risk)
The assumed risk in the laser group was est imated as the row sum of the events divided by the row sum of the part icipants (eyes) for dichotomous variables, and as the
(unweighted) median change of visual acuity or central ret ina thickness
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * The risk rat io was est imated f rom mixed (direct and indirect) comparisons.
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
5
A
n
ti-v
a
sc
u
la
r
e
n
d
o
th
e
lia
l
g
ro
w
th
fa
c
to
r
fo
r
d
ia
b
e
tic
m
a
c
u
la
r
o
e
d
e
m
a
:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Diabetic retinopathy (DR) is the most frequent and severe ocular
complication of diabetes mellitus (DM) and the leading cause of
blindness in the working age population in developed countries
(Frank 2004; Klein 1984; Tranos 2004).
Diabetic macular oedema (DMO) is the swelling of the retina re-
sulting from the exudation and accumulation of extracellular fluid
and proteins in themacula (Ciulla 2003), due to the breakdown of
the blood-retina barrier with an increase in vascular permeability
(Antcliff 1999). About a third of people with diabetes have DR
and one in 10 is affected by DMO (Yau 2012). The prevalence
of DMO increases with diabetes duration, haemoglobin A1c, and
blood pressure levels and is higher in people with type 1 compared
with type 2 diabetes (Yau 2012).
Intraretinal fluid accumulation results in significant reduction in
visual acuity that may be reversible in the short term, but pro-
longed oedema can cause irreversible damage resulting in perma-
nent visual loss. Blurred vision represents the most common clin-
ical symptom of DMO. Other symptoms can include metamor-
phopsia (distortion of visual image), floaters, changes in contrast
sensitivity, photophobia (visual intolerance to light), changes in
colour vision and scotomas (a localised defect of the visual field).
During the last decades, the clinical gold standard to detect mac-
ular oedema has been fundus examination with contact lens, but
non-contact lenses can also be used for this purpose with good sen-
sitivity. Optical coherence tomography (OCT) has progressively
been used as an objective and reproducible tool to measure reti-
nal thickness and has been suggested to be the new gold standard
for diagnosing DMO (Olson 2013; Ontario HTA 2009). The
most severe form of DMO is CSMO, which was defined by the
Early Treatment Diabetic Retinopathy Study (ETDRS) as: retinal
oedema within 500 µm of the centre of the fovea; hard exudates
within 500 µm of the centre of the fovea, if associated with adja-
cent retinal thickening (which may be outside the 500 µm limit);
and one disc area of retinal oedema (1500 µm) or larger, any part
of which is within one disc diameter of the centre of the fovea
(ETDRS 1985). Since its introduction, OCT was found to be in
good agreement with the clinical gold standard (slit-lamp exami-
nation with a contact lens) for detecting the presence of macular
oedema and was found to be potentially more sensitive in cases
of mild foveal thickening (Brown 2004). A simple OCT-based
classification of DMO is often used as centre-involving or non-
centre-involving DMO (Browning 2008).
Description of the intervention
Antiangiogenic therapy has been believed a standard of care for
treatment of DMO and has largely replaced laser photocoagula-
tion (Jampol 2014), than which it was proven to be more effec-
tive (Virgili 2014). Anti-vascular endothelial growth factor (anti-
VEGF) treatments inhibit VEGF angiogenic activity, binding to
VEGF protein and thus preventing its receptor activation or in-
teraction. These drugs were originally hypothesised as an alterna-
tive adjunctive treatment for DMO (Cunningham 2005), follow-
ing evidence that VEGF-A plays a key role in the occurrence of
increased vascular permeability in ocular diseases such as DMO
(Aiello 2005).
Grid or focal laser photocoagulation could not be used in all pa-
tients with DMO; thus, either laser or sham procedures were cur-
rent practice comparators in initial studies on the efficacy of an-
tiangiogenic drugs for DMO (Macugen 2005; RESOLVE 2010;
RESTORE 2011; Soheilian 2007), and only recently have directly
comparative RCTs been conducted (DRCRnet 2015).
Safety of intravitreal antiangiogenic therapy is acceptable; endoph-
thalmitis, the major adverse event (< 1/1000 injections) is related
to the surgical injection procedure, rather than the drug itself.
These drugs were shown not to increase systemic adverse events
such as arterial thromboembolic events, but differences between
drugs are not well known (Virgili 2014).
Another therapeutic option for DMO treatment is represented
by steroids, administered as intravitreal injections or sustained re-
lease implants in order to obtain high local concentrations, max-
imising their anti-inflammatory, angiostatic and anti-permeabil-
ity effects while minimising systemic toxicity (Ciulla 2004; Haller
2010; Kuppermann 2010). However, intravitreal steroids may
cause cataract and ocular hypertension and the visual outcome
is dependent on the lens status or the need for cataract surgery
after about one year (Haller 2010; Campochiaro 2010). Cur-
rently, some investigators think intravitreal steroids are preferred
in patients with anti-VEGF resistant and chronic DMO (Hussain
2015), as an alternative to switching between anti-VEGF drugs.
This is also consistent with the EU label of the only approved dex-
amethasone intravitreal implant in Europe: “Ozurdex is indicated
for the treatment of adult patients with visual impairment due to
diabetic macular oedema (DME) who are pseudophakic or who
are considered insufficiently responsive to, or unsuitable for non-
corticosteroid therapy” (accessed on EMA on 4 December 2016).
For ranibizumab, the EU label prescribes a 0.5 mg dosage, and
that “treatment is initiated with one injection per month until
maximum visual acuity is achieved and/or there are no signs of dis-
ease activity i.e. no change in visual acuity and in other signs and
symptoms of the disease under continued treatment. In patients
with wet AMD, DME and RVO, initially, three or more consec-
utive, monthly injections may be needed. Thereafter, monitoring
and treatment intervals should be determined by the physician
and should be based on disease activity, as assessed by visual acuity
and/or anatomical parameters” (accessed on EMA on 4 Decem-
ber 2016). In the USA, ranibizumab “0.3 mg is recommended to
be administered by intravitreal injection once a month (approxi-
mately 28 days)” (accessed on FDA on 4 December 2016).
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Aflibercept has been approved in the USA, as accessed on FDA on
4 December 2016, and “the recommended dose for EYLEA is 2
mg (0.05 mL) administered by intravitreal injection every 4 weeks
(monthly) for the first 5 injections followed by 2 mg (0.05 mL)
via intravitreal injection once every 8 weeks (2 months)”. The EU
label is similar (accessed on EMA on 4 December 2016).
Bevacizumab is widely used off-label although its use has been
questioned based on regulatory or safety issues (Banfi 2013), but
is still key for treating chorioretinal vascular disease in low- and
middle-income countries thanks to its low cost (Stewart 2016).
How the intervention might work
VEGF plays a key role in the occurrence of increased vascular
permeability in ocular diseases such as DMO (Aiello 2005). Anti-
VEGF agents inhibit VEGF angiogenic activity, binding to VEGF
protein thus preventing its receptor activation and interaction.
Why it is important to do this review
DMO results in a significant burden of low vision and blindness,
thus the extent of the existing evidence base for the effectiveness
and safety of these agents needs to be assessed and updated. There
is a continuing clinical need to establish evidence-based recom-
mendations regarding anti-VEGF agents.
O B J E C T I V E S
The 2014 update of this review found high-quality evidence of
benefit with antiangiogenic therapy with anti-VEGF modalities,
compared to laser photocoagulation, for the treatment of DMO.
As was concluded in the previous version (Virgili 2014), the objec-
tive of this updated review is to compare the effectiveness and sa-
fety of the different anti-VEGF drugs in preserving and improving
vision and quality of life using network meta-analysis methods.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
People with DMO for whom anti-VEGF treatment is indicated.
We expected to include most of the studies also included in Virgili
2014.
Types of interventions
Any antiangiogenic drug with anti-VEGF modalities compared
with another drug with anti-VEGF modalities, laser treatment,
sham treatment or no treatment. The reasons for selecting treat-
ments of direct and indirect treatment have been discussed in the
Description of the intervention section. As explained above, we
remark that steroids may be compared with anti-VEGF drugs but
this needs a different approach, specifically patient subgroups and
timing, and their inclusion could lead to violation of similarity in
a review aiming to compare different anti-VEGF drugs such as
this.
Regarding drug dose and monitoring/retreatment regimen, in ef-
ficacy analyses we included schemes that are either on-label or
commonly used in clinical practice, such as the PRN regimen, as
presented in the Description of the intervention section. Partic-
ularly, both 0.3 mg and 0.5 mg ranibizumab dose are included
as available in studies. These two ranibizumab doses were merged
into one group in our NMA since studies suggest no difference be-
tween them when used monthly (Heier 2016). Regarding afliber-
cept, we selected the bi-monthly retreatment regimen since this is
the approved label in theUSA.We used all available data regardless
of safety and dose for safety analyses as previously done in Moja
2014.
Types of outcome measures
Primary outcomes
Best-corrected visual acuity (BCVA) expressed as the proportion
of participants with at least 15 ETDRS letters (3 ETDRS lines
or 0.3 logMAR) of improvement in BCVA from baseline to 12
months.
Secondary outcomes
• Mean change in BCVA from baseline to 12 months,
measured using ETDRS charts.
• Mean change in central retinal thickness (CRT), from
baseline to 12 months, measured using optical coherence
tomography (OCT).
• Mean change in quality of life from baseline to 12 months,
measured using a validated instrument.
Measurements at varying lengths of follow-up were pooled at an-
nual intervals, plus or minus six months, the primary analysis be-
ing that at 12 months. The time point closer to 12 months, or the
7Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
latest time point in the window frame in the case of symmetry,
was chosen where multiple time points were available.
Adverse events
The following adverse events were considered.
• All-cause mortality.
• Arterial thromboembolic events (ATC 1994).
• Systemic serious adverse events (SSAEs).
Adverse events were analysed at the longest available follow-up
time (Moja 2014).
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
or publication year restrictions. The date of the searchwas 26 April
2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 3) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 26
April 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 26 April 2017) (Appendix 2);
• Embase Ovid (1980 to 26 April 2017) (Appendix 3);
• LILACS (Latin American and Caribbean Health Science
Information database (1982 to 26 April 2017) (Appendix 4);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 26 April 2017) (Appendix 5);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 26 April
2017) (Appendix 6);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp; searched
26 April 2017) (Appendix 7).
Searching other resources
We handsearched the reference lists of the included trials for
other possible trials. We accessed the Novartis Clinical Trials
database (www.novctrd.com/ctrdWebApp/clinicaltrialrepository/
public/main.jsp) on 28 May 2014 and checked all trials indexed
under the headings: Ophthalmic Disorders and ranibizumab.
Data collection and analysis
Selection of studies
Two review authors independently selected the studies for inclu-
sion. The titles and abstracts of all reports identified by the elec-
tronic searches and handsearching were examined by the review
authors. We classified the abstracts as (a) definitely include, (b)
unsure and (c) definitely exclude. We obtained and re-assessed
full-text copies of those classified as either (a) definitely include
or (b) unsure. Having reviewed the full-text copies, we classified
the studies as (1) included, (2) awaiting assessment and (3) ex-
cluded. Studies identified by both review authors as ’excluded’
were excluded and documented in the review. Studies identified
as ’included’ were included and assessed for methodological qual-
ity. The review authors were unmasked to the report authors, in-
stitutions and trial results during this assessment. Disagreements
between the two review authors were resolved by a third review
author.
Data extraction and management
Two review authors independently extracted the data for the pri-
mary and secondary outcomes onto paper data extraction forms
developed by the Cochrane Eyes and Vision Group. A pilot test
of this form was carried out using a small number of studies. We
resolved discrepancies by discussion. One review author entered
all data into Review Manager 5 (Review Manager 5 2014). The
entered data were checked by a second author. In case standard
deviations were not available in the publication, and could not
be obtained from the authors, these were imputed from standard
deviations of other studies with the same comparison.
Assessment of risk of bias in included studies
Two review authors independently assessed the included trials
for bias according to the methods described in Chapter 8 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011b). The following parameters were assessed: sequence gener-
ation; allocation concealment; masking (blinding) of participants,
personnel and outcome assessors; incomplete outcome data; selec-
tive outcome reporting. We evaluated these parameters for each
outcome measure or class of outcome measure. We classified each
parameter as low risk of bias, high risk of bias or unclear.
If the information available in the published trial reports was in-
adequate to assess methodological quality, we contacted the trial
authors for clarification. We had planned that if they did not re-
spond within six months we would assess the trial based on the
available information. However, in the latest update of this review
we assessed the trial had the authors not responded within one
month.
We followed Salanti 2014 to assess the risk of bias of mixed evi-
dence (mixed evidence not defined previously).
1. Summary risk of bias for each trial: we considered all
domains but gave more importance to allocation concealment
and masking of outcome assessor.
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2. Summary risk of bias for the mixed evidence: based on the
percentage contribution of each direct comparison to each
network estimate using the contribution plot (Chaimani 2013).
We finally integrated the risk of bias of a given comparison with
the assessment of transitivity, or similarity of the characteristics of
the studies. We expected the transitivity assumption would hold
as long as treatment comparisons were not related to:
• acute versus chronic DMO, defined using the cut-off of
three or more years of duration;
• average severity of DMO using OCT CRT of 400
micrometres as a cut-off;
• treatment regimen, such as monthly versus less than
monthly and number of injections in the first year;
• drug dose for ranibizumab, since this is commercially
available in two doses (0.3 mg in the USA, 0.5 mg otherwise);
• whether the trial was industry sponsored.
Measures of treatment effect
Data analysis followed the guidelines set out in Chapter 9 of the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). For dichotomous outcomes, we calculated a summary risk
ratio (RR). For continuous outcome, we calculated the mean dif-
ference (MD). We planned to calculate a standardised mean dif-
ference (SMD) had different scales been used to measure the same
continuous outcome.
We did not use ranking measures in this review, since our main
interest was to compare only three drugs: aflibercept, bevacizumab
and ranibizumab.
Unit of analysis issues
The unit of randomisation was the eye of individual participants.
We included one cross-over study comparing ranibizumab and be-
vacizumab and treated this as a parallel arm study (Wiley 2016),
which equals to assume a moderate (0.5) correlation within-per-
son. However, relative drug safety is impossible to assess with a
paired design.
We accepted studies presenting systemic adverse events as the unit
of analyses, i.e. when an individual suffers from more than one
severe adverse event in the study.
Dealing with missing data
Where data were missing due to dropping out of participants, we
conducted a primary analysis based on participants with complete
data (available case analysis). Following the guidance available in
Chapter 16 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a), we considered that missing outcome
data are missing at random if the reasons for loss to follow-up are
documented and judged to be unrelated to outcome in both study
arms.
Assessment of reporting biases
To investigate small-study bias at the network level we employed
the comparison-adjusted funnel plot, which is an adaptation of
the funnel plot. We subtracted from each study-specific effect size
the mean of meta-analysis of the study-specific comparison and
plotted it against the study’s standard error (Chaimani 2013).
Data synthesis
Methods for direct treatment comparisons
If there was no substantial statistical heterogeneity, and if there
was no clinical heterogeneity between the trials, we combined the
results in a meta-analysis using a random-effects model. A fixed-
effect model was used if the number of trials was three or less.
In the case of substantial statistical heterogeneity (that is I² value
more than 50%) or clinical heterogeneity, we combined the results
in a meta-analysis using a random-effects model if the individual
trial results were all consistent in the direction of the effect (that is
the RR or MD and confidence intervals largely fall on one side of
the null line); when the individual trial results were inconsistent
in the direction of the effect, we did not combine study results but
presented a narrative or tabulated summary of each study.
Methods for indirect and mixed comparisons
We performed network meta-analysis using the methodology of
the multivariate meta-analysis model where different treatment
comparisons are treated as different outcomes (Salanti 2012). For
this analysis, we used the ’network’ suite of commands available in
STATA (StataCorp, 2011; Stata Statistical Software: Release 14.
College Station, TX) (White 2015).
We presented mixed effects as RRs or MDs against laser photoco-
agulation as a single comparison. We prepared league tables pre-
sentingmixed comparisons in the inferior-left part and direct com-
parisons in the superior-right part of the table in order to allow for
the inspection of both types of evidence. The same information
was presented graphically. We also presented the contribution of
direct and indirect evidence to mixed evidence using contribution
plots (Chaimani 2013).
Assessment of statistical heterogeneity
In standard pairwise meta-analyses, we estimated heterogeneity
variances for each direct comparison. We assessed statistically the
presence of heterogeneity within each pairwise comparison using
the I² statistic (Higgins 2011b). The I² statistic measures the per-
centage of variability that cannot be attributed to random error.
In network meta-analysis, we assumed a common estimate for
the heterogeneity variance across the different comparisons. The
assessment of statistical heterogeneity in the entire network was
based on the magnitude of the heterogeneity variance parameter
(τ ²) estimated from the network meta-analysis models.
9Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of statistical inconsistency
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally, we used the node-
splitting approach (Dias 2010). We assumed a common hetero-
geneity estimate within each loop.
Global approaches for evaluating inconsistency
To check the assumption of consistency in the entire network, we
used the ’design-by-treatment’ model using the ’network’ com-
mand in STATA (White 2015). This method accounts for dif-
ferent sources of inconsistency that can occur when studies with
different designs (two-arm trials versus three-arm trials) give dif-
ferent results as well as disagreement between direct and indirect
evidence. Using this approach, we judged the presence of incon-
sistency from any source in the entire network based on a Chi²
test.
’Summary of findings’ table and GRADE assessment
We prepared one ’Summary of findings’ table for each relevant
comparison, including all seven outcomes in a table (GRADEpro
2014). As originally intended, the primary analysis was conducted
at 12 months. Relevant comparisons were identified to answer the
question of which antiangiogenic drug is most effective among
on-label (aflibercept, ranibizumab) and off-label (bevacizumab)
drugs that are currently available. Because most of the available
evidence is around ranibizumab, we reported on the comparison
of aflibercept and bevacizumab with ranibizumab. Analyses con-
ducted at 24 months were presented textually because a network
meta-analysis was not feasible.
We graded the certainty of the evidence for mixed estimates as
explained above. We started from the premise that RCTs provide
high-certainty evidence and downgraded for each GRADE pa-
rameter to get an overall certainty for each outcome as high, mod-
erate, low or very low (Higgins 2014; Salanti 2014; Schünemann
2011). We estimated the absolute risk in the control group from
the data in the included studies as the raw proportion with event
for dichotomous outcomes and the median value for continuous
outcomes.
Sensitivity and subgroup analyses
We had not planned sensitivity analyses but we decided post-hoc
to conduct one excluding studies which were assessed as being at
overall high or unclear risk of bias. Moreover, we acknowledge that
DRCRnet 2015 emphasised that the differences in absolute benefit
between aflibercept, bevacizumab and ranibizumab at one year
were dependent on baseline visual acuity, but when we considered
this post hoc subgroup analysis we did not find enough study data
to conduct such meta-regression analyses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies and Characteristics of
studies awaiting classification.
The previous version of this review included 18 trials. Update
searches run in April 2017 yielded a further 1166 records (Figure
1). After 397 duplicates were removed, the Cochrane Information
Specialist screened the remaining 769 records and removed 577
references that were not relevant to the scope of the review. We
screened the remaining 192 references and obtained 19 full-text
reports for further assessment. We identified eight reports of six
new trials for inclusion in the review (DRCRnet 2015, Ishibashi
2014, Lopez-Galvez 2014, REVEAL 2015, Turkoglu 2015,Wiley
2016). A further four trials were deemed eligible but did not
provide sufficient data for analysis (Chen 2016; Huang 2016;
Jovanovic 2015; Fouda 2017. We have contacted these authors
to ask for further information and will assess these studies if we
receive additional data. We excluded one study (NCT02985619
(BEVATAAC)) and have identified six new ongoing studies and
will assess these for inclusion in the review when data becomes
available (NCT02194634;NCT02259088; NCT02348918;
NCT02645734; NCT02699450; NCT02712008).
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Figure 1. Study flow diagram.
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Included studies
We included a total of 24 studies in this updated systematic re-
view and network meta-analysis. BOLT 2010, DA VINCI 2011,
Ishibashi 2014,Korobelnik 2014,Macugen 2005,Macugen 2011,
READ2 2009, RELATION 2012, RESOLVE 2010, RESPOND
2013, RESTORE 2011, and RISE-RIDE were industry-spon-
sored,multicentreRCTs conducted in theUSAorEurope,whereas
REVEAL 2015 was industry-sponsored but conducted in Asia.
Ahmadieh 2008, Azad 2012, Ekinci 2014, LUCIDATE 2014,
Nepomuceno 2013, Soheilian 2007, and Turkoglu 2015 were in-
dependent studies conducted in Brazil, India, Iran, Turkey, and
the UK, five of which included bevacizumab. DRCRnet 2010,
DRCRnet 2015, Wiley 2016 were publicly-sponsored studies,
mainly by the US National Eye Institute, and conducted in the
USA or UK. DRCRnet 2015 was the only large parallel-arm study
that compared all commercially available drugs (aflibercept, beva-
cizumab, ranibizumab) and was a large publicly-funded trial com-
paring aflibercept, bevacizumab and ranibizumab with monthly
monitoring and treatment as needed (PRN). Wiley 2016 was a
cross-over trial comparing the same three drugs. Lopez-Galvez
2014 was an open-label trial comparing ranibizumab with laser; it
was conducted in Spain and results were available only in abstract
form.
Only six trials maintained the randomisation scheme at two
years’ follow-up (BOLT 2010; DRCRnet 2010; DRCRnet 2015;
Macugen 2011; READ2 2009; RISE-RIDE). Two industry-spon-
sored trials used randomisation up to two years (Macugen 2011;
RISE-RIDE), while three others obtained follow-up data but al-
lowed anti-VEGF treatment in the control arm after one year
(Korobelnik 2014; RESOLVE 2010; RESTORE 2011).
We did not extract data on comparisons of antiangiogenic ther-
apy with triamcinolone and other intravitreal steroids, which were
study arms in Ahmadieh 2008, Azad 2012, DRCRnet 2010 and
Soheilian 2007, for reasons presented above and also because this
comparison is the subject of another Cochrane Review (Grover
2008). Standard deviations of change in CRT were imputed from
other studies in REVEAL 2015.
Types of participants
Trials included participants with DMO diagnosed clinically, and
often these trials usedOCT for confirmingmacular centre involve-
ment. Baseline visual acuity of participants was generally between
20/200 and 20/40. Most trials required a three- to six-month in-
terval from previous central or peripheral laser, and a few small
studies required that participants had not received previous an-
tiangiogenic treatment.
Types of interventions
Eleven studies assessed ranibizumab (DRCRnet 2010; Lopez-
Galvez 2014; LUCIDATE 2014; READ2 2009; RELATION
2012; RESOLVE 2010; RESPOND 2013; RESTORE 2011;
REVEAL 2015; RISE-RIDE; Turkoglu 2015), six investigated
bevacizumab (Ahmadieh 2008; Azad 2012; BOLT 2010; Ekinci
2014; Nepomuceno 2013; Soheilian 2007), two pegaptanib
(Macugen 2005; Macugen 2011), and three aflibercept (DA
VINCI 2011; and two studies conducted in the USA and Eu-
rope using the same protocol, which we will refer to as a single
study (Korobelnik 2014). DRCRnet 2015 and Wiley 2016 were
the only studies comparing ranibizumab, bevacizumab or afliber-
cept directly. The drug dose was the same in most studies (0.5
mg ranibizumab, 1.25 mg bevacizumab, 0.3 mg pegaptanib, 2 mg
aflibercept) except forRESOLVE2010where dose adjustmentwas
allowed for ranibizumab, and also RISE-RIDE, DRCRnet 2015
and Wiley 2016 where 0.3 mg ranibizumab was also delivered.
Anti-VEGF treatment regimens were monthly in RISE-RIDE,
in one arm of Korobelnik 2014 and in Wiley 2016. Monthly,
bimonthly and ’as needed’ or pro re nata (PRN) regimens were
adopted in four arms of DA VINCI 2011, and we selected PRN
for efficacy data extraction because this is current practice with
other anti-VEGF drugs. Ahmadieh 2008 was a short-term study
which delivered only the first three injections. Most other studies
adopted three initial injections followed by various maintenance
regimens. Two studies on aflibercept, reported inKorobelnik 2014
(VISTA and VIVID), compared laser photocoagulation with both
monthly injections (2q4) and a regimen of five initial monthly
injections followed by bimonthly injections (2q8) followed by a
’treat-and-extend’ regimen in year two.
PRN retreatment criteria were based on: visual acuity only in
Nepomuceno 2013 and REVEAL 2015; OCT only in BOLT
2010, Macugen 2011 and READ2 2009; OCT and visual acuity
in Azad 2012, DRCRnet 2010, DRCRnet 2015, Ekinci 2014,
RESOLVE 2010 and in the PRN arm of DA VINCI 2011;
inclusion of clinical examination or at the examiners’ discre-
tion in Macugen 2005, RESTORE 2011 and Soheilian 2007.
They were unclear in Lopez-Galvez 2014, RELATION 2012 and
RESPOND 2013.
Types of outcomes
The data structure of our efficacy and safety outcomes can be seen
in Table 1 where the sum of cases for each outcome is shown.
Studies awaiting assessment
Several trials were included as ongoing in the previous
version of this review. We checked the completion status
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on the study trial register and tried to contact the au-
thors, but were not able to obtain additional information
(NCT00387582; NCT00997191 (IBeTA); NCT01445899
(MATISSE); NCT01565148 (IDEAL)).
Two Chinese trials (Chen 2016, 72 participants; Huang 2016,
78 participants) compared ranibizumab plus laser or, respectively,
ranibizumab to grid laser. These trials provided baseline and final
CRT data at six months as well as the proportion with visual
improvement, but the improvement cut-off was unclear, as was
the measurement tool.
Jovanovic 2015 included 72 participants (120 eyes) randomised
to either bevacizumab (one or more injections with or without
macular laser photocoagulation depending on results after four
to six weeks) or macular laser alone to treat DMO. However,
results were not provided at desired fixed follow-up times by each
randomisation group.
Fouda 2017 included 42 participants (70 eyes) randomised to
aflibercept or ranibizumab and treated with three initial injections
and then PRN. The authors did not find any significant difference
between the two drugs in terms of BCVA, but used decimal rather
than logMAR visual acuity and we could not use these data in
analyses (authors contacted). The authors reported no difference
regarding CRT and a smaller but statistically significant number
of injections with aflibercept versus ranibizumab.
Excluded studies
See ’Characteristics of excluded studies’ table for the list of exclu-
sions with reasons.
Risk of bias in included studies
See ’Risk of bias in included studies’; Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Sequence generationwas judged at low risk of bias in 12 studies and
was unclear in nine (Azad 2012; Ekinci 2014; Lopez-Galvez 2014;
Ishibashi 2014; Korobelnik 2014; READ2 2009; RELATION
2012; RESPOND 2013; Turkoglu 2015). Method for allocation
concealment was also unclear in these studies, as they were in
Nepomuceno 2013. Allocation concealment was judged at high
risk of bias in Ishibashi 2014.
Blinding
Masking of participants and outcome assessors was obtained in 14
and 12 trials respectively, and was unclear in seven and nine trials
respectively. LUCIDATE 2014, READ2 2009 and RESPOND
2013 were unmasked.
Incomplete outcome data
Eleven trials were judged at low risk of attrition bias (Azad
2012; BOLT 2010; DAVINCI 2011;DRCRnet 2010;DRCRnet
2015; Korobelnik 2014; LUCIDATE 2014; Macugen 2005;
Nepomuceno 2013; RESOLVE 2010; RESTORE 2011); and
eight trials were judged at unclear risk of bias in which some partic-
ipants were missing but reasons for missingness were not fully re-
ported (Ahmadieh 2008; Ishibashi 2014;Macugen 2011; READ2
2009; RISE-RIDE; Soheilian 2007; Turkoglu 2015;Wiley 2016).
Five trials were judged at high risk of attrition bias: Ekinci 2014 ex-
cluded 15 participants after randomisation due to ocular and sys-
temic complications; Lopez-Galvez 2014 lost about 20% of par-
ticipants in each arm and did not report the reasons; RELATION
2012, RESPOND 2013 and REVEAL 2015 lost many more par-
ticipants in the laser arm than in the ranibizumab arms.
Selective reporting
Table 1 shows the reporting of all outcomes across 24 trials. Re-
porting was almost complete for mean VA change at one year (21
studies, 4489 complete cases). Mean CRT change was available in
16 studies (3491 cases). Gain of 3 or more VA lines was reported
at one year in 17 studies (4031 cases). SSAEs at one or two years
were reported from18 studies (4229 cases). ATC thromboembolic
events were reported in 15 (3718 cases) and death in 17 (4455
cases).
Other potential sources of bias
The baseline visual acuity was not balanced in Soheilian 2007; the
visual acuity was around 20/100 in the bevacizumab and beva-
cizumab-triamcinolone arms and 20/70 in the laser arm, suggest-
ing that milder CSMOwas included in the laser arm. The trial in-
vestigators adjusted for baseline values in the analyses, which also
took into account the within-participant correlation (150 eyes of
129 participants, 16% of participants with both eyes in the anal-
yses). However, we could not take within-participant correlation
into account when analysing dichotomous visual acuity.
Three studies included both eyes of some participants in analyses:
Ahmadieh 2008 14 out of 101 participants; Nepomuceno 2013
15 out of 48 participants; Wiley 2016 6 out of 56 participants.
RELATION 2012 was terminated early when ranibizumab was
approved for DMO in Germany. Early termination was unlikely
to be associated with treatment effect.
Effects of interventions
See: Summary of findings for the main comparison
Antiangiogenic therapy versus control; Summary of findings
2 Ranibizumab versus aflibercept for diabetic macular oedema;
Summary of findings 3 Ranibizumab versus bevacizumab for
diabetic macular oedema
Antiangiogenic drugs versus laser photocoagulation
or control: efficacy and safety
Summary of findings for the main comparison presents the evi-
dence on the comparison of each drug with laser photocoagulation
(efficacy at one year) or control (laser photocoagulation or sham
at the longest available follow-up of one or two years).
Efficacy at one year
As found in the previous version of this review based on direct
meta-analyses (Virgili 2014), there was high-certainty of evidence
of benefit for aflibercept, bevacizumab and ranibizumab compared
to laser photocoagulation at one year. Specifically, aflibercept, be-
vacizumab and ranibizumab were all more effective than laser for
improving vision by 3 or more lines after one year, since about
one in 10 people improve vision with laser, and about three in 10
people improve with anti-VEGF treatment: risk ratio (RR) versus
laser was 3.66 (95% CI 2.79 to 4.79) for aflibercept; 2.47 (95%
CI 1.81 to 3.37) for bevacizumab; and 2.76 (95%CI 2.12 to 3.59)
for ranibizumab. Regarding change of mean BCVA, on average
there was no change with laser after one year, compared with a
gain of 1 or 2 lines with anti-VEGF treatment: laser versus afliber-
cept mean difference (MD) −0.20 (95% CI −0.22 to −0.17)
logMAR; versus bevacizumab −0.12 (95% CI −0.15 to −0.09)
logMAR; versus ranibizumab −0.12 (95% CI −0.14 to −0.10)
logMAR (negative logMAR in favour of anti-VEGF group).
The certainty of evidence was moderate for bevacizumab versus
laser regarding mean BCVA change due to inconsistency of direct
and indirect evidence.
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Safety at the longest available follow-up
This network meta-analysis confirms that aflibercept, beva-
cizumab and ranibizumab do not increase the risk of all SSAEs
compared to laser photocoagulation or sham at one year. We con-
sidered this evidence of high-certainty. (Summary of findings for
the main comparison), Of notice, SSAEs are a generic indicator
of harm, mostly including hospitalisation or death for any cause
and unrelated to antiangiogenic effect.
Regarding ’Antiplatelet Trialists Collaboration arterial throm-
boembolic events’ and all-cause death, no statistically significant
difference was found between any anti-VEGF drug and control,
but the certainty of the evidence was generally low due to impre-
cision (large 95% CIs).
Quality of life
Only RESTORE 2011, RESPOND 2013 and Turkoglu 2015
presented quality of life data for ranibizumab versus laser pho-
tocoagulation at six to 12 months (3 studies, 412 participants).
Ranibizumab improved NEI-VFQ composite score by 5.14 units
(95% CI 2.96 to 7.32) compared to laser (Summary of findings
for the main comparison). The certainty of the evidence was mod-
erate due to risk of bias issues (RESPOND 2013 was unmasked
and Turkoglu 2015 was unclear for most items).
Macugen 2011 obtained QOL data at two years and we did not
include these data since pegaptanib was not of direct interest and
sham, rather than laser, was the comparator. RISE-RIDE obtained
QOL data at two years and was not included since sham, rather
than laser, was the control group.
Ranibizumab versus aflibercept and bevacizumab
Efficacy at one year
Table 2 presents the number of studies (participants/eyes) in all
treatment arms of the network for the efficacy outcomes at one
year. Figure 3 presents the corresponding networks’ structure. As
seen, more data was available for ranibizumab, alone or combined
with laser, with respect to aflibercept and bevacizumab. Figure 4,
Figure 5 and Figure 6 present forest plots with effects for each
study, estimates from direct pairwise meta-analysis and mixed es-
timate from the network meta-analysis. Summary of findings 2
and Summary of findings 3 present comparisons of ranibizumab
versus aflibercept and bevacizumab.
Figure 3. Network structure for efficacy outcomes at 1 year
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Figure 4. All direct and mixed comparisons: gain of 3 or more lines of visual acuity at 1 year
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Figure 5. All direct and mixed comparisons: mean change in visual acuity at 1 year
18Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. All direct and mixed comparisons: mean change in central retinal thickness at 1 year (micron)
Comparing the available drugs as monotherapy, all efficacy
outcomes significantly favoured aflibercept over ranibizumab
and bevacizumab (Table 3; Table 4; Table 5). Compared with
ranibizumab and bevacizumab, aflibercept increased the chances
of gaining 3 or more lines (17 studies, 4031 eyes) by about 30%,
since the RR for gain was 0.75 (95% CI 0.60 to 0.94) and 0.68
(95% CI 0.53 to 0.86) versus ranibizumab and bevacizumab, re-
spectively. The corresponding figures for mean BCVA change (21
studies, 2689 eyes) were a difference of 0.08 (95% CI 0.05 to
0.11) logMAR and 0.08 (95%CI 0.05 to 0.11) logMAR and were
38.90 (95% CI 2.27 to 75.52) micron and 68.32 (95% CI 28.69
to 107.96) micron for CRT change (16 studies, 3491 eyes), all
favouring aflibercept.
Ranibizumab and bevacizumab did not differ in term of functional
outcomes: RR of gain 1.11 (95% CI 0.87 to 1.43) and difference
inmean VA change 0.00 (95%CI−0.02 to 0.03) logMAR. How-
ever, CRT reduction favoured ranibizumab by −29.4 (95% CI
−58.2 to −0.70) micron.
There was no evidence of overall statistical inconsistency in our
efficacy analyses (Table 3; Table 4; Table 5). We found evidence
of statistical inconsistency in one comparison (bevacizumab ver-
sus laser) for mean BCVA change and in the loop connecting
ranibizumab, ranibizumab plus prompt laser and laser for mean
CRT change, where two direct meta-analyses also showed high
heterogeneity in the same loop.
Mean risk of bias was low for mixed and direct comparisons
among aflibercept, bevacizumab and ranibizumab for all effi-
cacy outcomes, except for the comparison between bevacizumab
and ranibizumab regarding mean BCVA change and mean CRT
change, which were judged at unclear risk of bias (Figure 7).
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Figure 7. Contribution plot of mean overall study risk of bias to pairwise network estimates. Legends show
the risk of bias of each direct comparison.
We had not pre-planned any subgroup analyses and were unable
to obtain data to carry out post hoc subgroup analyses by base-
line BCVA. DRCRnet 2015, the only large study comparing the
three drugs, found that aflibercept was superior to bevacizumab
and ranibizumab for participants with lower vision (69 ETDRS
letter or less or approximately 20/50 or 0.4 logMAR or worse),
whereas differences between the three drugs were unimportant for
participants with better vision.
Efficacy at two years
Three publicly funded studies (BOLT 2010; DRCRnet 2010;
DRCRnet 2015) and two industry-sponsored studies (Macugen
2011; RISE-RIDE) provided data at two years. There was only one
study for each comparison, making data unsuitable for a network
meta-analysis.
Only DRCRnet 2015 (complete cases: aflibercept n = 201, beva-
cizumabn=185, ranibizumabn =191) compareddifferent antian-
giogenic drugs, and found noVAdifferences between ranibizumab
0.3 mg and aflibercept (gain 3+ VA lines, RR 0.94, 95% CI 0.73
to 1.22; difference in mean VA change 0.01, 95% CI −0.04 to
0.06). Ranibizumab and bevacizumab did not differ in terms of
gain of 3 or more VA lines (RR 0.94, 95% CI 0.72 to 1.24) but
the difference in mean VA change favoured ranibizumab (mean
difference −0.05, 95% CI −0.09 to 0.00), although it was not
precisely estimated. Although effects on CRT favoured afliber-
cept over ranibizumab and ranibizumab over bevacizumab, none
was statistically significant: mean difference−22 micron (95%CI
−50 to 6 micron) and −23 micron (95% CI −52 to 6 micron)
respectively.
Wewere unable to obtain data allowing subgroup analyses by base-
line BCVA. DRCRnet 2015 found that such subgroup differences
were attenuated at two years.
Safety at the longest available follow-up
Table 6 presents the number of studies (participants/eyes) in the
network for safety outcomes at the longest available follow-up,
and Figure 8 presents the corresponding network structure. Figure
9, Figure 10 and Figure 11 present forest plots for each study as
well as their direct meta-analysis and mixed estimates from the
network meta-analysis.
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Figure 8. Network structure for safety outcomes at 1 year
Figure 9. All direct and mixed comparisons: serious systemic adverse events at the longest available follow-
up (1 or 2 years)
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Figure 10. All direct and mixed comparisons: arterial thromboembolic events at the longest available
follow-up (1 or 2 years)
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Figure 11. All direct and mixed comparisons: all-cause death at the longest available follow-up (1 or 2 years)
Two-year data were available and reported in only four RCTs in
this review. Most industry-sponsored studies were open-label after
one year. Differently from efficacy analyses at one year, our safety
analyses included data from RISE-RIDE on ranibizumab with
monthly treatments up to two years, as well as data from the
monthly treatment arm (2q4) of Korobelnik 2014, which became
PRN in the second year.
Though no analysis suggested a difference among drugs for any
safety outcome, only estimates for SSAEs (18 studies, 4229 eyes)
reached sufficient precision to exclude very large differences among
drugs. Overall, no difference was detected in mixed evidence es-
timates for any drug compared to laser or sham. Moreover, RR
95% CI width excluded differences of 20% to 30% or more be-
tween aflibercept, bevacizumab and ranibizumab, while estimates
for pegaptanib were less precise (Table 7). No overall (P = 0.86)
or loop-specific inconsistency was detected.
Fifteen studies (3718 eyes) contributed to this analysis on ’An-
tiplatelet Trialists Collaboration arterial thromboembolic events’
(Table 8). No difference was detected in mixed evidence estimates
for any drug compared to laser or sham or between drugs, but esti-
mates were very imprecise. No overall inconsistency was detected
(P = 0.19), but direct evidence from DRCRnet 2015 showed in-
creased risk for ranibizumab compared to aflibercept (RR 2.26,
95% CI 1.15 to 4.23) which was larger and inconsistent with in-
direct evidence (P = 0.002), resulting in mixed evidence showing
no difference (RR 1.25, 95% CI 0.50 to 3.05).
Seventeen studies (4455 eyes) contributed to the analysis of ’all-
cause mortality’ (Table 9). No difference was detected for direct,
indirect and mixed evidence estimates for any drug compared to
laser or sham or between drugs, but estimates were imprecise.
Mean risk of bias was low for mixed and direct comparisons be-
tween aflibercept and ranibizumab and unclear for bevacizumab
versus ranibizumab for SSAEs. Regarding ATC arterial throm-
boembolic events and all-cause death, risk of bias was low for
aflibercept versus ranibizumab but it was unclear or high for be-
vacizumab versus ranibizumab (Figure 7).
Quality of the evidence
See above for the discussion of risk of bias of mixed evidence in
pairwise comparisons of interest.
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Statistical heterogeneity between studies
When a direct meta-analysis was possible, no heterogeneity of ef-
fects was found for the following outcomes: gain of 3 or more
BCVA lines, mean BCVA change, SSAEs, ATC arterial thrombe-
mbolic events, death. As reported above, there was high hetero-
geneity in the meta-analysis of change in CRT for the compar-
isons of ranibizumab with laser (I² = 91%) and ranibizumab plus
deferred laser versus laser (I² = 80%), but not in other two meta-
analyses in this network.
Estimates of between-study standard deviation τ in the network
meta-analyses suggested little heterogeneity for dichotomous out-
comes, except for ATC arterial thrombembolic events when it was
moderate (τ = 0.51) . Values for BCVA change and CRT change
were 8−10 logMARand27micron, respectively. These valuesmean
that heterogeneity was negligible for VA change, but was com-
patible with a predictive intervals width increased by at least 100
micron for the CRT change.
Similarity between studies
Table 10 shows baseline characteristics (BCVA, CRT) and the
number of injections across study and treatment arms. Overall,
most studies included participants with mean BCVA about 20/60
and CRT between 400 and 500 micron, which we believe suffi-
ciently homogeneous. The number of injections was high com-
pared with current practice (seven to 10 in year one), except for
few small studies delivering a low number of injections. No het-
erogeneity was suspected between studies using 0.3 versus 0.5 mg
ranibizumab. In the safety analyses, we included two studies with
monthly injections - one arm of Korobelnik 2014 for aflibercept
and RISE-RIDE for ranibizumab - and, again, no heterogeneity
seemed to arise from lower intensity regimens in other studies. Re-
garding sponsorship, there were fewer industry-sponsored studies
on bevacizumab, but these studies were also smaller than other
studies, and the impact of such differences cannot be assessed. Fi-
nally, we did not consider the OCT model used in each study as
a source of heterogeneity in CRT change since this was balanced
between the arms of each study.
Selective reporting
Comparison adjusted funnel plots showed some asymmetry for
the outcome ’gain of 3 or more VA lines’, but no specific direct
comparison seemed to be affected (Figure 12). Instead, asymmet-
ric observations to the left of the non-significance area were seen
for the outcome ’mean CRT change at one year’ regarding the
comparison ’ranibizumab versus laser’, which also suffered high
heterogeneity.
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Figure 12. Comparison-adjusted funnel plot for all outcome measures
Overall quality of evidence for the main comparisons
between drugs
Summary of findings 2 and Summary of findings 3 show summary
data as well as the overall quality of evidence for the comparisons
of interest in this review, based on the data reported above.
Sensitivity analyses on studies at low risk of bias
We conducted analyses of efficacy outcomes after excluding 10
studies at unclear or high risk of bias. These analyses confirmed
the findings with all studies.
• Gain of 3 or more BCVA lines: ranibizumab versus
aflibercept RR 0.74 (95% CI 0.59 to 0.93); bevacizumab versus
ranibizumab RR 0.89 (95% CI 0.69 to 1.15); no overall or
comparison-specific inconsistency.
• Mean change in BCVA: ranibizumab versus aflibercept 0.08
(95% CI 0.05 to 0.12) logMAR; bevacizumab versus
ranibizumab 0.0 (95% CI 0.2 to −0.03); no overall
inconsistency (P = 0.130), some inconsistency for the
comparisons of bevacizumab versus laser (P = 0.046) and
ranibizumab versus laser (P = 0.043), same direction of effects.
• Mean change in CRT: ranibizumab versus aflibercept 84
(95% CI 43 to 125) micron; bevacizumab versus ranibizumab
16 (95% CI −35 to 67) micron; overall inconsistency was
detected (P = 0.012), which was due to the loop ranibizumab
plus prompt laser versus ranibizumab plus deferred laser versus
laser (P < 0.001 for all comparisons).
Therefore, sensitivity analyses confirmed the results of main anal-
yses.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Ranibizumab versus aflibercept for diabetic macular oedema
Patient or population: people with diabet ic macular oedema
Settings: ophthalmology clinics
Interventions: af libercept, ranibizumab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI), mixed evi-
dence* *
Certainty of the evi-
dence
(GRADE)
Reason for downgrad-
ing certainty of evi-
dence
Assumed risk Corresponding risk
Aflibercept Ranibizumab
Gain 3+ lines of visual
acuity at 1 year
370 per 1000 278 per 1000
(222 to 348)
RR: 0.75
(0.60 to 0.94)
⊕⊕⊕
moderate
−1 for imprecision as
conf idence intervals in-
clude both clinically im-
portant and clinically
unimportant ef fects
Visual acuity change at
1 year
M easured on the log-
M AR scale, range −1.
3 to 1.3. Higher values
represent worse visual
acuity.
On average visual acu-
ity improved by−0.23
logM AR units in the
af libercept group be-
tween the start of treat-
ment and 1 year
Average change in vi-
sual acuity was 0.08
(0.05 to 0.11) log-
M AR units worse with
ranibizumab
compared with af liber-
cept
⊕⊕⊕
moderate
−1 for imprecision as
conf idence intervals in-
clude both clinically im-
portant and clinically
unimportant ef fects
Central retinal thick-
ness µm (CRT) change
at 1 year
The aim of treatment is
to reduce central mac-
ular thickness so thin-
ner is better.
On av-
erage CRT changed by
−181 µm in the af liber-
cept group between the
start of treatment and 1
year (became thinner)
Average change in CRT
was 39 (2 to 76)
µm more (thicker) with
ranibizumab
compared with af liber-
cept
⊕⊕
low
−1 for high heterogene-
ity in two direct com-
parisons and large pre-
dict ive intervals
−1 for imprecision
Quality of life at 1 year No data available.26
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All serious systemic
adverse events at 1 to
2 years
345 per 1000 338 per 1000
(283 to 411)
RR 0.98
(0.82 to 1.19)
⊕⊕⊕⊕
high
Arterial thromboem-
bolic events at 1 to 2
years
60 per 1000 74 per 1000
(29 to 191)
RR 1.24
(0.48 to 3.19)
⊕
very low
Inconsistency between
direct and indirect evi-
dence (−1), and impre-
cise est imates (−2)
Death at 1 to 2 years 30 per 1000 35 per 1000
(11 to 108)
RR 1.16
(0.38 to 3.58)
⊕
very low
Inconsistency between
direct and indirect evi-
dence (−1), and impre-
cise est imates (−2)
The assumed risk in the af libercept group was est imated as the row sum of the events divided by the row sum of the part icipants (eyes) for
dichotomous variables, and as the (unweighted) median change of visual acuity or central ret ina thickness
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the
intervent ion (and its 95% CI).
* * The risk rat io was est imated f rom mixed (direct and indirect) comparisons.
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the
est imate.
Very low-certainty: we are very uncertain about the est imate.
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Ranibizumab versus bevacizumab for diabetic macular oedema
Patient or population: people with diabet ic macular oedema
Settings: ophthalmology clinics
Interventions: bevacizumab, ranibizumab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI), mixed evidence* *
Certainty of the evidence
(GRADE)
Reason for downgrading
certainty of evidence
Assumed risk Corresponding risk
Bevacizumab Ranibizumab
Gain 3+ lines of visual acu-
ity at 1 year
300 per 1000 333 per 1000
(261 to 429)
RR 1.11
(0.87 to 1.43)
⊕⊕⊕
moderate
Imprecise est imate (−1)
Visual acuity change at 1
year
M easured on the logM AR
scale, range −1.3 to 1.
3. Higher values represent
worse visual acuity.
On average visual acuity im-
proved by −0.19 logM AR
units in the bevacizumab
group between the start of
treatment and 1 year
Average change in visual
acuity was0.00 (−0.02 to
0.03) logM AR
units (same) with
ranibizumab compared with
bevacizumab
⊕⊕⊕
moderate
Unclear risk of bias (−1)
Central retinal thickness
(CRT) change at 1 year
The aim of treatment is
to reduce central macular
thickness so thinner is bet-
ter.
On average CRT changed
by −98 µm in the beva-
cizumab group between the
start of treatment and 1 year
(became thinner)
Average change in CRT was
−29 (−58 to −1) µm more
(thinner) with ranibizumab
compared with
bevacizumab
⊕⊕
low
Unclear risk of bias (−1)
Imprecise est imate (−1)
Quality of life at 1 year No data available
All serious systemic ad-
verse events at 1 to 2 years
240 per 1000 250 per 1000
(202 to 307)
RR 1.04
(0.84 to 1.28)
⊕⊕⊕
moderate
Unclear risk of bias (−1)
Arterial thromboembolic
events at 1 to 2 years
60 per 1000 70 per 1000
(26 to 189)
RR 1.17
(0.43 to 3.13)
⊕
very low
Unclear risk of bias (−1)
Imprecise est imate (−2)
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Death at 1 to 2 years 40 per 1000 29 per 1000
(9 to 95)
RR 0.73
(0.22 to 2.37)
⊕
very low
High risk of bias (−2) Im-
precise est imate (−2)
The assumed risk in the bevacizumab group was est imated as the row sum of the events divided by the row sum of the part icipants (eyes) for dichotomous variables, and as
the (unweighted) median change of visual acuity or central ret ina thickness
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * The risk rat io was est imated f rom mixed (direct and indirect) comparisons.
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
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D I S C U S S I O N
Summary of main results
This review and network meta-analysis confirms the findings of
the previous version which found high-certainty evidence that an-
tiangiogenic therapy provides benefit over laser treatment in peo-
ple with DMO at one year and concluded that further studies
should compare different drugs. This update found four studies
with direct comparisons between drugs and augmented this evi-
dence with indirect comparisons in a network meta-analysis based
on 24 included studies.
At one year, all efficacy outcomes significantly favoured afliber-
cept over ranibizumab and bevacizumab. Aflibercept increased the
chances of gaining 3 or more BCVA lines by about 30%, and
conferred an advantage of between half and 1 BCVA line over the
other drugs (moderate-certainty of evidence). Ranibizumab and
bevacizumab did not differ in terms of functional outcomes (mod-
erate-certainty of evidence), but ranibizumab was more effective
in terms of CRT reduction (low-certainty of evidence). There was
no evidence of statistical inconsistency in our analyses, except for
the comparison between ranibizumab and bevacizumab for mean
BCVA change, but the differences between direct and indirect ev-
idence were clinically irrelevant.
The BCVA difference between aflibercept versus ranibizumab or
bevacizumabwas largely below the threshold of 1ETDRS line (five
letters or 0.1 logMAR) that was used for non-inferiority in trials
on DMO (OZDRY 2015, PLACID 2013) and AMD (CATT
2011), suggesting this difference was not clinically relevant.
The previous version of this review found moderate-certainty ev-
idence of good safety of antiangiogenic drugs, including afliber-
cept, bevacizumab, ranibizumab and pegaptanib, versus con-
trol. This update found high-certainty evidence that aflibercept,
ranibizumab and bevacizumab do not differ regarding SAEs, ex-
cluding RR differences between drugs by more than 25%. How-
ever, estimates were imprecise on well-defined hard events such as
death or arterial thromboembolic events (very low-certainty evi-
dence).
Two-year data on direct comparisons were available only for one
large multicentre publicly funded study showing smaller differ-
ences between aflibercept, bevacizumab and ranibizumab as com-
pared to one year (DRCRnet 2015).
Overall completeness and applicability of
evidence
This review confirms and enhances the findings of DRCRnet
2015: that aflibercept confers some advantage over bevacizumab
and ranibizumab at one year. Two-year data were available and
reported in only fourRCTs in this review.Most industry sponsored
studies were open-label after one year. Thus, long-term outcomes
have to be inferred from observational trials.
We could not investigate subgroup effects in this review due to lack
of subgroup data. DRCRnet 2015 found the relative benefit with
aflibercept versus ranibizumab and bevacizumab is larger when
visual acuity is lower than about 20/50, and modest above this
level. Moreover, we could not investigate the potential effect of
differences in dose and regimen. Nonetheless, our review includes
studies with a broad range of characteristics, but without major
differences in populations. Particularly, 0.3 mg ranibizumab was
used in the direct comparison with aflibercept and bevacizumab
in DRCRnet 2015; yet indirect evidence, mostly based on 0.5
mg ranibizumab, was consistent. Regarding treatment frequency:
the only study on monthly 0.3 mg ranibizumab was RISE-RIDE
for indirect evidence, but this could not be included since one-
year data were not available. We excluded the monthly aflibercept
treatment arms of Korobelnik 2014 for efficacy outcomes at one
year since this is not the registered label.
We would like to remark that this evidence is obtained in clinical
trials with high treatment and monitoring standards. A pragmatic
RCTwould be needed to assess the real-world effectiveness of anti-
VEGF treatment forDMO, since it could be dependent on the ad-
equacy of monitoring treatment response, which is also sensitive to
resource constraints, as found for AMD (Pagliarini 2014). More-
over, evidence on safety fromnon-randomised, real-world datawas
not included in our review. As found for AMD, real-world studies
suggest that people with DMO may differ from those in RCTs
(Ziemssen 2017). However there is more compelling real-world
evidence that patients are under-treated and have less favourable
outcomes than in RCTs for AMD (Chong 2016) compared to
DMO (Jiang 2015; Patrao 2016).
Quality of the evidence
The quality of evidence has been presented above with reasons for
downgrading shown in Summary of findings 2 and Summary of
findings 3. Overall, inconsistency was not an issue in our network
meta-analyses. We also think that transitivity and generalisablilty,
or indirectness according to GRADE (Schünemann 2011), were
not a problem since studies included a broad range of people with
DMO that resembles those in clinical practice. Minor funnel plot
asymmetry was detected only for CRT change and did not involve
the treatments of direct interest in this review.
The tight monitoring of participants in RCTs differs from clini-
cal practice, where a lower number of intravitreal injections and
under-treatment are common. As for age-related macular degen-
eration, this may overestimate benefit with anti-VEGF treatment.
However, effect differences among drugs may be less biased if sim-
ilar regimens are compared in RCTs, although this remains pre-
sumptive.
Potential biases in the review process
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Bevacizumab is an off-label drug for treating DMO inmost coun-
tries. Because small RCTs using bevacizumab may have been con-
ducted but not published because no difference was found, we
could have missed small unpublished studies.
Agreements and disagreements with other
studies or reviews
Although we did not systematically search for other reviews on
anti-VEGF treatments for DMO, the previous version of this re-
view, which focused on anti-VEGF drugs effects compared to
control, reported on other network meta-analyses which were in-
conclusive (Ford 2012; MEDCAC 2012; Regnier 2014); and in-
cluded amuch smaller set of studies, as did Korobelnik 2015 more
recently. Zhang 2016 conducted a network meta-analysis of 21
studies of anti-VEGF drugs versus any control, including stud-
ies on intravitreal steroids, such as dexamethasone and triamci-
nolone, and one retrospective comparative, non-randomised study
(Arevalo 2013). The authors concluded that aflibercept was su-
perior to other drugs at 12 months: they found a difference of
about 0.04 logMAR (2 ETDRS letters) between aflibercept and
ranibizumab as well as between ranibizumab and bevacizumab,
but these did not reach statistical significance, as did differences
in retinal thickness. Differently from Zhang 2016, we included a
larger number of studies on anti-VEGF drugs, but not intravitreal
steroids since their benefit profile, as well as their local and systemic
harm profile, only partly overlap with that of anti-VEGF drugs
and similarity of studies regarding study design and target popu-
lation would be less likely achieved. Currently, some investigators
think intravitreal steroids are preferred in people with anti-VEGF
resistant and chronic DMO (Hussain 2015), as an alternative to
switching between anti-VEGF drugs. We suggest that a network
meta-analysis including both anti-VEGF drugs and steroids is of
interest, but a different approach should be used, specifically re-
garding heterogeneity of effects by time horizon and participants’
subgroups.
TheEuropeanSociety ofRetina Specialists have recently published
guidelines on the management of DMO, which cover a broad
spectrumof clinical questions ranging from imaging interpretation
to diabetes management (EURETINA 2017). These guidelines
rely on individual study results, particularly those of DRCRnet
2015 which compared aflibercept, bevacizumab and ranibizumab
directly regarding anti-VEGF drug choice. They concluded that
“aflibercept is the drug of choice in DME eyes with baseline BCVA
below 69 letters, as it shows superiority to bevacizumab over 2 years
and over ranibizumab in the first year of treatment” and that “all
three medications are equivalent in improving vision in eyes with a
baseline BCVA letter score of 69 or more”. Our review does not pro-
vide additional evidence regarding the effect of baseline vision on
visual outcome, since few studies maintained randomisation be-
yond one year and subgroup data were not available to conduct a
network meta-analysis. Regarding the difference between afliber-
cept and ranibizumab at one year, EURETINA 2017 stated that
“it remains unclear to which extent the slower effect of ranibizumab
seen in Protocol T [DRCRnet 2015] compared to aflibercept can be
accounted to the lower dose (0.3 mg) of ranibizumab used in this
study”. Our review found that the difference between aflibercept
and ranibizumab was consistent with indirect evidence based on
studies that mostly used ranibizumab 0.5 mg, suggesting no dose
effect as previously suggested (Heier 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is moderate-certainty evidence that aflibercept confers some
advantage in improving visual function over ranibizumab and be-
vacizumab in people with DMO at one year. An anatomic bene-
fit was found with ranibizumab over bevacizumab (low-certainty
evidence), but there was little difference on functional outcomes
(low- and moderate-certainty evidence). Relative effects among
anti-VEGFdrugs at two years are less well known, sincemost stud-
ies did not maintain randomisation after one year or were short
term. A single large publicly-funded trial found no differences in
visual outcomes among these drugs at two years. Evidence from
RCTs may not apply to real-world practice, where people in need
of antiangiogenic treatment are often under-treated and under-
monitored.
We found no signals of differences in safety between the three
antiangiogenic drugs that are currently available to treat DMO,
particularly for a summary outcome measure such as the sum of
all SSAEs (high- or moderate-certainty evidence). However, our
estimates were imprecise regarding arterial thromboembolic events
and all-cause death (very low-certainty evidence).
Implications for research
Further studies should be directed to effectiveness in real-world
use and focus on monitoring and treatment regimens. A network
meta-analysis including steroids forDMOis needed,which should
take into account different harms as well as account for differences
in populations (e.g. regarding pseudophakic patients and chronic
DMO). A network meta-analysis of the relative safety of different
antiangiogenic drugs could be conducted including people with
different diseases.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmadieh 2008
Methods Parallel group RCT
People were randomly allocated to treatment but in bilateral cases eyes were randomly
allocated to treatment
Participants Country: Iran
Number of people randomised: 101 (115 eyes)
Average age: 60 years (range 39 to 74)
Sex: 51% women
Inclusion criteria:
• CSMO unresponsive to previous macular laser photocoagulation (with the last
session being more than 3 months prior)
Exclusion criteria:
• VA ≥ 20/40
• history of cataract surgery within the past 6 months
• prior intraocular injection or vitrectomy
• glaucoma or ocular hypertension
• PDR with high-risk characteristics
• vitreous haemorrhage
• significant media opacity
• presence of traction on the macula
• monocular
• pregnancy
• serum creatinine level ≥ 3 mg/100ml
Interventions Intervention:
• bevacizumab (1.25 mg) n = ? (41 eyes)
Comparator:
• sham injection n = ? (37 eyes)
“Three consecutive injections were performed at 6-week intervals. Injections were done un-
der sterile conditions with topical anesthesia and insertion of a lid speculum. For the IVB
group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel,
Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a
30-gauge needle through the superotemporal quadrant.” Page 485
“In the control group, a needleless syringe was pressed against the conjunctiva and sclera in
each session.” Page 485
There was another intervention arm that combined bevacizumab with triamcinolone
acetonide, but this is not included in this review (n = 37 eyes)
Outcomes Primary outcome:
• change in CRT
“Central macular thickness was defined by the average thickness of a central macularregion
1,000 ìm in diameter centered on the patient’s foveola.” Page 485
Secondary outcomes:
• change in BCVA (logMAR)
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Ahmadieh 2008 (Continued)
• intraocular pressure
• cataract progression
• intraocular inflammation
• any serious adverse event
Follow-up: 18 and 24 weeks
Notes Date study conducted: November 2005 to September 2006
Funding: not reported
Conflict of interest: “The authors have no proprietary interest in this study.”
Trial registration: NCT00370422
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block lengths varied randomly. A random al-
location sequence was performed by a bio-
statistician. Details of the series were un-
known to the investigators.” Page 485
Allocation concealment (selection bias) Low risk “Randomization was performed using a ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block lengths varied randomly. A random al-
location sequence was performed by a bio-
statistician. Details of the series were un-
known to the investigators.” Page 485
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects were masked to the treatment
modality. Visual acuity assessment and OCT
were performed by optometrists who were
masked to the groups.” Page 485
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete outcome data were re-
ported, but number of participants at 24
weeks’ follow-up was not specied
Selective reporting (reporting bias) High risk The study protocol is mentioned. How-
ever, dichotomous VA outcomes are not
provided
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Ahmadieh 2008 (Continued)
Other bias Low risk 28 eyes of 14 participants (14%) with bi-
lateral CSMOwere included in the analysis
Overall risk of bias Low risk Low risk of bias for most items
Azad 2012
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: India
Number of people randomised: 40 (40 eyes)
Average age: 54 years
Sex: 42% women
Inclusion criteria:
• diffuse DMO on FFA refractory to at least two prior sessions of macular laser
photocoagulation
• CRT > 250 µm on TD-OCT
• no evidence of vitreo-retinal traction
• good metabolic control (HbA1c < 7.0%)
Exclusion criteria:
• history of having received prior intraocular, peribulbar or systemic steroids or
prior anti-VEGF therapy
• uncontrolled diabetes mellitus
• diabetic nephropathy
• uncontrolled hypertension
• history of myocardial infarction, stroke or other thromboembolic
• episode
• monocular
• not available for a follow-up duration of at least 6 months
Interventions Intervention:
• bevacizumab (1.25 mg) n = 20 (20 eyes)
Comparator:
• macular grid augmentation n = 20 (20 eyes)
“IVB [...] injected via pars plana route in the doses mentioned above by a single experienced
investigator using full aseptic precautions. Postinjection, all patients were prescribed topical
moxifloxacin 0.5% qid for 5 days. Macular grid laser augmentation was performed by a
single experienced examiner according to the modified ETDRS protocol with a spot size of 100
µ, pulse duration of 100 ms, and a power of 50-100 mW titrated to produce mild intensity
burns in areas showing diffuse leakage on the FFA in a ‘C’ shaped zone between 500 and
3000µ from the foveal center sparing the papilla-macular bundle.” Page 167
Another intervention arm evaluated triamcinolone acetonide, but is not included in this
review (n = 20 eyes)
Outcomes Outcomes:
• BCVA measured used Snellen chart (mean at follow-up, gain/loss of 3 lines)
• CRT assessed using OCT
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Azad 2012 (Continued)
• adverse effects (increased IOP, cataract progression, others)
Primary outcome: not specified
Follow-up: 1, 3 and 6 months
Notes Date study conducted: not reported
Funding: not reported
Conflict of interest: not reported
Trial registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported
Selective reporting (reporting bias) High risk VA data and other outcomes incompletely
reported
Other bias Low risk No other bias identified
Overall risk of bias Unclear risk Unclear risk of bias for most items
BOLT 2010
Methods Parallel group RCT
One eye per person; if both eyes were eligible eye with worse VA was selected
Participants Country: UK
Number of people randomised: 80 (80 eyes)
Average age: 64 years (range 40 to 86)
Sex: 31% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• BCVA in the study eye between 35 and 69 ETDRS letters at 4 m (Snellen
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BOLT 2010 (Continued)
equivalent 6/60 or 6/12)
• centre-involving CSMO with CRT on OCT of ≥ 270 µm
• media clarity, pupillary dilation, and subject co-operation sufficient for adequate
fundus imaging
• at least 1 prior macular laser therapy
• intraocular pressure < 30 mmHg
• ability to return for regular study visits
• fellow eye ≥ BCVA 3/60
• fellow eye received no anti-VEGF treatment within the past 3 months and there
was no expectation of such treatment during the study
Exclusion criteria: (for study eye)
• macular ischaemia (FAZ ≥ 1000 µm GLD or severe perifoveal intercapillary loss
on FFA)
• macular oedema due to a cause other than DMO
• pre-existing ocular condition that was likely to preclude VA improvement despite
resolution of macular oedema
• ocular condition that may affect macular oedema or alter VA during the course of
the study, any treatment for DMO in the preceding 3 months
• PRP within 3 months of enrolment or anticipated 6 months thereafter
• PDR except for tufts of new vessels elsewhere < 1 disc in area with no vitreous
haemorrhage
• HbA1c > 11.0%
• medical history of chronic renal failure requiring dialysis or kidney transplantation
• BP > 170/100 mmHg
• any thromboembolic event within 6 months
• unstable angina, or evidence of active ischaemia on electrocardiogram at time of
screening
• major surgery within 28 days of randomisation or planned during the subsequent
12 months
• participation in an investigational drug trial within 30 days of randomisation (or
any time during the study)
• systemic anti-VEGF or pro-VEGF treatment within 3 months of enrolment
• pregnancy, breast feeding, or intention to become pregnant within the study
period
• intraocular surgery within 3 months of randomisation
• aphakia
• uncontrolled glaucoma
• significant external ocular disease
Interventions Intervention:
• bevacizumab (1.25 mg) n = 42 (42 eyes)
Comparator:
• macular laser therapy (MLT) n = 38 (38 eyes)
“Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Roche Registration Limited, UK)was prepared
by Moorfields Pharmaceuticals (London, UK) as a prefilled syringe containing 0.13 ml. In
a designated intravitreal treatment room, under sterile conditions, using topical anesthesia
and povidone-iodine 5% into the conjunctival sac and onto the lid margins, and following
application of a drape and insertion of a lid speculum, injections were undertaken with a 30-
gauge needle through the supra- or infratemporal quadrant, with a drop of ofloxacin placed
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BOLT 2010 (Continued)
in the fornix at the end of the procedure. Patency of the central retinal artery was determined
by indirect ophthalmoscopy and VA of hand movements or better. The IOP was checked
30 minutes after the injection, and if the pressure was increased (30 mmHg) appropriate
treatment was commenced. After the injection, topical ofloxacin was instilled 4 times per day
for 4 days”. Page 1080
“After baseline IVB, patients received 2 further IVB injections (6- and 12-week time points).
Subsequent IVBinjections were guided by an OCT-based retreatment protocol. In brief, if the
thinnest recorded central retinal thickness was less than 270 m at 18 weeks, then treatment
was continued only if macular thickness was not “stable.” If central retinal thickness was
greater than 270 m at 18 weeks and subsequent visits, then IVB injections were administered
until a “stable” macular thickness was attained. “Stable macular thickness” was defined as
3 consecutive visits with the central retinal thickness within 20 m of the patient’s thinnest
recorded central retinal thickness. Patients could thereby receive a minimum of 3 injections
and a maximum of 9 injections in the first 12 months.” Page 1080
“Modified ETDRSMLT comprised 50 m argon laser spot size, laser applied only greater than
500 m from the edge of the FAZ, with focal treatment aiming to cause mild blanching of the
retinal pigment epithelium and not darkening/whitening of microaneurysms. Areas of diffuse
leakage or nonperfusion were similarly treated in a grid pattern.” Page 1080
Outcomes Primary outcome:
• mean change in BCVA (EDTRS letters measured at 4 m)
Secondary outcomes:
• mean CRT and mean change in CRT
• gain and loss of 15 and 10 letters of ETDRS
• loss of 30 ETDRS letters
• retinopathy severity (ETDRS grading)
• safety
◦ GLD of the FAZ
◦ area of the FAZ
◦ Retinal Nerve Fibre Layer thickness
◦ other ocular side effects
◦ systemic side effects, including thromboembolic events, BP, and ECG
findings
Follow-up: 12 and 24 months
Notes Date study conducted: May 2007 to August 2009
Funding:“Supported by grants from Moorfields Special Trustees and the National Institute
for Health Research UK to the Biomedical Research Center for Ophthalmology based at
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.”
Conflict of interest: “The author(s) have no proprietary or commercial interest in any ma-
terials discussed in this article”
Trial registration: eudract.ema.europa.eu Identifier: 2007-000847-89
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Patients were randomised into 2 groups by
means of an in-house computerized random-
ization program. The research investigator
was not involved in the randomization pro-
cess. Patients were stratified for BCVA, with
the aim being that both groups would have
comparable mean baseline BCVAs.” Page
1080
Allocation concealment (selection bias) Low risk The doctor had to phone the Clinical Trial
Unit in order to obtain a randomisation
from the statistician [personal communica-
tion from investigators]
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Although the patient and the study physician
were not masked to the therapeutic modal-
ity, the study optometrist, OCT technician,
photographer, graders performing assessment
of the FAZ and ETDRS retinopathy grading,
and study statistician were all masked to the
patient randomization.” Page 1080
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two patients in the laser group did not com-
plete 12months of follow-up (1 patientmoved
away, and 1 patient could not be contacted)
. They were last reviewed at the 32-week
time point,with these data being carried for-
ward and an intention-to-treat analysis un-
dertaken. All 42 patients in the IVBgroup
completed the study.” Page 1082
Selective reporting (reporting bias) Low risk We could not find a protocol but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other bias identified
Overall risk of bias Low risk Low risk for most items; we considered
masking of outcome assessors, though not
of participants and physicians, sufficient to
ensure unbiased outcome measurement
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DA VINCI 2011
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: USA, Canada and Austria
Number of people randomised: 221 (221 eyes)
Average age: 64 years (range 40 to 86)
Sex: 31% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• DMO involving the central macula defined as CRT ≥ 250 µm in the central
subfield based on Stratus OCT
• BCVA letter score at 4 m of 73-24 (Snellen equivalent: 20/40-20/320) measured
by the ETDRS protocol
• women of childbearing potential were included only if they were willing to not
become pregnant and to use a reliable form of birth control during the study period
Exclusion criteria:
(for study eye)
• history of vitreoretinal surgery
• PRP or macular laser photocoagulation or use of intraocular or periocular
corticosteroids or anti-angiogenic drugs within 3 months of screening
• vision decrease due to causes other than DMO
• PDR (unless regressed and currently inactive)
• ocular inflammation
• cataract or other intraocular surgery within 3 months of screening
• laser capsulotomy within 2 months of screening
• aphakia
• spherical equivalent of > −8 dioptres or any concurrent disease that would
compromise VA or require medical or surgical intervention during the study period
(in either eye)
• active iris neovascularisation
• vitreous haemorrhage
• traction retinal detachment
• preretinal fibrosis involving the macula
• visually significant vitreomacular traction or epiretinal membrane evident
biomicroscopically or on OCT
• history of idiopathic or autoimmune uveitis
• structural damage to the center of the macula that is likely to preclude
improvement in VA after the resolution of macular oedema
• uncontrolled glaucoma or previous filtration surgery
• infectious blepharitis, keratitis, scleritis, or conjunctivitis
• current treatment for serious systemic infection
(systemic)
• uncontrolled diabetes mellitus
• uncontrolled hypertension
• history of cerebral vascular accident or myocardial infarction within 6 months
• renal failure requiring dialysis or renal transplant
• pregnancy or lactation
• history of allergy to fluorescein or povidone iodine
47Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DA VINCI 2011 (Continued)
• only 1 functional eye
• ocular condition in the fellow eye with a poorer prognosis than the study eye
Interventions Intervention:
• VEGF Trap-Eye n = 177 (177 eyes)
Comparator:
• laser photocoagulation n = 44 (44 eyes)
“Patients were randomly assigned in a 1:1:1:1:1 ratio to 1 of 5 treatment regimens in 1 eye
only: 0.5 mg VEGF Trap-Eye every 4 weeks (0.5q4); 2 mg VEGF Trap-Eye every 4 weeks
(2q4); 2 mg VEGF Trap-Eye for 3 initial monthly doses and then every 8 weeks, (2q8); 2 mg
VEGF Trap-Eye for 3 initial monthly doses and then on an as-needed (PRN) basis (2 PRN)
; or macular laser treatment by the modified ETDRS protocol” Page 1820
Outcomes Primary outcome:
• change in BCVA from baseline to week 24 (ETDRS chart at 4 m)
Secondary outcomes:
• retinal thickness assessed by OCT
• safety and tolerability
• change in BCVA from baseline at week 52
• proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with
baseline at weeks 24 and 52
• the change in CRT (central subeld on OCT) from baseline to weeks 24 and 52
• number of focal laser treatments given
Follow-up: 24 and 52 weeks
Notes Date study conducted: December 2008 to June 2009
Funding: “Sponsored by Regeneron Pharmaceuticals, Inc., Tarrytown, New York.”
Conflict of interest: “The author(s) have made the following disclosure (s): Diana V.
Do: Genentech (financial support), Regeneron Pharmaceuticals (financial support). Ursula
Schmidt-Erfuth: Alcon Labs (consultant, lecturer), Bayer Healthcare (consultant, lecturer),
Novartis (consultant, lecturer), Regeneron Pharmaceuticals (lecturer), Pfizer (lecturer). Victor
H.Gonzalez: Pfizer (consultant, lecturer), Genentech (lecturer), Eyetech (consultant, lecturer)
, Regeneron (lecturer). CarmelinaM. Gordon: Allergan (consultant), Regeneron Pharmaceu-
ticals (lecturer), Novartis (consultant, lecturer). Michael Tolentino: Genentech (consultant,
lecturer), Eyetech (consultant, lecturer), Regeneron Pharmaceuticals (consultant, lecturer).
Alyson J Berliner: Regeneron Pharmaceuticals (employee, equity owner). Robert Vitti: Re-
generon Pharmaceuticals (employee, equity owner). Rene Rückert: Bayer Schering Pharma
(employee). Rupert Sandbrink: Bayer Schering Pharma (employee). David Stein: Regeneron
Pharmaceuticals (employee,equity owner). Ke Yang: Regeneron Pharmaceuticals (employee,
equity owner). Karola Beckmann: Bayer Schering Pharma (employee). Jeff S.Heier: Genen-
tech (consultant, lecturer), Regeneron Pharmaceuticals (consultant,lecturer), Fovea (consul-
tant).
Trial registration:NCT00789477
Risk of bias
Bias Authors’ judgement Support for judgement
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DA VINCI 2011 (Continued)
Random sequence generation (selection
bias)
Low risk ”The randomizationwas handled by an IVRS
vendor. The study statistician at REGEN-
ERONprovided the randomization plan and
reviewed and approved the dummy rand ta-
ble. Study Data Management at REGEN-
ERON tested the randomization function ex-
tensively along with the Clinical team.“
Allocation concealment (selection bias) Low risk ”Sites called into IVRS to randomize patients
and received the randomization number and
drug kit assignment at the completion of the
call. The site also received a confirmation
email. Neither of these contained the actual
randomization assignment. The randomiza-
tion assignments were kept by the IVRS ven-
dor in a secure, access-controlled database and
were delivered to REGENERONby the IVRS
vendor at the primary endpoint database lock.
“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”To maintain participant masking, sham in-
jections were performed on visits when an ac-
tive dose was not given, and a sham laser was
given to the VEGFTrap-Eye groups at week 1.
Study drug and sham injections and laser and
sham laser treatments were performed by an
unmasked physician who had no other role in
the study except to assess adverse events (AEs)
immediately posttreatment. Sham injections
followed the active treatment protocol with
the exception that no needle was attached to
the syringe, and the syringe hub was gently
applied to the sclera to mimic an injection.
Sham laser consisted of placing a contact lens
on the study eye and positioning the patient in
front of the laser machine for the approximate
duration of a laser treatment.“ Page 1820-1
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A separate masked physician was assigned to
assess adverse events (AEs) and retreatment
and rescue criteria and to supervise themasked
assessment of efficacy. Every effort was made
to ensure that all other study site personnel
remained masked to treatment assignment to
facilitate an unbiased assessment of efficacy
and safety.”
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DA VINCI 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two randomised patients did not receive
treatment and 19 patients discontinued the
study after receiving at least 1 treatment for
the following reasons: lost to follow-up (6 pa-
tients), withdrew consent (6 patients), death
(3 patients), treatment failures (2 patients)
, AE (1 patient), and protocol deviation (1
patient). Discontinuations were evenly dis-
tributed among the 5 treatment groups.” Page
1821
Comment: LOCF used
Selective reporting (reporting bias) Low risk Primary outcome declared and consistent
with our review
Other bias Low risk No other bias identified
Overall risk of bias Low risk Low risk of bias for most items
DRCRnet 2010
Methods Parallel group and within-person RCT
One or two study eyes per person. If both eyes eligible, right eye randomised first and
then left eye assigned to “sham plus prompt laser group”. If right eye already assigned to
this group then left eye assigned randomly to 1 of the other 3 groups
Participants Country: USA
Number of people randomised: 691 (854 eyes)
Average age: 63 years
Sex: 44% women
Inclusion criteria:
• 18 years and older
• diabetes
(in study eye)
• best-corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-
ETDRS Visual Acuity Test) VA letter score 78-24 (20/32-20/320)
• definite retinal thickening due to DMO on clinical examination involving the
centre of the macula assessed to be the main cause of visual loss
• retinal thickness measured on TD-OCT ≥ 250 micron in the central subfield
Exclusion criteria:
• treatment for DMO within previous 4 months
• PRP within the previous 4 months or anticipated need for PRP within the next 6
months
• major ocular surgery within the previous 4 months
• history of open-angle glaucoma or steroid-induced IOP elevation that required
IOP-lowering treatment
• IOP ≥ 25 mmHg
(participant)
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• systolic BP was 180 mmHg or diastolic BP was 110 mmHg, or if a myocardial
infarction, other cardiac event requiring hospitalisation, cerebrovascular accident,
transient ischaemic attack, or treatment for acute congestive heart failure occurred
within 4 months before randomisation
Interventions Intervention:
• ranibizumab (0.5 mg) and laser photocoagulation n = ? (375 eyes)
Comparator:
• sham injection and laser photocoagulation n = ? (293 eyes)
Ranibizumab group was also randomly allocated to prompt laser photocoagulation (187
eyes) which occurred within 3 to 10 days of the injection and deferred laser photocoag-
ulation (188 eyes) which happened after 24 weeks. All eyes in comparator group were
treated within 3 to 10 days of the sham injection
Complex retreatment algorithm using web-based, real-time data-entry system (page
1066)
There was another intervention arm that combined triamcinolone with prompt laser
photocoagulation, but this was not included in this review. n = ? (186 eyes)
Outcomes Primary outcome: BCVA and safety at 12 months
Secondary outcomes: CRT
Follow-up: every 4 weeks for 12 months. After 12 months, the trial was unmasked and
follow-up continued to 3 years
Notes Dates participants enrolled: March 2007 to December 2008
Funding: “Supported through a cooperative agreement from the National Eye Institute and
the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Department of Health and Human Services EY14231, EY14229, and EY018817.
The funding organization (National Institutes of Health) participated in oversight of the
conduct of the study and review of themanuscript but not directly in the design or conduct of the
study; the collection, management, analysis, or interpretation of the data; or the preparation
of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc.,
provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided
funds to the DRCR.net to defray the study’s clinical site costs. As described in the DRCR.net
Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete
control over the design of the protocol, the ownership of the data, and all editorial content of
presentations and publications related to the protocol.”
Conflict of interest: “A complete list of all DRCR.net investigator financial disclosures can
be found at www.drcr.net”
Trial registration: NCT00445003
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was com-
puter-generated by the DRCR.net co-ordi-
nating centre
“...study participants with 1 study eye were as-
signed randomly on theDRCR.net studyweb-
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site (using a permuted blocks design stratified
by study eye visual acuity)” Page 1065
Allocation concealment (selection bias) Low risk Randomisation assignments were obtained
through the DRCR.net study website,
therefore no study personnel had access to
the list or to the next assignment before it
was assigned
“study participants with 1 study eye were as-
signed randomly on theDRCR.net studyweb-
site (using a permuted blocks design stratified
by study eye visual acuity)” Page 1065
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Study participants in the 3 groups receiving
laser were masked to treatment assignment
through the primary outcome visit, whereas
the ranibizumab deferred laser group was not
masked.” Page 1065-6
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Visual acuity examiners and OCT techni-
cians were masked to treatment group assign-
ment before and at the 1-year primary out-
come visit.” Page 1066
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants randomised in each group
were: 293 laser, 187 ranibizumab + prompt
laser, 188 ranibizumab + deferred laser and
186 IVTA + laser. At 1 year complete par-
ticipants were 274, 171, 178, 176 respec-
tively (91% to 95%)
At 2 years complete participants were 211,
136, 139, 142 respectively (72% to 76%)
Causes ofmissingdatawere balanced across
groups
Selective reporting (reporting bias) Low risk We could not find a protocol but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other source of bias identified
Overall risk of bias Low risk Low risk of bias for most items
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Methods Parallel group study
“One eye of each participant was randomly assigned in a 1:1:1 ratio to be injected with
aflibercept (at a dose of 2.0 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg). Ran-
domization was performed at the DRCR.net study website, in permuted blocks and with
stratification according to study site and visual acuity in the study eye.”
Participants Country: USA
Number of people (eyes) randomised: 660
Average age: 61 years
Sex: not reported
Inclusion criteria:
• 18 years and older
• diabetes
(in study eye)
• best-corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-
ETDRS Visual Acuity Test) VA letter score 78-24 (20/32-20/320)
• definite retinal thickening due to DMO on clinical examination involving the
centre of the macula assessed to be the main cause of visual loss
• retinal thickness measured on TD-OCT ≥ 250 micron in the central subfield
Exclusion criteria:
• treatment for DMO within previous 4 months
• PRP within the previous 4 months or anticipated need for PRP within the next 6
months
• major ocular surgery within the previous 4 months
• history of open-angle glaucoma or steroid-induced IOP elevation that required
IOP-lowering treatment
• IOP ≥ 25 mmHg
(participant)
• systolic BP was 180 mmHg or diastolic BP was 110 mmHg, or if a myocardial
infarction, other cardiac event requiring hospitalisation, cerebrovascular accident,
transient ischaemic attack, or treatment for acute congestive heart failure occurred
within 4 months before randomisation
Interventions Interventions:
• aflibercept 2 mg: 224 eyes
• bevacizumab 1.25 mg: 218 eyes
• ranibizumab 0.3 mg: 218 eyes
Randomisation was stratified by site and visual acuity: ≥ 66 letter score/ ≤ 65 letter
score
retreatment algorithm:
“In general, an eye will continue to receive an injection if the eye is improving or worsening
on OCT or visual acuity. The first time an eye has not improved or worsened, the eye will
receive an injection. If the eye has not improved or worsened for at least 2 consecutive 4-week
injections and OCT central subfield thickness is <250µ and visual acuity is 20/20 or better,
the injection will be deferred.”
“In general, focal/grid laser will be initiated at or after the 24 week visit if 1) the OCT central
subfield thickness is ≥250µ or there is edema that is threatening the fovea and 2) the eye has
not improved on OCT or visual acuity from the last two consecutive injections.”
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Outcomes Primary outcome: BCVA and safety at 12 months
Secondary outcomes: CRT
Follow-up: after 12 months the trial was unmasked and follow-up continued to 3 years
Notes Dates participants enrolled: March 2007 to December 2008
Funding:“Supported through a cooperative agreement from the National Eye Institute and
the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Department of Health and Human Services EY14231, EY14229, and EY018817.
The funding organization (National Institutes of Health) participated in oversight of the
conduct of the study and review of themanuscript but not directly in the design or conduct of the
study; the collection, management, analysis, or interpretation of the data; or the preparation
of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc.,
provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided
funds to the DRCR.net to defray the study’s clinical site costs. As described in the DRCR.net
Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete
control over the design of the protocol, the ownership of the data, and all editorial content of
presentations and publications related to the protocol.”
Conflict of interest: “A complete list of all DRCR.net investigator financial disclosures can
be found at www.drcr.net”
Trial registration: NCT00445003 (Protocol T)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was com-
puter-generated by the DRCR.net co-ordi-
nating centre
“Randomization was performed at the
DRCR.net study website, in permuted blocks
and with stratification according to study site
and visual acuity in the study eye.” Page 3
Allocation concealment (selection bias) Low risk Randomisation assignments were obtained
through the DRCR.net study website,
therefore no study personnel had access to
the list or to the next assignment before it
was assigned
See above, Page 3
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study participants, reading-center graders,
and the medical monitor who reviewed all
adverse events were unaware of the treatment
group assignments. Visual-acuity and OCT
technicians were unaware of the treatment-
group assignments at the 1-year visit. Investi-
gators and study coordinators were aware of
the treatment group assignments.” Page 3
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Visual-acuity and OCT technicians were
unaware of the treatment-group assignments
at the 1-year visit.” Page 3
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The 2-year visit was completed by 90%,
85%, and 88% of the 660 randomised par-
ticipants (91%, 90%, and 91% exclud-
ing deaths) in the aflibercept, bevacizumab,
and ranibizumab groups, respectively (Fig
S1, available at www.aaojournal.org). There
were no substantial differences identified in
the baseline characteristics of those who com-
pleted and those who did not complete the 2-
year visit (Table S1, available at www.aao-
journal.org).”
Selective reporting (reporting bias) Low risk Outcomes match those in the Study Proto-
col available at http://publicfiles.jaeb.org/
AntiVEGFCompPrtclv5 03 18 14.pdf
Other bias Low risk No other source of bias identified
Overall risk of bias Low risk Low risk of bias for most items
Ekinci 2014
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: Turkey
Number of people randomised unclear: 100 (100 eyes) completed follow-up
Average age: 67 years (range 50 to 89)
Sex: 68% women
Inclusion criteria:
• clinically significant DMO (CRT > 300 mm), as found through FFA and OCT
evaluations and dilate fundus examination, after 1-year follow-up period
Exclusion criteria:
• participants who received intravitreal treatment at another centre
• additional diseases that might have an effect on sight (age related macular
degeneration, uveitis, occlusion on the vein root or branch, hereditary macular diseases)
• PRP, grid or focal laser photocoagulation application or intraocular surgery within
6 months
• participants with acute ocular infection, stroke, myocardial infarction,
uncontrolled hypertension, pregnancy, renal failure and cataract formation during the
follow-up period were excluded from the study
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Interventions Intervention:
• bevacizumab (1.25 mg) n = 50 (50 eyes)
Comparator:
• ranibizumab (0.05 mg) n = 50 (50 eyes)
”Topical anesthetic drops were instilled, and a drape application and blepharostat attachment
were applied. Afterward, fornix lavage was applied using diluted povidone iodine. For Group
1, 1.25 mg (0.05 ml) of bevacizumab was injected into the eye that needed treatment, using
a 30 gauge needle; for Group 2, 0.05 mg (0.05 cc) of ranibizumab was injected into the
vitreous humor through the lower temporal quadrant, 3.5-4 mm behind the limbus. After
the treatment, all patients were treated with topical antibiotics four-times a day for 1 week.“
Page 140
Bevacizumab and ranibizumab injections were applied, with an interval of 1 month for
the first three doses. Retreatment criteria. “After the third dose of bevacizumab/ranibizumab
for patients in Groups 1 and 2, an additional three consecutive bevacizumab/ranibizumab
injections were applied if the central macular thickness was greater than 275 µm or if there
was an increase in BCVA of at least three letters compared with baseline. After the sixth
intravitreal injection, if the central macular thickness was greater than 275 mm or if there was
an increase in BCVA of at least two letters, additional intravitreal injections were performed
until stable visual acuity was obtained.” Page 140
Outcomes Outcomes:
• BCVA using the Snellen chart
• CRT assessed with OCT
• IOP assessed with applanation tonometry
Primary outcome not specified
Follow-up: monthly intervals after treatment to 12 months
Notes Dates participants enrolled: 2011 to 2014
Funding: not reported
Conflict of interest: “The authors have no relevant affiliations or financial involvement with
any organization or entity with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript. This includes employment, consultancies,
honoraria, stock ownership or options, expert testimony, grants or patents received or pending,
or royalties.” Page 142
Trial registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if participants, care providers or
outcome assessors were masked to treat-
ment method
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants, care providers or
outcome assessors were masked to treat-
ment method
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusion after randomisation: 15 partici-
pants excluded
“Patients with acute ocular infection (en-
dophthalmitis after intravitreal injection, n
= 3), stroke, myocardial infarction (n = 2),
uncontrolled hypertension (n = 4), pregnancy
(n = 1), renal failure (n = 1) and cataract
formation during follow-up period (n = 4)
were excluded from the study.” Page 140
Selective reporting (reporting bias) High risk We could not find a protocol and our pri-
mary outcomes were not reported
Other bias Low risk No other bias identified
Overall risk of bias High risk Most items at high or unclear risk of bias
Ishibashi 2014
Methods Allocation: randomised endpoint classification; safety/efficacy study intervention model;
parallel assignment Masking: double-masked
Participants n = 243; country: Japan
43 recruiting hospitals
Interventions Drug: pegaptanib sodium (n = 123)
Other: sham injection (n = 120)
Sex: female 113, male 130
Age: (SD) pegaptanib 65.9 (9.0), sham 66.0 (9.2) years
Inclusion criteria:
• Participants with macular oedema including central fovea diagnosed by
fluorescein angiography
• Thickening of the retina (≥ 250 µm)
• Corrected VA is 35-68 letters by ETDRS charts
Exclusion criteria:
• Participants who underwent focal/grid laser within 4 month before study started
• Atrophy, scar and fibrosis Including the centre of macula
• Underwent any eye surgery within 3 months before study started
• Participants with HbA1c 12.5% ≤ or with symptoms of uncontrolled diabetes
Outcomes • Number of participants who experience a ≥ 10 letter improvement of VA in
ETDRS chart from baseline to week 24
• Change from baseline in VA: double-masked phase (time frame: baseline, weeks
6, 12, 18, and 24); changes in VA were monitored through refraction and BCVA
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measurements using retro-illuminated, modified Ferris-Bailey ETDRS charts
• Number of participants underwent focal/grid laser, or vitrectomy: double-masked
phase (time frame: up to 24 weeks; included focal laser photocoagulation, grid laser
photocoagulation, and vitrectomy
• Number of participants who experience a ≥ 10 letter improvement of VA in
ETDRS chart from baseline at week 54: open phase (time frame: baseline and week
54); BCVA measurements performed using retro-illuminated, modified Ferris-Bailey
ETDRS charts
• Change from baseline in VA: open phase (time frame: baseline, weeks 30, 36, 42,
48 and 54); changes in VA were monitored through refraction and BCVA
measurements using retro-illuminated, modified Ferris-Bailey ETDRS charts
• Number of participants who underwent focal/grid laser, or vitrectomy: open
phase (time frame: weeks 24 to 54; included focal laser photocoagulation, grid laser
photocoagulation, and vitrectomy
Notes Completion Date: August 2012 (results also partly available on ClinicalTrials.gov, ac-
cessed on 5 December 2013)
Sponsor: Pfizer, two authors (Isogawa N, Esaka E) employee of Pfizer
Author contact not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) High risk “Pegaptanib sodium or a syringe of sham was
enclosed by aluminium bag, then the alu-
minium bag was put in a box. These boxes
were supplied to each hospitals. These box
could maintain masking. However, Pfizer
Japan Inc, which requested this drug trial,
made the mistake of allowing to open the box
for some hospitals during transportation, so it
was clear that it was possible not to ensure the
masking sufficiently.”
In 71 cases, there was the evidence of open-
ing the box of study drugs
In 172 cases, therewas no evidence of open-
ing the box.
In 50 cases, there was evidence of not open-
ing the box, so it was clear that masking is
sufficient
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treating physician and his/her assistants
were not masked and other staff (physi-
cian who did not directly give the drug,
orthoptist, clinical research coordinator,
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nurses, laboratory technician, administra-
tor for study drugs and other staffs) were
masked
Participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up: 6 pegaptanib, 4 sham
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
Overall risk of bias High risk Unclear or high risk for most items
Korobelnik 2014
Methods Parallel group RCT
Eyes: 862 eyes from 862 participants. One eye per participant. “For patients who met
eligibility criteria in both eyes, the eye with the worst BCVA was selected as the study eye. If
a patient had DME with similar BCVA in both eyes, the eye with the clearest media was
selected as the study eye. If the ocular media of the both eyes were similar in clarity, the patient’s
non-dominant eye (if identifiable) was selected as the study eye. If neither eye is dominant,
the right eye was designated as the study eye.” (Appendix 2)
Participants Country: 54 centres in USA (VISTA study, 446 participants) and 73 centres in Europe,
Japan, and Australia (VIVID study, 406 participants)
Number of people randomised: 852 (852 eyes)
Average age: 63 years
Sex: 42% women
Inclusion criteria:
• adults ≥ 18 years with type 1 or 2 diabetes mellitus
• central DMO involvement (defined as retinal thickening involving the 1 mm
central (OCT) subfield thickness)
• retinal thickness ≥ 300 µm (assessed by OCT)
• decrease in vision determined to be primarily the result of DME in the study eye
• BCVA ETDRS letter score of 73-24 (20/40-20/320) in the study eye
Exclusion criteria:
• laser photocoagulation (panretinal or macular) in the study eye within 90 days of
day 1
• more than 2 previous macular laser treatments in the study eye
• previous use of intraocular or periocular corticosteroids in the study eye within
120 days of day 1
• previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium,
bevacizumab, ranibizumab etc.) within 90 days of day 1
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• active PDR in the study eye, with the exception of inactive, regressed PDR
• uncontrolled diabetes mellitus, as defined by HbA1c > 12%
• only 1 functional eye even if that eye is otherwise eligible for the study
See paper for details
Interventions Intervention:
• aflibercept 2q4 n = 290 (290 eyes): aflibercept 2 mg every 4 weeks
• aflibercept 2q8 n = 286 (286 eyes): aflibercept 2 mg monthly for 5 months, then
every 8 weeks
Comparator
• laser photocoagulation and sham monthly injection = 286 (286 eyes)
“Eyes were randomised in a 1:1:1 ratio to receive either 2 mg IAI every 4 weeks (2q4), 2
mg IAI every 8 weeks after 5 initial monthly doses (from baseline to week 16) with sham
injections on non-treatment visits (2q8), or macular laser photocoagulation at baseline and
sham injections at every visit (laser control group)” Page 2
Outcomes Primary outcome:
• change in BCVA from baseline to week 52 (ETDRS chart at 4 m)
Secondary outcomes:
• proportion of eyes that gained at least 10 ETDRS letters in BCVA at week 52
compared with baseline
• proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with
baseline
• change in CRT (central subfield on OCT) from baseline to week 52
• proportion of eyes with a 2-step improvement in the ETDRS Diabetic
Retinopathy Severity Scale (DRSS) score
• change from baseline in the National Eye Institute Visual Function
Questionnaire-25 (NEI VFQ-25) near activities subscale score
• change from baseline in the NEI VFQ-25 distance activities subscale score
Follow-up: 52 weeks
Notes Date study conducted: May 2011 to June 2013
Funding: “The VISTA and VIVID studies were funded by Regeneron Pharmaceuticals, Inc.
, Tarrytown, NY and Bayer HealthCare, Berlin, Germany. The sponsors participated in the
design and conduct of the study, analysis of the data, and preparation of the manuscript.”
Conflict of interest: “Assistance with the study design and conduct and data analysis was
provided by Karen Chu, MS, and Xiaoping Zhu, PhD, Regeneron Pharmaceuticals, Inc.
(VISTA), and Jana Sachsinger, PhD, and Christiane Norenberg, MS, Bayer HealthCare
(VIVID). Editorial and administrative assistance to the authors was provided byHadiMoini,
PhD, and S. Balachandra Dass, PhD, Regeneron Pharmaceuticals, Inc.”Other conflicts of
interest reported in the paper.
Trial registration: VISTA NCT01363440, VIVID NCT01331681
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details available
60Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Korobelnik 2014 (Continued)
Allocation concealment (selection bias) Unclear risk No details available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A masked investigator assessed safety and ef-
ficacy and decided on the need for laser re-
treatment and additional treatment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Masked graders at independent central read-
ing centers evaluated OCT images for central
retinal thickness (center subfield))”
Incomplete outcome data (attrition bias)
All outcomes
Low risk About 93% participants completed 52-
week follow-up in each arm and causes of
loss to follow-upwere balanced across arms.
Slightly higher loss to follow-up in laser
group in VIVID - approx 15% compared
to 8% and 11% in aflibercept groups
Selective reporting (reporting bias) Unclear risk Some differences between trial registration
and final reports
Other bias Low risk No other bias identified
Overall risk of bias Low risk Though some items could not be fully as-
sessed, we believe randomisation and allo-
cation concealment should be adequate in
this multicentre trial aiming at drug regis-
tration, as per regulatory requirement
Lopez-Galvez 2014
Methods Multicentre, randomised, and open-label controlled trial
Participants Country: Spain
Number of people randomised: 83 participants (40 ranibizumab, 43 grid laser)
Average age: 63.5 (9.4) years.
Sex: 59.8% M
Inclusion criteria:
• ≥18 years old
• diabetes mellitus type 1/2
• altered VA due to DMO. The study eye must have had a BCVA = 78-25 letters,
and CRT = 250 µm
Interventions Participants were randomised to intravitreal injection of ranibizumab (0.5 mg) with 3
loading doses and then PRN treatment or to LP (ratio 1:1)
Outcomes Primary outcome:
• Differences in mean change in best corrected visual acuity (BCVA) of treatment
with ranibizumab 0.5 mg versus laser photocoagulation (LP) over 12 months in
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participants with DMO.
Secondary outcomes:
• % of participants with VA > 73 letters with ranibizumab (0.5 mg) versus laser
• Time and mean change in CRT by OCT with ranibizumab (0.5 mg) versus laser
• Monitoring and registry of all adverse events, serious adverse events, VA,
concomitant medications, ophthalmologic exams (including count of fingers and
movement of the hands), IOP, vital constants and analytical parameters
Notes Sponsor: Novartis
Trial Registration: NCT00901186
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information (abstract only; authors
contacted but no response yet)
Allocation concealment (selection bias) Unclear risk No information (abstract only; authors
contacted but no response yet)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information (abstract only; authors
contacted but no response yet)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information (abstract only; authors
contacted but no response yet)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 9 and 11 participants lost to follow-up for
ranibizumab and laser respectively
Selective reporting (reporting bias) Unclear risk No information (abstract only; authors
contacted but no response yet)
Other bias Unclear risk Insufficient information (abstract only; au-
thors contacted but no response yet)
Overall risk of bias Unclear risk Most items at unclear risk
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Methods Parallel group RCT
One eye per person, unclear how eye selected
“One eye per participant was included to avoid exposure of both eyes to the study drug. If
both eyes were eligible, the eye with worse visual acuity became the study eye. Subjects were
randomised with 2:1 probability to receive the intervention or standard care (ETDRSmacular
laser). The randomization list was created using permuted blocks of varying sizes, held by
the trial statistician and concealed from the researcher who enrolled, assessed, and allocated
treatment to participants.” (Page 961)
Participants Country: UK
Number of people randomised: 37 (37 eyes)
Average age: 66 years
Sex: 36% women
Inclusion criteria:
• adult participants with type 1 or 2 diabetes
• BCVA of 55-79 ETDRS letters (Snellen equivalent, 20/30-20/80) resulting from
centre-involving DMO , with Spectralis OCT (Heidelberg Engineering GmbH,
Heidelberg, Germany) central subfield thickness of 300 mm or more in the study eye
Exclusion criteria:
• uncontrolled glaucoma
• aphakia
• cataract precluding fundus photography
• external ocular infections
• previous anti-VEGF or laser treatment in the preceding 3 months in both eyes
• angiographic evidence of macular ischaemia defined as FAZ GLD of > 1000 mm
or severe perifoveal capillary loss
• other causes for macular oedema, for example after cataract surgery
• other causes of visual loss in the study eye; other diseases that may affect the
course of macular oedema in the study eye
• PDR, either active or treated within the previous 3 months
• systemic conditions that precluded trial enrolment included HbA1c > 11.0%;
past medical history of chronic renal failure requiring either dialysis or kidney
transplantation; BP > 170/100 mmHg; an arteriothrombotic event within 6 months
before randomisation, including myocardial infarction, acute congestive heart failure or
other cardiac event, and stroke or transient ischaemic attack
• planned surgery
• pregnancy or breastfeeding
Interventions Intervention:
• ranibizumab (0.5 mg) n = 25
Comparator:
• laser photocoagulation n = 12
“Subjects were randomised with 2:1 probability to receive the intervention or standard care
(ETDRS macular laser).” Page 961. “Intravitreal injections of ranibizumab (Lucentis, 0.5
mg in 0.05 mL solution for injection; Novartis Pharmaceuticals UK Ltd., Frimley, United
Kingdom) at baseline, 4 weeks, and 8 weeks then every 4 weeks as required according to
predefined retreatment criteria to amaximum of 12 injections. Retreatment occurred if BCVA
was reduced by 5 letters or more from maximum acuity or if OCT central subfield thickness
was more than 300 mm. Subjects in the laser arm received ETDRS macular laser at baseline
guided by fluorescein angiography,OCT, and clinical examination. Laser retreatment occurred
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at 12, 24, and 36 weeks if clinically significantmacular edemawas still present, in accordance
with standard clinical practice at the time; this was guided by the most recent fluorescein
angiogram, OCT, and clinical examination results” Page 961
Outcomes Outcomes:
• change in ETDRS BCVA
• retinal sensitivity
• colour vision
• electrophysiologic parameters
• macular thickness and volume
• change in ETDRS severity grade of diabetic retinopathy from fundus photographs
Follow-up: 48 weeks
Notes Date study conducted: November 2010 to July 2011
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Conflict of interest: “Dr Comyn receives travel support from Novartis. Dr Sivaprasad is a
consult for and receives payment for lectures or speaker bureaus and travel support fromNovar-
tis, Allergan, and Bayer, and receives payment for development of educational materials from
Allergan. Dr Holder is a consultant to Servier. Dr Patel receives grant support from Allergan,
Heidelberg United Kingdom, and Topcon United Kingdom and is a consultant to Bayer,
Novartis, and Thrombogenics. Dr Hykin is a consultant to and receives grant support from
Novartis, Allergan, and Bayer. Drs Comyn, Sivaprasad, Peto, Patel, Egan, Bainbridge, and
Hykin have received a proportion of their funding from the Department of Health’s National
Institute for Health Research Biomedical Research Centre for Ophthalmology at Moorfields
Eye Hospital and University College London, Institute of Ophthalmology. Dr Bainbridge is
supported by a National Institute for Health Research Professorship. Supported by an unre-
stricted research grant from Novartis and the National Institute for Health Research Biomed-
ical Research Centre based at Moorfields Eye Hospital National Health Service Foundation
Trust and University College London Institute of Ophthalmology.” Page 970
Trial registration: NCT01223612
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list was created using
permuted blocks of varying sizes, held by the
trial statistician and concealed from the re-
searcher who enrolled, assessed, and allocated
treatment to participants.” Page 96
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No sham procedure
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The microperimetry and electrophysiologic
assessors were masked to the patient treatment
arm. Evaluation of OCT scans, fundus pho-
tographs and fluorescein angiograms was per-
formed by masked Reading Centre graders.
The protocol states that the visual acuity asses-
sors were also masked to the patient treatment
arm but due to a protocol deviation they had
access to the source notes and were potentially
unmasked.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 22/25 (88%) of anti-VEGF group com-
pared to 11/12 (92%) laser group followed
up
Selective reporting (reporting bias) Unclear risk Unclear risk
Other bias Low risk No other source of bias identified
Overall risk of bias Unclear risk High or unclear risk of bias for nearly half
the items
Macugen 2005
Methods Parallel group RCT
One eye per person, chosen by participant and physician. In 81% of cases the eye with
the worse VA was chosen
Participants Country: USA
Number of people randomised: 172 (172 eyes)
Average age: 62 years (range 27 to 89)
Sex: 49% women
Inclusion criteria:
• 18 years or older
• diabetes
(study eyes)
• macular oedema involving the centre of the macula demonstrated on OCT with
corresponding leakage from microaneurysms, retinal telangiectasis, or both on
fluorescein angiography
• an area of retinal thickening of at least half a disc area involving the central macula
as confirmed by graders at an independent fundus photograph and angiogram reading
center (University of Wisconsin, Madison, Wisconsin)
• clear ocular media and adequate pupillary dilation to permit good stereoscopic
fundus photographs
(participants)
• BCVA letter scores between 68-25 inclusive (approximate Snellen equivalent, 20/
50-20/320) in the study eye and at least 35 (20/100 or better) in the fellow eye
• IOP ≤ 23 mmHg
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• assessment by the treating ophthalmologist that focal photocoagulation could be
deferred safely for 16 weeks
• an electrocardiogram that demonstrated no abnormalities judged to be clinically
relevant and serological test results that suggested no clinically meaningful
haematological, liver, or renal abnormalities
• women enrolling in the study were required to be postmenopausal for 12 months
before the study, surgically sterile, or not pregnant and on 2 forms of effective
contraception
Exclusion criteria:
• history of PRP or focal photocoagulation
• neodymium:yttrium-aluminum-garnet laser or peripheral retinal cryoablation
within the previous 6 months
• any abnormality thought likely to confound VA assessments or fundus
photography, including cataract; vitreoretinal traction within 1 disc diameter of the
fovea confirmed either clinically or on OCT
• vitreous incarceration in a previous wound or incision
• any retinal vein occlusion involving the macula; and atrophy/scarring/fibrosis or
hard exudates involving the centre of the macula that would preclude improvement in
VA
• a history of any intraocular surgery within the previous 12 months, myopia of ≥
8 dioptres, axial length of ≥ 25 mm, and the likelihood of requiring either scatter
(panretinal) photocoagulation within the ensuing 9 months or cataract surgery within
12 months
• active ocular or periocular infection
• previous therapeutic radiation to the eye, head, or neck
• any treatment with an investigational agent for any condition in the 60 days
before enrolment. Known serious allergies to fluorescein dye
• glycosylated haemoglobin (GHb) levels of ≥ 13%
• 3 episodes of severe hypoglycaemia within 3 months of study entry
• 2 episodes of ketoacidosis within 1 year of baseline
• any episode of ketoacidosis within 3 months of baseline
• evidence of severe cardiac disease
• clinically significant peripheral vascular disease (previous surgery, amputation, or
symptoms of claudication)
• uncontrolled hypertension (treated systolic BP 155 or diastolic BP 95), or stroke
within the preceding 12 months
Interventions Intervention:
• pegaptanib (0.3 mg, 1 mg, or 3 mg) n = 130 (130 eyes)
Comparator:
• sham injection n = 42 (42 eyes)
“Intravitreous pegaptanib or sham injections were administered at entry, week 6, and week
12, for a minimum of 3 injections. Thereafter, additional injections were administered every
6 weeks at the discretion of investigators if judged indicated, to a maximum of 6 injections
up to week 30. [...] Pegaptanib was formulated for intravitreous injection at 0.3 mg/90 µl,
1 mg/90 µl, and 3 mg/90 µl concentrations in preservative-free phosphate-buffered saline
(pH 5-7). Pegaptanib was packaged in sterile, single-use, United States Pharmacopeia type
1 graduated glass 1-ml syringes with preattached 27-gauge needles” Page 1748
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Outcomes Outcomes:
• BCVA (measured using ETDRS chart)
• CRT on OCT
• change in retinal thickness derived by comparing measurements at baseline with
those at week 36 or nal examination if before week 36
• focal photocoagulation applied at week 12 or later
• size of the area of retinal thickness measured by photography
• macular capillary leakage and cystoid spaces
• adverse events
• laboratory test abnormalities
Follow-up: 36 weeks
Notes Dates participants enrolled: not reported, study published 2005
Funding:“The study was sponsored by Eyetech Pharmaceuticals, Inc., New York, New York,
and Pfizer Inc., New York, New York.” Page 1747
Conflict of interest: not reported
Trial registration: NCT00040313
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were allocated [...] by a dynamic
minimization procedure using a stochastic
treatment allocation algorithm based on the
variance method. Randomization was strati-
fied by study site, size of the thickened retina
area [...] and baseline VA [...]”. Page 1748
Allocation concealment (selection bias) Low risk “An independent fundus photograph and an-
giogram reading center confirmed eligibility
and appropriate retinal thickness classifica-
tion both for study entry and for randomiza-
tion and stratification using baseline fluores-
cein angiography and OCT.” Page 1748
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study subjects receiving sham or study med-
ication were treated identically in all regards,
including ocular antisepsis procedures and
subconjunctival anesthetic, except that sub-
jects receiving active treatment had pegap-
tanib injected into the vitreous, whereas those
receiving sham had a needleless syringe pressed
against the conjunctiva and sclera. The in-
jection procedure prevented subjects from see-
ing the syringe and needle, to minimize the
risk of unmasking. In all but 3 subjects, injec-
tion was administered by a staff member other
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than the study ophthalmologist responsible for
all other aspects of the protocol, to maintain
investigator masking.” Page 1748
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Study subjects receiving sham or study med-
ication were treated identically in all regards,
including ocular antisepsis procedures and
subconjunctival anesthetic, except that sub-
jects receiving active treatment had pegap-
tanib injected into the vitreous, whereas those
receiving sham had a needleless syringe pressed
against the conjunctiva and sclera. The in-
jection procedure prevented subjects from see-
ing the syringe and needle, to minimize the
risk of unmasking. In all but 3 subjects, in-
jection was administered by a staff member
other than the study ophthalmologist respon-
sible for all other aspects of the protocol, to
maintain investigator masking. Visual acuity
was determined by a separate VA examiner
masked to treatment.” Page 1748
“At baseline and at each study visit thereafter,
refraction and VAwere determined andOCT
was performed by certified examiners masked
both to randomization and to findings of the
previous measurement.” Page 1749
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine participants were discontinued from
the study before week 36. None in pegap-
tanib groups 0.3 mg and 1 mg, 3 in pe-
gaptanib 3 mg group (3 mg subgroup: 2
participants by request at weeks 12 and 16
and 1 by other reason at week 1), 6 in sham
group (5 participants by request at weeks
6, 11, 18, 30, and 33 and 1 due to death at
week 8)
Selective reporting (reporting bias) Low risk The study protocol is available and all (pri-
mary and secondary) outcomes that are of
interest in the study have been reported in
the pre-specied way
Other bias Low risk No other source of bias identified
Overall risk of bias Low risk Low risk of bias for all items
68Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Macugen 2011
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: Australia, Europe, India, North America, and South America
Number of people randomised: 288 (288 eyes)
Average age: 62 years (20 to 83)
Sex: 43% women
Inclusion criteria:
• 18 years or older
• diabetes
• DMO involving the centre of the macula not associated with ischaemia
(study eye)
• foveal thickness of ≥ 250 µm (centre point thickness measured on OCT)
• BCVA with a letter score of 65-35 (20/50-20/200 Snellen equivalents)
• IOP ≤ 21 mmHg
• clear ocular media and adequate pupillary dilation to allow good quality
stereoscopic fundus photography
• focal or grid laser photocoagulation could be deferred for 18 weeks in the opinion
of the treating ophthalmologist
Exclusion criteria:
• yttrium-aluminum-garnet laser, peripheral retinal cryoablation, laser retinopexy
for retinal tears, or focal or grid photocoagulation within the prior 16 weeks or scatter
PRP 6 months before baseline or likely to be needed within 9 months
• macular ischaemia if a nonperfusion area of > 1 disc area involving the foveal
avascular zone (2 quadrants centred around the FAZ)
Interventions Intervention:
• pegaptanib sodium (0.3 mg) n = 145 (145 eyes)
Comparator:
• sham injection n = 143 (143 eyes)
Participants received pegaptanib 0.3 mg or sham injections every 6 weeks in year 1
(total 9 injections) and could receive focal/grid photocoagulation beginning at week 18.
During year 2, participants received injections as often as every 6 weeks according to
pre-specified criteria
Outcomes Primary outcome:
• 10-letter (2-line) improvement from baseline at 12 months (ETDRS chart)
Secondary outcomes: (at 12 and 24 months unless otherwise specified)
• 10-letter improvement from baseline at 24 months
• changes from baseline in mean VA
• 15-letter (3-line) improvement in VA
• change in degree of retinopathy of 2 steps based on the 12-step scale of retinopathy
• decrease in retinal thickness at the centre point by 25% and 50%
• focal or grid laser
• change in NEI VFQ-25 and EQ-5D
Follow-up: 12 and 24 months
Notes Dates participants enrolled: September 2005 to July 2009
Funding:“Sponsored by Pfizer Inc, New York, New York. The sponsor participated in the
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design of the study, in the management, analysis, and interpretation of the data, and in the
preparation and review of the manuscript.” Page 12
Conflict of interest: The authors were employees of Pfizer, the sponsor
Trial registration: NCT00605280
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[...] subjects were centrally allocated to re-
ceive either pegaptanib 0.3 mg or sham in-
jections (1:1) using a dynamic minimization
procedure stratified by the site, hemoglobin
A1c (<7.6% vs >=7.6%), systolic blood pres-
sure (<140 vs >=140mmHg), diastolic blood
pressure (80 vs 80 mmHg), and baseline
BCVA (<54 vs >=54 letters); the dynamic
minimization used a stochastic treatment al-
location algorithm based on the variance
method.” Page 3
Allocation concealment (selection bias) Low risk “...subjects were centrally allocated...” Page 3
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To maintain masking, the intravitreal pro-
cedure was identical between the sham and
comparator arms, with the difference lying
only in the application of an empty barrel of
a needleless syringe in the sham procedure de-
signed to mimic the intravitreal injection.”
Page 3
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Throughout the study, BCVA was measured
at 4 m by the study refractionist/ophthalmol-
ogist, who was masked to the subject’s treat-
ment and to the subject’s previous visual acu-
ity (VA) assessments”. Page 3
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk At 1 year 116/144 (81%) pegaptanib-
treated participants and 114/142 (80%)
controls completed the 54-week visit. Ad-
verse events led to discontinuation of 5
treated and 7 control participants
At 2 years 66 participants in each group
completed the 102 week visit
ITT analysis with LOCF was used leading
to the analysis of 133 treated and 127 con-
trol participants
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Selective reporting (reporting bias) Low risk All primary outcomes reported
Other bias Low risk No other biases identified
Overall risk of bias Low risk Low risk of bias for most items
Nepomuceno 2013
Methods Parallel group RCT and within-person study
People randomised to treatment but two eyes sometimes included. If two eyes included
then fellow eye randomised to other treatment
Participants Country: Brazil
Number of people randomised: 48 (63 eyes)
Average age 64 years
Sex: 55% women (based on eyes included in analyses)
Inclusion criteria:
• centre-involved DMO defined as a central subfield thickness > 300 mm on
Spectral Domain-OCT, despite at least 1 session of macular laser photocoagulation
performed at least 3 months previously
• BCVA ETDRS measurement between 0.3 logMAR (Snellen equivalent: 20/40)
and 1.6 logMAR (Snellen equivalent: 20/800)
Exclusion criteria:
• vitreomacular traction on SD-OCT
• PDR needing PRP or anticipated to need PRP in the next 12 months
• macular capillary dropout on fluorescein angiography
• history of glaucoma or ocular hypertension (defined as an intraocular pressure >
22 mmHg)
• an ocular condition (other than diabetes) that, in the opinion of the investigator,
might affect macular oedema or alter VA during the course of the study (e.g. retinal
vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc)
• systemic corticosteroid therapy
• any condition that, in the opinion of the investigator, might preclude follow-up
throughout the study period
Interventions Intervention:
• bevacizumab (1.5 mg) n = 32 eyes
Comparator:
• ranibizumab (0.5 mg) n = 28 eyes
“Retreatment with the originally assigned treatment was performedmonthly if central subfield
thickness was greater than 275 mm.”
“If, after 3 consecutive injections, there was not a reduction in central subfield thickness of at
least 10%or an increase in BCVA of at least 5 letters comparedwith baseline, the patient could,
at the discretion of the treating ophthalmologist, receive focal/grid laser photocoagulation or
continue to receive the same intravitreal medication for an additional 3 consecutive visits.”
Page 503
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Outcomes Outcomes reported in publication (primary outcome not specified):
• BCVA (standardised ETDRS refraction protocol)
• retinal thickness (using OCT)
On ClinicalTrials.gov following outcomes listed:
• Primary outcome measures: CSFT change (time frame: monthly from baseline to
week 48; not designated as a safety issue); CSFT measured with SD-OCT
• Secondary outcome measures: BCVA change (time frame: monthly from baseline
to week 48; not designated as a safety issue); BCVA using ETDRS charts
Notes Dates participants enrolled: July 2010 to August 2011
Funding:“Fundacao de Amparo a‘ Pesquisa do Estado de Sao Paulo (FAPESP), grant number
2010/013368; and Fundacao Apoioao Ensino, Pesquisa e Assistencia (FAEPA) do Hospital
das Cl nicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo.”
Conflict of interest: Rodrigo Jorge received travel support from Novartis to attend the
2012 American Society of Retina Specialists (ASRS) meeting
Trial registration: NCT01487629
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “.... received the randomised treatment ac-
cording to a computer-generated sequence”
Page 503
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Examiners (E.T., F.P.P.A., R.P.) weremasked
regarding which treatment drug was used for
each patient. Throughout the study, a single
masked, certified examiner performed BCVA
measurements prior to any other study proce-
dure. Patients, OCT technicians, and fundus
photographers were also masked to treatment
group”. Page 504
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Examiners (E.T., F.P.P.A., R.P.) weremasked
regarding which treatment drug was used for
each patient. Throughout the study, a single
masked, certified examiner performed BCVA
measurements prior to any other study proce-
dure. Patients, OCT technicians, and fundus
photographers were also masked to treatment
group”. Page 504
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The 3 patients excluded from the outcomes
analyses consisted of 1 patient in the IV
ranibizumab group who developed Staphylo-
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coccus aureus endophthalmitis after the first
injection (this patient chose to exit the study
and he did not complete any further study
visits); 1 patient in the IV bevacizumab
group who developed advanced posterior sub-
capsular cataract, which precluded adequate
SDOCT images, after the ninth follow-up
visit; and 1 patient from the IV bevacizumab
groupwho missed 3 consecutive follow-up vis-
its.” Page 504
Selective reporting (reporting bias) Low risk Both outcomes listed on trial registration
reported
Other bias Unclear risk Fifteen out of 48 participants with both
eyes in analyses
Overall risk of bias Low risk Low risk of bias for most items
READ2 2009
Methods Parallel group RCT
One eye per person; if both eyes were eligible, the eye with the greater centre subfield
thickness was entered
Participants Country: USA
Number of people randomised: 126 (126 eyes)
Average age: 62 years
Sex: 59% women
Inclusion criteria:
• 18 years and older
• diabetes
• DMO
• reduction in VA between 20/40-20/320
• centre subfield thickness measured by OCT ≥ 250 µm
• HbA1c ≥ 6% within 12 months before randomisation
• no potential contributing causes to reduced VA other than DMO
• reasonable expectation that scatter laser photocoagulation would not be required
for the next 6 months
Exclusion criteria:
• received focal/grid laser treatment within 3 months
• intraocular injection of steroid within 3 months
• intraocular injection of a VEGF antagonist within 2 months
Interventions Intervention:
• ranibizumab 0.5 mg n = 42 (42 eyes)
• ranibizumab 0.5 mg plus laser photocoagulation n = 42 (42 eyes)
Comparator:
• laser photocoagulation n = 42 (42 eyes)
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Participantswere randomised 1:1:1 to receive 0.5mg ranibizumab at baseline andmonths
1, 3, and 5 (group 1), focal or grid laser photocoagulation at baseline and month 3 if
needed (group 2), or a combination of 0.5 mg ranibizumab and focal or grid laser at
baseline and month 3 (group 3). Starting at month 6, if retreatment criteria were met,
all participants could be treated with ranibizumab
Duration: primary outcome at 6 months, extension to 24 and 36 months
Outcomes As reported in publications:
Primary outcome:
• change in BCVA between baseline and follow-up
Secondary outcomes:
• change in BCVA between baseline and month 24
• 3 or more lines or 2 or more lines improvement at month 24
• change in foveal thickness between baseline and month 24
• elimination of 90% or 50% excess foveal thickness
On ClinicalTrials.gov
“Primary Outcome Measures: Improvement in vision of 15 or more letters, or achieve a final
vision of 50 letters (20/25) or better if baseline VA was 40 letters (20/40) [Time Frame: 6
mos, 12 mos and 24 mos. Study Extended to 36 mos.] [Designated as safety issue: Yes]
SecondaryOutcomeMeasures: Several outcomes related toOCTmeasurements and fluorescein
angiography. [TimeFrame: 6mos, 12mos and 24mos, study extended to 36mos.] [Designated
as safety issue: Yes]”
Follow-up: 6 months and 24 months.
Notes Dates participants enrolled: not reported
Funding: “Sponsored by the Juvenile Diabetes Research Foundation and Genentech, Inc.”
Conflict of interest: “QDN and PAC have served as members of Expert Panels for Genentech,
Inc. without receiving an honorarium during the time of this study, but JHU has recently
negotiated a contract through which JHU receives compensation. QDN is a consultant for
Bausch and Lomb and has research support from Genentech, Inc., and Regeneron, Inc.
PAC serves on the data and safety monitoring committee for a phase III trial sponsored
by Regeneron, Inc., and has research support from Genentech, Alimera, and CoMentis for
diabetic macular edema trials. Diana Do receives research support from Genentech. These
activities are being managed by the Conflict of Interest Committee of the Johns Hopkins
University School of Medicine. JSH is a consultant for Genentech, Alcon, Allergan, Bausch
and Lomb, Eyemaginations, Fovea, Genzyme, Heidelburg, IScience, ISTA, Jerini, LPath,
NeoVista, Nodal Vision, Novagali, Novartis, Optherion, Oxigene, Paloma, Pfizer, Regeneron,
Resolvyx, Schering Plough, Scyfix, andVisionCare and has received honoraria fromGenentech,
Heidelberg, Jerini, NeoVista, Optimedica, and Regeneron. JL has received honoraria from
Genentech. DB is a consultant and has received honoraria from Genentech, Novartis, Alcon,
Allergan, and Pfizer. PA is a consultant for Genentech” Page 2181
Trial registration: NCT00407381
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Unclear method of sequence generation
and information could not be obtained
from the authors
Allocation concealment (selection bias) Unclear risk Unclear method of allocation concealment
and information could not be obtained
from the authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unclear ifmasked andwhowasmasked and
information could not be obtained from
the authors
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unclear ifmasked andwhowasmasked and
information could not be obtained from
the authors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants randomised to each group: 33
ranibizumab, 34 ranibizumab + laser, 34
laser
Completed participants at 1 year: 29, 29,
30 (85% to 88%)
Completed participants at 2 years: 24, 26,
24 (71% to 76%)
Causes ofmissingdatawere balanced across
groups
Selective reporting (reporting bias) High risk The primary outcome differed in the pro-
tocol and the final report
Other bias Low risk No other source of bias identified
Overall risk of bias High risk High risk of bias for nearly half the items
and unclear risk for the others
RELATION 2012
Methods Parallel group RCT
One eye per person, eye with worse VA selected
Participants Country: Germany
Number of people randomised: 128 (128 eyes)
Average age: 64 years (range 31 to 79)
Sex: 37% women
Inclusion criteria:
• 18 years or older
• diabetes
• visual impairment (BCVA between 78-39 letters, testing distance 4 m) due to
focal or diffuse DMO in at least one eye eligible for laser treatment in the opinion of
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the investigator
Exclusion criteria:
• other eye diseases and conditions that might affect VA
• other eye and systemic treatments
• pregnancy or possibility of being pregnant
• Inability to comply with follow-up
Interventions Intervention:
• ranibizumab (0.5 mg) plus laser n = 85 (85 eyes)
• laser plus sham injection n = 43 (43 eyes)
Ranibizumabwas applied at baseline, 30, 60, 90 days and reapplied at intervals no shorter
than 28 days and laser was applied at baseline and re-applied if needed at intervals no
shorter than 3 months
Outcomes Primary outcome:
• mean change in BCVA from baseline to month 12 (ETDRS chart, 4 m)
Secondary outcomes:
• adverse events
Notes Dates participants enrolled: July 2010 to May 2011, terminated early
Funding: Novartis
Conflict of interest: Novartis
Trial registration: NCT01131585
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-masked, but no details
given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-masked, but no details
given
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing
data: combined laser and ranibizumab: 7/
85 (7%); laser 11/43 (26%)
Selective reporting (reporting bias) High risk Only mean change of VA and harms re-
ported
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Other bias Low risk Study terminated early due to European
Medicine Agency approval of ranibizumab
for DMO but this is independent of effect
estimates
Overall risk of bias Unclear risk Unclear risk of bias for most items
RESOLVE 2010
Methods Parallel group RCT
One eye per person, eye with worse VA selected
Participants Country: unclear exactly where conducted. Investigators from Australia, Denmark, Aus-
tria, France, Germany, Italy, Korea, Portugal, Spain, Switzerland, UK
Number of people randomised: 151 (151 eyes)
Average age: 64 years (range 32 to 85)
Sex: 46% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• stable HbA1c levels (≤ 12%)
• DMO with centre involvement in at least one eye
(study eye)
• CRT ≥ 300 µm (Stratus Zeiss Meditec)
• BCVA score between 73-39 letters inclusively, using ETDRS charts at a testing
distance of 4 m (approximate Snellen equivalent of 20/40-20/160)
• decreased vision attributed to foveal thickening from DMO, that was not
explained by any other causes in the opinion of the investigator
• laser photocoagulation, additional or first treatment, could be withheld for at least
3 months after randomisation
Exclusion criteria:
• PRP (focal peripheral laser photocoagulation) performed within 6 months prior
to study entry. Grid/central laser photocoagulation was excluded except for participants
with only mild laser burns at least 1000 µm from the centre of the fovea performed
more than 6 months before the trial commenced
• PDR in the study eye, with the exception of tufts of neovascularization < 1 disc
area with no vitreous haemorrhage. As well as those with area of retinal ischaemia ≥
500 µm and located ≤ 500 µm from the centre of the macula of the study eye as
assessed by fluorescein angiography at visit 1 and confirmed by a central reading centre
• participants with unstable medical conditions such as poor glycaemic or BP
control
• participants with hypertension for whom a change in antihypertensive treatment
was initiated within 2 months preceding start of trial were not enrolled unless BP was
maintained below 160/100 mmHg for at least 1 month prior to the first day of the trial
by antihypertensive treatment
• history of treatment with systemic corticosteroids within 4 months prior to
randomisation or topical, rectal or inhaled corticosteroids in current use more than 2
times per week
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• previous participation in a study on antiangiogenic drugs
• ocular disorders and history of any condition that might confound the
interpretation of study results or might render participant at high risk for treatment
complications
• ocular inflammation in either eye or history of cataract surgery in the study eye
within 6 months before study initiation
• pre-menopausal women not using adequate contraception and pregnant or
nursing women
Interventions Intervention:
• ranibizumab (0.3 mg or 0.5 mg) n = 102 (102 eyes)
Comparator:
• sham injection n = 49 (49 eyes)
Outcomes Primary outcome:
• mean change in BCVA from baseline at 1 month and 12 months
Secondary outcomes:
• mean change in BCVA and CRT from baseline at 12 months
• categorised BCVA outcome
• safety
Notes Dates participants enrolled: not reported
Funding: Novartis
Conflict of interest: authors served on advisory boards forNovartis and receivedhonoraria
and travel and accommodation payments; Novartis employees assisted with the analysis,
interpretation and writing
Trial registration:NCT00284050
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomised 1:1:1 to
either ranibizumab (0.3 mg or 0.5 mg) or
sham treatment according to a computer-gen-
erated randomised allocation schedule” On-
line appendix page 1
Allocation concealment (selection bias) Low risk “...allocation schedule (kept at a secure site
and accessible only to the injecting physician”
Online appendix page 1
“Based on the patient strata the injecting
physician would take the treatment allocation
card and tear-off the cover and follow instruc-
tions to choose vial from the box as indicated
(3 boxes, randomisation block size 3). The
randomisation data were kept strictly confi-
dential until database
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lock; not accessible to anyone involved in the
study with the exception of injecting physician
(s) and drug accountability monitor.”Online
appendix page 1
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Sham injection for masking participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Masking was maintained through appoint-
ment of a minimum of 2 investigators at each
study site; unmasked injecting physician and a
masked evaluating physician (roles could not
be switched).” Online appendix page 1
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who completed the trial at 1
year: 92/102 ranibizumab and40/49 sham.
Causes of missingness were balanced
ITT analysis with LOCF was used
Selective reporting (reporting bias) Low risk We could not find a protocol, but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other source of bias identified
Overall risk of bias Low risk Low risk of bias for most items
RESPOND 2013
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: Canada
Number of people randomised: 239 (239 eyes)
Average age: 62 years (range 26 to 87)
Sex: 40% women
Inclusion criteria:
• 18 years or older
• stable type 1 or type 2 diabetes with HbA1c ≤ 10%
• visual impairment due to focal or diffuse DMO in at least one eye eligible for laser
treatment in the opinion of the investigator
Exclusion criteria:
• active conditions in study eye that could prevent improvement in VA
• active eye infection or inflammation
• history of stroke, renal failure or active hypertension
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Interventions Intervention:
• ranibizumab (0.5 mg) n = 80 (80 eyes)
• ranibizumab (0.5 mg) plus laser n = 78 (78 eyes)
Comparator:
• laser n = 81 (81 eyes)
For combination and monotherapy, ranibizumab was administered as 3 monthly injec-
tions, then 10 months PRN injections given/withheld based on DME stability criteria.
Laser was administered according to ETDRS guidelines at intervals of > 3 months
Outcomes On ClinicalTrials.gov
Primary Outcome Measures: Measure: mean change from baseline in Best Correct Visual
Acuity (BCVA) [Time Frame: 12 months] [Designated as safety issue: No]
Secondary Outcome Measures: Measure: number of patients with visual acuity above 73
letters [Time Frame: 3, 6, 9 and 12 months]
Measure: number of patients with improvement in BCVA [Time Frame: 3, 6, 9 and 12
months]
Measure: time course of BCVA changes [Time Frame: 3, 6, 9 and 12 months]
Measure: change in central retinal thickness and other anatomical changes [Time Frame: 3,
6, 9 and 12 months]
Measure: 15-letter (3-line) gain in BCVA [Time Frame: 3, 6, 9 and 12 months]
Notes Dates participants enrolled: July 2010 to March 2013
Funding: Novartis
Conflict of interest: authors not reported since the study was obtained as a Novartis
public report
Trial registration: NCT01135914
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified by centre and
followed a permutated block size of 6.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unmasked study (described as open-label)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unmasked study (described as open-label)
Incomplete outcome data (attrition bias)
All outcomes
High risk More missing data in the laser arm (27%)
, mainly due to lack of efficacy, compared
to the 2 ranibizumab arms (5% to 6%)
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Selective reporting (reporting bias) Low risk VA, OCT data and harms adequately re-
ported (only loss of vision not reported)
Other bias Low risk No other bias identified
Overall risk of bias High risk High risk of bias for most items
RESTORE 2011
Methods Parallel group RCT
One eye per person, eye with worse VA selected unless other eye more suitable for
treatment
Participants Country: 10 European countries, Australia, Canada, Turkey
Number of people randomised: 345 (345 eyes)
Average age: 63 years
Sex: 42% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus (according to the American Diabetes Association or World
Health Organization guidelines)
• HbA1c ≤ 10%
• visual impairment due to DMO
• stable medication for the management of diabetes within 3 months before
randomisation and expected to remain stable during the study
• visual impairment due to focal or diffuse DMO in at least 1 eye that was eligible
for laser treatment in the opinion of the investigator
• BCVA letter score between 78-39, both inclusive, based on ETDRS-like VA
testing charts administered at a starting distance of 4 m (approximate Snellen
equivalent 20/32-20/160)
• decreased vision due to DMO and not other causes, in the investigator’s opinion
(at visit 1)
Exclusion criteria:
• concomitant conditions in the study eye that could prevent the improvement in
VA on the study treatment in the investigator’s opinion
• active intraocular inflammation or infection in either eye
• uncontrolled glaucoma in either eye (e.g. IOP > 24 mmHg on medication, or
from the investigator’s judgement)
• laser PRP (within 6 months) or focal/grid laser photocoagulation (within 3
months) before study entry
• treatment with antiangiogenic drugs in the study eye within 3 months before
randomisation
• history of stroke
• systolic BP > 160 mmHg or diastolic BP > 100 mmHg
• untreated hypertension
• change in antihypertensive treatment within 3 months preceding baseline
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Interventions Intervention:
• ranibizumab (0.5 mg) plus sham laser n = 116 (116 eyes)
• ranibizumab (0.5 mg) plus laser n = 118 (118 eyes)
Comparator
• laser treatment plus sham injections n = 111 (111 eyes)
Outcomes Primary outcome:
• mean average change in BCVA from baseline over 12 months
Secondary outcomes:
• VA improvement
• BCVA letter score 73 (20/40 Snellen equivalent) at month 12
• mean change in BCVA letter score
• mean change in central retinal (subfield) thickness
• patient-reported outcomes
• safety
Follow-up: 12 months
Notes Dates participants enrolled: not reported
Funding: Novartis
Conflict of interest: authors reported financial support of Novartis or were Novartis
employees
Trial registration: NCT00906464
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was produced by, or un-
der the responsibility of, Novartis Drug Sup-
plyManagement using a validated system that
automated the random assignment of treat-
ment arms to randomization numbers in the
specified ratio.” Appendix 1
Allocation concealment (selection bias) Low risk Central randomisation using an electronic
Case Report Form after each participant
was included by study investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The masked BCVA assessor evaluated the vi-
sual acuity of the patient and provided the
results to the evaluating investigator who also
was masked to the treatment assignment. The
evaluating investigator was responsible for all
other aspects of the study, excluding the injec-
tion procedures. Based on all the performed
clinical assessments and the visual acuity (VA)
results received from the BCVA assessor, the
evaluating investigator had to decide on the
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treatment requirements for the patient each
month and communicated this decision to the
treating investigator. The treating investiga-
tor was unmasked to the treatment assignment
and performed all injections or laser treat-
ment as well as the corresponding sham treat-
ments. He/she was required not be involved
in any other aspect of the study and not to
divulge the patient’s treatment assignment to
anyone. Once the designated roles were de-
termined, the roles could not be switched at
any time during the conduct of the study. Ev-
ery effort was made to limit the number of
unmasked study personnel to ensure the in-
tegrity of this masked study. An independent
review and standardized grading of fundus
photography, fluorescein angiography, and op-
tical coherence tomography (OCT) images for
the patients screened and enrolled in the study
was performed at a central reading center that
did not have access to any other data of the
patients.” Appendix 1
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants randomised in each group
were: 116 ranibizumab, 118 ranibizumab
+ laser, 111 laser
At 1 year complete participants were 87.
9%, 87.3% and 88.3% respectively
There were 2 deaths in each of the 3 treat-
ment arms
Used ITT analysis with LOCF
Selective reporting (reporting bias) Low risk We could not find a protocol, but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other source of bias identified
Overall risk of bias Low risk Low risk of bias for most items
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Methods Parallel group RCT
One eye per person, eye with worse VA selected unless other eye more suitable for
treatment
Participants Country: Asian population from 52 centres across 6 countries, or regions: China, Hong
Kong, Japan, South Korea, Singapore, and Taiwan
Number of people randomised: 396 (396 eyes)
Average age: 61 years
Sex: 44% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus (according to the American Diabetes Association or World
Health Organization guidelines)
• HbA1c ≤ 10%
• visual impairment due to DMO
• stable medication for the management of diabetes within 3 months before
randomisation and expected to remain stable during the study
• visual impairment due to focal or diffuse DMO in at least 1 eye that was eligible
for laser treatment in the opinion of the investigator
• BCVA letter score between 78-39, both inclusive, based on ETDRS-like VA
testing charts administered at a starting distance of 4 m (approximate Snellen
equivalent 20/32-20/160)
• decreased vision due to DMO and not other causes, in the investigator’s opinion
(at visit 1)
Exclusion criteria:
• concomitant conditions in the study eye that could prevent the improvement in
VA on the study treatment in the investigator’s opinion
• active intraocular inflammation or infection in either eye
• uncontrolled glaucoma in either eye (e.g. IOP > 24 mmHg on medication, or
from the investigator’s judgement)
• laser PRP (within 6 months) or focal/grid laser photocoagulation (within 3
months) before study entry
• treatment with antiangiogenic drugs in the study eye within 3 months before
randomisation
• history of stroke
• systolic BP > 160 mmHg or diastolic BP > 100 mmHg
• untreated hypertension
• change in antihypertensive treatment within 3 months preceding baseline
Interventions “Patients were randomised in a 1:1:1 ratio to 1 of 3 treatment arms: intravitreal ranibizumab
0.5 mg injection + sham laser, intravitreal ranibizumab 0.5 mg injection + active laser, or
active laser + sham injections for 12 months” Page 1404
Number in each group: ranibizumab + sham laser (n = 133), ranibizumab + active laser
(n =132), or sham injection + active laser (n = 131)
Outcomes Primary outcome:
• mean average change in BCVA from baseline over 12 months
Secondary outcomes:
• several BCVA expressions
• mean change in central retinal (subfield) thickness
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• safety
Follow-up: 12 months
Notes Dates participants enrolled: not reported
Funding: Novartis
Conflict of interest: authors reported financial support of Novartis or were Novartis
employees
Trial registration: NCT00989989
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “AtVisit 2, all patients who fulfilled all the in-
clusion/exclusion criteria were given the low-
est available number on the randomization
list. This number assigned them to one of the
treatment arms. The investigator entered the
randomization number on the electronic case
report form. A randomization list was pro-
duced by, or under the responsibility of No-
vartis Drug Supply Management using a val-
idated system that automated the random as-
signment of treatment arms to randomization
numbers in the specified ratio”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To ensure successful masking in this double-
masked study, at the start of the study and
at each study site, the following site personnel
were required to demonstrate their role: BCVA
assessor and evaluating investigator (masked
to the treatment assignment) and treating in-
vestigator (unmasked to the treatment assign-
ment” Page 1404
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
High risk Higher proportion of loss to follow-up in
the laser group; this can decrease the benefit
with anti-VEGF (see below)
“Overall, 345 (87.1%) patients completed
the study. The proportion of patients
who discontinued the study was 7.5%
in the ranibizumab arm, 13.6% in the
ranibizumab active laser treatment arm, and
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17.6% in the laser treatment arm (Fig 2,
available at www.aaojournal.org). Adverse
events (range, 3.0%-6.8%) were the most
common reason for discontinuation across all
treatment arms (Fig 2, available atwww.aao-
journal.org). Unsatisfactory therapeutic effect
(n= 7 [5.3%]) was reported only in the laser
arm.” Page 1405
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias identified
Overall risk of bias Low risk Low risk for most items
RISE-RIDE
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: USA and South America
Number of people randomised: 759 (759 eyes)
Average age: 62 years
Sex: 43% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• decreased vision from DMO (study eye BCVA, 20/40-20/320 Snellen equivalent
using ETDRS testing)
• macular oedema (TD-OCT) central subfield thickness ≥ 275 µm
Exclusion criteria:
• prior vitreoretinal surgery
• recent history (within 3 months of screening) of panretinal or macular laser in the
study eye
• intraocular corticosteroids antiangiogenic drugs
• uncontrolled hypertension
• uncontrolled diabetes (HbA1c > 12%)
• recent (within 3 months) cerebrovascular accident, or myocardial infarction
Interventions Intervention:
• ranibizumab (0.3 mg or 0.5 mg) n = 244 (244 eyes)
Comparator:
• sham injection n = 122 (122 eyes)
“The median number of ranibizumab injections was 24. The mean number of macular
laser treatments over 24 months was 1.8 and 1.6 in the sham groups and 0.3 to 0.8 in
the ranibizumab groups. Substantially more sham-treated patients received macular laser
under the protocol-specied criteria or underwent panretinal photocoagulation for proliferative
diabetic retinopathy.” Page 5
86Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Outcomes Primary outcome:
• gain of 15 or more ETDRS letters in BCVA score from baseline at 24 months
(corresponding to 3 lines on the eye chart)
Secondary outcomes: (at 24 months)
• mean change from baseline BCVA score over time
• proportion of participants with BCVA Snellen equivalent of 20/40
• mean change from baseline BCVA score over time in participants with focal
oedema as assessed on fluorescein angiography
• proportion of participants losing 15 letters in BCVA score from baseline
• mean change from baseline in OCT CFT over time
• proportion of participants with a 3-step progression from baseline in ETDRS
retinopathy severity on fundus photography
• proportion of participants with resolution of leakage on FA
• mean number of macular laser treatments
Follow-up: 24 months
Notes Dates participants enrolled: June 2007 to January 2009
Funding: “This study was supported by Genentech Inc. Support for third-party writing assis-
tance by Ivo Stoilov, MD, CMPP, of Envision Scientific Solutions was provided by Genentech
Inc.” “The sponsor participated in the design and conduct of the study; collection, manage-
ment, analysis, and interpretation of the data; and preparation and review of the manuscript.
” Page 1121
Conflict of interest: “Dr Ip is a consultant/advisor for Eye Technology Ltd, Genentech Inc,
NicOx, Notal Vision, QLT Phototherapeutics Inc, Regeneron, and Sirion and has received
grant support from Allergan Inc. Drs Hopkins and Ehrlich and Ms Wong are employees of
Genentech Inc, a member of the Roche Group. Drs Hopkins and Ehrlich hold equity and/or
options in Roche.” Page 1121
Trial registration: RIDE NCT00473382 RISE NCT00473330
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified by study eye
BCVA (55 vs 55 ETDRS letters), baseline
HbA1c (<=8% vs >8%), priorDME therapy
in the study eye (yes vs no), and study site. Dy-
namic randomization was used to obtain ap-
proximately a 1:1:1 ratio among groups (Fig
1). Randomization was done via interactive
phone system. The sponsor developed the spec-
ifications for the randomization, and a third
party programmed and held the randomiza-
tion algorithm.” Page 3, Nguyen et al
Allocation concealment (selection bias) Low risk “Randomization was stratified by study eye
BCVA (55 vs 55 ETDRS letters), baseline
HbA1c (<=8% vs >8%), priorDME therapy
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in the study eye (yes vs no), and study site. Dy-
namic randomization was used to obtain ap-
proximately a 1:1:1 ratio among groups (Fig
1). Randomization was done via interactive
phone system. The sponsor developed the spec-
ifications for the randomization, and a third
party programmed and held the randomiza-
tion algorithm.” Page 3, Nguyen et al
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Ocular assessments, including the need for
macular laser, were made by evaluating
ophthalmologists masked to patients’ treat-
ment assignments. Study treatments were ad-
ministered by treating ophthalmologists un-
masked to treatment assignments but masked
to ranibizumab dose. To improve patient
masking, all patients received subconjuncti-
val anesthesia before sham or active injections
(performed as previously described).22 Study
site personnel (except treating physicians and
assistants), central reading center personnel,
and the sponsor and its agents (except drug ac-
countability monitors) were masked to treat-
ment assignment. Treating physicians were
masked to the assigned dose of ranibizumab.
” Page 3, Nguyen et al
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The 2-year study period was completed by
83.3% of participants in RISE and by 84.
6% in RIDE; causes of missingness not re-
ported
Selective reporting (reporting bias) Low risk All VA cut-offs and secondary outcomes
available at 2 years, although not at 1 year,
as pre-planned
Other bias Low risk No other bias identified
Overall risk of bias Low risk Low risk of bias for most items
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Soheilian 2007
Methods Parallel group RCT
One or two eyes per person, in bilateral cases unclear how the second eye allocated
Participants Country: Iran
Number of people randomised: 129 (150 eyes)
Average age: 61 years
Sex: 49% women
Inclusion criteria:
• clinically significant DMO based on ETDRS criteria
Exclusion criteria:
• previous PRP or focal laser photocoagulation
• prior intraocular surgery or injection
• history of glaucoma or ocular hypertension
• VA of 20/40 or better, or worse than 20/300
• presence of iris neovascularisation
• high-risk PDR
• significant media opacity
• monocularity
• pregnancy
• serum creatinine ≥ 3 mg/dL
• uncontrolled diabetes mellitus
Interventions Intervention:
• bevacizumab (1.25 mg) n = 50 eyes
Comparator:
• laser photocoagulation n = 50 eyes
Re-treatment was performed at 12-week intervals whenever indicated
There was another intervention arm which combined bevacizumab with triamcinolone,
but this is not included in this review (n = 50 eyes)
Outcomes Primary outcome:
• change in BCVA (logMAR) at week 24 (data available at 36 weeks)
Secondary outcomes:
• VA change
• CRT change assessed by OCT
• injection-related complications
Notes Dates participants enrolled: September 2005 to May 2007
Funding: “Supported by the Ophthalmic Research Center of Shahid Beheshti University
(MC) Tehran, Iran.” Page 1150
Conflict of interest: “The author(s) have no proprietary or commercial interest in any ma-
terials discussed in this article” Page 1150
Trial registration: NCT00370669
Risk of bias
Bias Authors’ judgement Support for judgement
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Soheilian 2007 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomization was performed using ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block length varied randomly (6, 12). Ran-
dom allocation sequence was performed by a
biostatistician. The detail of series was un-
known by the study investigators.” Page 2 So-
heilian 2009
Allocation concealment (selection bias) Low risk “Randomization was performed using ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block length varied randomly (6, 12). Ran-
dom allocation sequence was performed by a
biostatistician. The detail of series was un-
known by the study investigators.” Page 2 So-
heilian 2009
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A sham laser procedure (20 seconds) was per-
formed by aiming the laser beam on the mac-
ula for the eyes in the IVB and IVB/IVT
groups. In the MPC group, a sham injection
was done by a needleless syringe pressed against
the conjunctiva. To keep the masking process,
patients were prevented from seeing the sy-
ringes. All procedures were run by staff mem-
bers other than the study investigators to pre-
serve investigator masking. Best-corrected VA
measurement and OCT were performed by
certified examiners masked both to the ran-
domization and to the findings of previous
measurements.” Page 2-3 Soheilian 2009
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were 6 missing eyes out of 50 at 36
weeks in the IVB group and 12 out of 50
in the photocoagulation group and causes
were not clearly unrelated to VA outcome,
except for 2 deaths. In a subsequent pub-
lication in 2012 the authors reported 39
(78%) and 38 (76%) eyes in the two arms;
8 participants (12 eyes) missing were dead
for causes unrelated to treatment, but other
causes of death were not reported
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Selective reporting (reporting bias) Low risk The primary outcomes are continuous
measures and no arbitrary cut-points were
used
Other bias High risk There was an imbalance of baseline VA
in the IVB and photocoagulation groups:
0.71 logMAR versus 0.55 logMAR. Al-
though there was a potential unit of anal-
ysis issue (150 eyes of 129 patients, 16%
of participants had both eyes included),
comparisons were made in a marginal re-
gression model (based on generalised esti-
mating equation methods) adjusted for the
baseline values and to eliminate any pos-
sible correlation effects between the 2 eyes
of participants in bilateral enrolled cases.
However, we could not take correlation
into account when analysing dichotomous
VA definitions
Overall risk of bias Unclear risk High or unclear risk of bias for two items
to a degree which we believe may influence
effect estimates
Turkoglu 2015
Methods Prospective study, treatment in the better-seeing eye
Participants Country: Turkey
Number of people randomised: 70 participants (35 ranibizumab, 35 grid laser)
Average age: 64.6 ± 8.2 years ranibizumab; 63.8 ± 7.4 years laser
Sex: 21% male ranibizumab, 18% male laser
Inclusion criteria:
• evidence of CSME by means of FFA
• at least 6 months of follow-up
• no other systemic or ocular disease that might affect vision
Exclusion criteria:
• participants with a history of intravitreal injection and laser photocoagulation for
proliferative diabetic retinopathy or CSME
• participants with vitreous haemorrhage present at the time of recruitment or
vitreous haemorrhage which developed after enrolment
Interventions Focal or grid laser photocoagulation treatment was performed in 35 participants and
laser settings, including power, spot size, duration and number of burns, were recorded
35 participants received initial injection of ranibizumab 0.5mg/0.05mL. All participants
of both groups received treatment in their better-seeing eye. After the inductionphase, the
intravitreal injections were administered if any of the following changes were observed:
presence of visual acuity loss; persistent or recurrent subretinal or intraretinal fluid
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Turkoglu 2015 (Continued)
Outcomes Group comparisons of absolute scores and mean changes from baseline scores at 6-
month visit were performed using analysis of the Turkish version of VFQ-25; it has
modifications to adjust for Turkish culture and lifestyle
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No data available
Allocation concealment (selection bias) Unclear risk No data available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No data available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No data available
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported
Selective reporting (reporting bias) Unclear risk No specific statement nor protocol avail-
able
Other bias Low risk No other bias identified
Overall risk of bias Unclear risk Most items not reported
Wiley 2016
Methods Randomised, double-masked, 3-period, 2-treatment crossover design with 4 treatment
sequence patterns
Each of 3 12-week periods consisted of 3 intravitreous injections of ranibizumab (0.3
mg) or bevacizumab (1.25 mg), given every 4 weeks, with evaluation of the treatment
period 4 weeks after the third dose (i.e. weeks 12, 24, and 36)
Participants Country: USA and UK
Number of people randomised: 56 participants (62 eyes, 6 pz both eyes)
Average age: 62 years
Sex: 38.7% women
Inclusion criteria:
Eligible participants had type 1 or type 2 diabetes mellitus, were at least 18 years of age,
and could enter one or both eligible eyes in the study. Principal eligibility criteria for a
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Wiley 2016 (Continued)
study eye included: (1) presence of DME involving the centre of the macula, (2) ETDRS
BCVA letter score of 78 to 24 (Snellen equivalent, 20/32-20/400), and (3) CSMT of
330 mm or more on Cirrus (Carl Zeiss Meditec, Inc, Dublin, CA) OCT
Exclusion criteria:
Eye included presence of factors or other conditions judged to impact the course of
oedema or to preclude possible improvement in vision with treatment; PRP, focal or grid
laser photocoagulation, or depot corticosteroid injection within the previous 3 months;
ocular injection with an anti-VEGF agent within the previous 2 months; more than
4 injections with an anti-VEGF agent within the previous year; or prior vitrectomy.
Potential participants were excluded for history of renal failure (requiring haemodialysis
or renal transplantation) and for a measured systolic BP of more than 180 mmHg or a
diastolic BP of more than 110 mmHg
Interventions Each of 3 12-week periods consisted of 3 intravitreous injections of ranibizumab (0.3
mg) or bevacizumab (1.25 mg), given every 4 weeks, with evaluation of the treatment
period 4 weeks after the third dose (i.e. weeks 12, 24, and 36)
Each study eye received 9 monthly injections over the course of the trial, according
to a pattern of treatments determined by 1 of 4 randomly assigned sequences: R-R-B
(n = 17), R-B-B (n = 15), B-B-R (n = 16), or B-R-R (n = 14), where R indicates a
series of 3 consecutive ranibizumab injections, and B represents a series of 3 consecutive
bevacizumab injections. Study eyes meeting predefined criteria for significant worsening
of DME at week 12 or later could receive focal or grid laser photocoagulation. Fellow
eyes in participants only enrolling 1 eye could receive any necessary ocular treatment
Outcomes The primary outcome: mean change in BCVA from baseline, estimated for a 3-month
dosing period in a linear mixed-effects model
The main prespecified secondary outcome was the change in CRT, measured as OCT
CSMT, estimated for a 3-month dosing period using the linear mixed-effects model
Notes June 2012 and January 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned to 1 of the 4 treat-
ment sequences using a randomization list
generated by the Data and Statistical Coor-
dinating Center before study initiation, with
balance after every 12 enrollments. The list
was provided to unmasked pharmacists at
each site, who confirmed a valid participant
identification code before dispensing study
treatment. Both clinical sites used the same
randomised list, but selected treatment assign-
ments from opposite ends. For participants
entering both eyes in the trial, the right eye
was assigned randomly as above to 1 of the
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Wiley 2016 (Continued)
4 treatment sequences, and the left eye was
assigned automatically to the sequencewith
the inverse schedule (for example, B-R-R in
the right eye and R-B-B in the left eye). Page
2
Allocation concealment (selection bias) Low risk Participants were assigned to 1 of the 4 treat-
ment sequences using a randomization list
generated by the Data and Statistical Coor-
dinating Center before study initiation, with
balance after every 12 enrollments. The list
was provided to unmasked pharmacists at
each site, who confirmed a valid participant
identification code before dispensing study
treatment. Both clinical sites used the same
randomised list, but selected treatment assign-
ments from opposite ends. For participants
entering both eyes in the trial, the right eye
was assigned randomly as above to 1 of the
4 treatment sequences, and the left eye was
assigned automatically to the sequencewith
the inverse schedule (for example, B-R-R in
the right eye and R-B-B in the left eye). Page
2
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants and investigators were masked
to treatment. Site staff collecting study data,
including research coordinators, technicians,
and photographers, were also masked.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Site staff collecting study data, including re-
search coordinators, technicians, and photog-
raphers, were also masked.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One participant with a single eye assigned to
the R-B-B group
withdrew after the week 4 visit after a hem-
orrhagic stroke. All
remaining participants completed the study,
including the week 12, 24, and 36 visits, and
were included in this analysis”
Selective reporting (reporting bias) Low risk VA (no SD), OCT (no SD) data and harms
adequately reported
Other bias Low risk Six out of 56 participants had both eyes
included in analyses
Overall risk of bias Low risk Low risk of bias for most items
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Abbreviations
BCVA: best-corrected visual acuity
BP: blood pressure
CRT: central retinal thickness
CSFT: central subfield thickness
CSMO: clinically significant macular oedema
CSMT: central subfield mean thickness
DMO: diabetic macular oedema (DME: US spelling edema)
ECG: electrocardiogram
EQ-5D: EuroQol 5D
ETDRS: Early Treatment Diabetic Retinopathy Study
FAZ: foveal avascular zone
FFA: fundus fluorescein angiography
GLD: greatest linear dimension
HbA1c: glycated haemoglobin
IOP: intraocular pressure
ITT: intention-to-treat
iv: intravenous
IV: intravitreal injection
IVB: intravitreal bevacizumab
IVT: intravitreal triamcinolone
LOCF: last observation carried forward
logMAR: log of the Minimum Angle of Resolution
NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25
OCT: optical coherence tomography
PDR: proliferative diabetic retinopathy
PFCL: perifoveal capillary loss
PRP: panretinal photocoagulation
RCT: randomised controlled trial
SD: standard deviation
SD-OCT: spectral-domain optical coherence tomography
TD-OCT: time-domain optical coherence tomography
VA: visual acuity
VEGF: vascular endothelial growth factor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmadieh 2013 Not an RCT
CRFB002DFR08 (LUDIC) Single-arm study
CRFB002DGB14 (RELIGHT) Single-arm study
CRFB002DNO02 (PTIMAL) Single-arm study
DRCRnet 2007 Follow-up at 12 weeks only
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DRCRnet 2011 Follow-up at 14 weeks only. RCT comparing ranibizumab (2 injections), triamcinolone (1 injec-
tion) to sham in participants with DMO undergoing grid and panretinal laser photocoagulation
DRCRnet 2012 Follow-up of DRCRnet 2010 comparing prompt to deferred laser in participants treated for
ranibizumab for DMO: does not report on comparison of ranibizumab with laser
Faghihi 2008 Follow-up at 16 weeks only
NCT02985619 (BEVATAAC) Triamcinolone as comparator, unpublished study
Paccola 2008 Single injection of intravitreal triamcinolone acetonide (4mg/0.1mL) compared to single injection
of intravitreal bevacizumab (1.5 mg/0.06 mL). Duration: 24 weeks
Solaiman 2010 Single intravitreal injection of bevacizumab (inadequate dose); follow-up 6 months
Zehetner 2013 Physiological study of anti-VEGF levels only
Abbreviations
DMO: diabetic macular oedema
RCT: randomised controlled trial
VEGF: vascular endothelial growth factor
Characteristics of studies awaiting assessment [ordered by study ID]
Chen 2016
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: unclear
Primary purpose: treatment
Participants 42 (72 eyes); country: China
Male 55%, average age 60 years
Interventions Experimental: ranibizumab 0.5 mg; one week after ranibizumab, the participants received grid photocoagulation
intervention: macular area C-shaped manner, spot size 100 µm to 200 µm, 1 spot width apart, level I to II power
and exposure time 0.1 second
Active comparator: laser only
Outcomes Primary outcome (time frame: 3 and 6 months):
• Improvement of VA (2 or more lines on a letter chart, but not ETDRS)
• Ranibizumab plus laser: 28/36 (78%)
• Laser only: 18/36 (50%)
Secondary outcome:
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Chen 2016 (Continued)
• Reduction in retinal thickening based on OCT
• Baseline: ranibizumab plus laser: 487 (SD: 85) micron; laser 480 (SD: 83) micron
• 6 months: ranibizumab plus laser: 246 (SD: 26) micron; laser: 370 (SD: 36) micron
Notes Articles in Chinese
Authors contacted to obtain additional data
Fouda 2017
Methods Allocation: randomised study but no other information reported
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: unclear
Primary purpose: treatment
Participants 70 eyes randomised (42 participants); country: Egypt
Male % not reported, average age 55 years
Interventions Experimental: ranibizumab 0.5 mg; aflibercept 2 mg
Outcomes Primary outcome (time frame: 12 months): VA and CRT (cut-off and instrument not specified)
Decimal VA used: no significant difference between ranibizumab and aflibercept
Reduction in retinal thickening based on OCT: no significant difference between ranibizumab and aflibercept
Number of re-injections after the loading dose: 2.62 (SD 0.68) aflibercept, 3.03 (SD 0.95) ranibizumab (P = 0.02)
Notes Authors contacted to obtain additional data
Huang 2016
Methods Allocation: quasi-randomised, participants with even visit numbers were allocated to intervention group, whereas
participants with odd visit numbers were allocated to control group
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: unclear
Primary purpose: treatment
Participants 78; country: China
Male 55%, average age 51 to 54 years
Interventions Experimental: ranibizumab 0.5 mg
Active comparator: argon laser 532µm, green, 50 µm to 100 µm spots, intensity 100 mW to 200 mW and exposure
time 0.1 second
Outcomes Primary outcome (time frame: 3 and 6 months):
• Improvement of VA (cut-off and instrument not specified)
• Ranibizumab plus laser: 24/41 (59%)
• Laser only: 11/27 (30%)
Secondary outcome:
97Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Huang 2016 (Continued)
• Reduction in retinal thickening based on OCT
• Baseline: ranibizumab: 401 (SD: 39) micron; laser: 387 (SD: 31) micron
• 6 months: ranibizumab: 289 (SD: 34) micron; laser: 320 (SD: 37) micron
Notes Article in Chinese
Authors contacted to obtain additional data
Jovanovic 2015
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: unclear
Primary purpose: treatment
Participants 72 (120 eyes); country: Poland
Average age: 60 years
Inclusion criteria: severe DMO that affects the fovea, reduction in VA and/or metamorphopsia, diffuse oedema with
or without cystic oedema (confirmed by fluorescein angiography and by OCT), CRT ≥ 300 µm, the absence of
hard lipid exudates in the form of plaque in the subfoveal region, no prior laser treatment, no prior VEGF inhibitor
treatment, and no previous intravitreal or subtenonian corticosteroid administration. The exclusion criteria were:
high risk and advanced proliferative DR (PDR), the presence of other eye diseases that could affect VA, prior eye
surgeries
Interventions Experimental: bevacizumab 1.25 mg, one or more injections, with or without laser photocoagulation after 4 to 6
weeks depending on clinical response
Active comparator: laser only
Outcomes Primary outcome: not specified
Outcommes reported: VA (logMAR), CRT based on OCT
Quantitative results are available, but not at specified follow-up times and by number of injection and combination
rather than by assigned subgroup
Notes Sponsor: none reported
Authors contacted to obtain additional information
NCT00387582
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants 49, country: USA
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Interventions Experimental: I
• Lucentis injections for the first 3 months of the study and then according to the protocol for the duration of
the trial
Active comparator: II
• Argon laser treatment at enrolment and then according to the protocol for the duration of the study
Outcomes Primary outcome (time frame: 6 and 12 months):
• Prevention of vision loss at 1 year as evidenced by ETDRS VA
Secondary outcome:
• Reduction in retinal thickening based on OCT
Notes Completion Date: February 2009 (No Results)
Author contact not found
Sponsor: Rocky Mountain Retina Consultants
Collaborator: Genentech, Inc.
NCT00997191 (IBeTA)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants 12; country: Brazil
Interventions Procedure: laser photocoagulation
Drug: intravitreal triamcinolone
Drug: intravitreal bevacizumab
Outcomes Primary outcome (time frame: 1 year):
• BCVA
Secondary outcomes:
• macular mapping test
• multifocal electroretinogram
• CRT
Notes Completion date: November 2011 (no results)
Author could not be contacted
Sponsor: University of Sao Paulo
Collaborator: Fundacao de Amparo a Pesquisa do Estado de Sao Paolo
99Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01445899 (MATISSE)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-masked (participant, caregiver, investigator)
Participants 264; countries: USA, Israel
Interventions Drug: PF-04523655 (Stratum I)
Drug: PF-04523655 and ranibizumab
Drug: ranibizumab
Drug: PF-04523655 (Stratum II)
Outcomes Primary outcomes:
Safety and dose-limiting toxicities (Stratum I): to determine the safety and dose-limiting toxicities of a single intrav-
itreal (IVT) injection of PF-04523655 in people with low vision
Pharmacokinetics (Stratum I): to determine the pharmacokinetics (PK) of a single IVT injection of PF-04523655
in people with low vision
Safety and tolerability (Stratum II): to evaluate the safety and tolerability of PF-04523655 alone and in combination
with ranibizumab in participants with DMO
Efficacy (Stratum II): to evaluate the ability of PF-04523655 alone and in combination with ranibizumab to improve
VA compared to ranibizumab alone in people with DMO
Notes Completion date: November 2013 (no results)
Author contact not found
Sponsor: Quark Pharmaceuticals
Consider putting in excluded studies
NCT01565148 (IDEAL)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: factorial assignment
Masking: open-label
Participants 208; country: USA
Interventions Experimental Group 1: drug: iCo-007 350 µg as an intravitreal injection at baseline followed by another iCo-007
dose (350 µg) at month 4
Experimental Group 2: drug: iCo-007 700 µg as an intravitreal injection at baseline followed by another iCo-007
dose (700 µg) at month 4
Experimental Group 3: drug: iCo-007 350 µg as an intravitreal injection at baseline followed 7 days later by laser
photocoagulation. At month 4, intravitreal injection of iCo-007 (350 µg) will be given as mandatory treatment. If
the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Experimental Group 4: drug: ranibizumab 0.5 mg intravitreal injection at baseline followed by iCo-007 350 µg
intravitreal injection 2 weeks later; re-treatment with ranibizumab 0.5 mg mandatory at month 4 followed by iCo-
007 350 µg 2 weeks later
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NCT01565148 (IDEAL) (Continued)
Outcomes Primary outcome:
• Change in VA from baseline to month 8
Secondary outcomes:
• Number of participants in a given study arm experiencing the same drug-related serious adverse event as a
measure of safety and tolerability
• Safety of repeated iCo-007 intravitreal injections in treatment of people with DMO as monotherapy and in
combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more
participants in a particular treatment arm experience the same drug-related serious adverse event
• Change in VA from baseline to month 12
• Change in retinal thickness measured by OCT from baseline to month 8
• Change in retinal thickness measured by OCT from baseline to month 12
• Duration of iCo-007 treatment effect during the 12-month follow-up period as measured by VA and OCT
thickness
• Peak plasma concentration (Cmax) of iCo-007 after multiple injections
Notes Study has passed its completion date and status has not been verified in more than 2 years on ClinicalTrials.gov
Author contacted
Sponsor: Quan Dong Nguyen
Collaborators: Juvenile Diabetes Research Foundation, iCo Therapeutics Inc
Abbreviations
BCVA: best-corrected visual acuity
CFST: central subfield macular thickness
CRT: central retinal thickness
DMO: diabetic macular oedema
EQ-5D: EuroQol 5D
ETDRS: Early Treatment Diabetic Retinopathy Study
OCT: optical coherence tomography
PRN: pro re nata
SD: standard deviation
TE: treat and extend
VA: visual acuity
VEGF: vascular endothelial growth factor
VFQ-25: Visual Function Questionnaire 25-item
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-TRC-12002417
Trial name or title A randomised controlled trial to compare the efficacy and safety of 1) macular laser vs 2) repeated intravitreal
bevacizumab vs 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema
Methods Parallel group RCT
Participants People with type 2 diabetes and DMO
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ChiCTR-TRC-12002417 (Continued)
Interventions Group 1 (Control): macular laser photocoagulation performed every 4 months unless the deferral criteria are
met. Group 2: intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months and repeated en
bloc every 4 months unless the deferral criteria are met
Group 3: Intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months, followed by macular
laser photocoagulation at month 3; and repeated en bloc every 4 months unless the deferral criteria are met
Outcomes BCVA at 2 years
Starting date Unknown; trial registered 13 August 2013
Contact information Joyce Kung (joycekung@cuhk.edu.hk); Carmen Chan (kmcc2001@hotmail.com)
Notes Status checked on Chictr.Org.Cn on 1 December 2016. Author contacted
NCT01635790 (BRDME)
Trial name or title Comparing the effectiveness and costs of bevacizumab to ranibizumab in participants with diabetic macular
edema (BRDME)
Methods Parallel group RCT
Participants 246 people with DMO
Interventions Ranibizumab compared to bevacizumab
Outcomes From clinical trials record:
Primary outcome:
• change in BCVA in the study eye from baseline to month 6 (designated as safety issue: no)
Secondary outcome measures:
• proportion of participants with a gain or loss of 15 letters or more at 6 months compared to baseline
BCVA (designated as safety issue: no)
• change in leakage on fluorescein angiography, baseline compared to 6 month exit visit (designated as
safety issue: no)
• change in foveal thickness (central retinal area) by OCT, 6 month exit visit compared to baseline
(designated as safety issue: no)
• total number of adverse events that occurred during the 6 month study, with secondary a classification
of the types of adverse events (designated as safety issue: yes)
• costs per quality adjusted life-year of the 2 treatments (time frame: 6 months; designated as safety
issue: no), results will be based on the use of standardised health questionnaires (EQ-5D or Health Utility
Index Mark 3)
• proportion of participants with a BCVA of 20/40 or more at 6 months compared to baseline BCVA
(designated as safety issue: no)
http://clinicaltrials.gov/show/NCT01635790
Starting date Study start date: June 2012
Estimated primary completion date: June 2016 (Final data collection date for primary outcome measure)
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NCT01635790 (BRDME) (Continued)
Contact information Reinier O Schlingemann (r.schlingemann@amc.uva.nl); Monique Wezel (m.wazel@amc.uva.nl)
Notes Recruiting (status checked on ClinicalTrials.gov on 1 December 2016)
NCT02194634
Trial name or title Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
Methods Parallel group RCT
Participants type 1 or type 2 diabetes mellitus with DMO
Interventions Experimental: Conbercept treatment group
Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether
the participants need to get repeated treatment according to monthly assessment
Active Comparator: Laser treatment group
Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated
laser treatment is needed according to monthly results during the visit after 3 months
Outcomes Primary outcome measures:
• Mean change from baseline in BCVA at month 12 (time frame: baseline and month 12) (designated as
safety issue: no)
• To compare mean change from baseline BCVA between treatment group and controlled group at
month 12
Secondary outcome measures:
• Mean change from baseline in CRT between two groups (time frame: baseline and month 12
(designated as safety issue: no)
• To compare mean change from baseline CRT between two groups at month 12
• Safety (e.g. incidence of adverse events) of Conbercept ophthalmic injection (time frame: 12 months)
(designated as safety issue: yes)
• To assess safety parameters during the study, such as incidence of adverse events, incidence of adverse
drug reactions etc
Starting date July 2014
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome
measure)
Contact information Chengdu Kanghong Biotech Co.,Ltd.
Notes This study is recruiting participants. (Status checked on ClinicalTrials.Gov on 5 December 2016)
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NCT02259088
Trial name or title A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME
Patients
Methods Parallel group RCT
Participants Participants with DMO with BCVA score between 78 and 39
Interventions Ranibizumab PRN versus laser
Outcomes Primary outcome measures:
• Mean average BCVA change (time frame: 12 months)
• Mean average BCVA change from Month 1 through Month 12 compared to baseline.
Secondary Outcome Measures:
• Mean BCVA change by visit (time frame: 12 months)
• Mean BCVA change from baseline at each visit
• Mean change in CSFT (time frame: 12 months)
• Mean change in CSFT from baseline at each visit
• BCVA improvement of ≥ 10 and ≥ 15 letters (time frame: 12 months)
• Proportion of participants achieving BCVA improvement of ≥ 10 and ≥ 15 letters from baseline to
Month 12
• BCVA loss of < 10 and < 15 letters (time frame: 12 months)
• Proportion of participants with BCVA loss of < 10 and < 15 letters from baseline to Month 12
• VA ≥ 73 letters (time frame: 12 months)
• Proportion of participants with VA ≥ 73 letters (approximate 20/40 Snellen chart equivalent) at
Month 12
• Mean average BCVA change after month 3 (time frame: 12 months)
• Mean average BCVA change from Month 4 to Month 12 compared to Month 3
• Mean change in patient-reported visual functioning scale (time frame: 6 and 12 months)Mean change
in the patient-reported visual functioning through VFQ-25 composite and subscale scores at Month 6 and
Month 12 compared to baseline.
• Adverse events (time frame: 12 months)
• To evaluate the safety of 0.5 mg ranibizumab intravitreal injections relative to laser photocoagulation,
as assessed by the type, frequency and severity of ocular and non-ocular adverse events over 12 months.
• Evaluation of treatment patterns (time frame: 12 months)
• To evaluate the number of re-treatments and retreatment patterns (assessed by time of stabilization/
time to re-initiation of treatment) in participants treated with 0.5 mg ranibizumab
Starting date November 2014
Estimated study completion date: January 2017
Estimated primary completion date: January 2017 (final data collection date for primary outcome measure)
Contact information Novartis (Novartis Pharmaceuticals)
Notes This study is ongoing, but not recruiting participants. (Status checked on ClinicalTrials.gov on 5 December
2016)
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NCT02348918
Trial name or title A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the
Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser
Photocoagulation in the Treatment of Diabetic Macular Edema
Methods Parallel group RCT
Participants DMO participants
Interventions Experimental: Luminate 1.0 mg group
• Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with
PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham
injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is
not required; sham laser treatment will be administered at baseline and at 16 weeks
Experimental: Luminate 2.0 mg group
• Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with
PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham
injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is
not required; sham laser treatment will be administered at baseline and at 16 weeks
Experimental: Luminate 3.0 mg group
• Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with
PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham
injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is
not required; sham laser treatment will be administered at baseline and at 16 weeks
Active Comparator: Avastin® group
• Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with
PRN Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham
injections may be performed at weeks 12, 16, and 20 if PRN Avastin is not required; sham laser treatment
will be administered at baseline and at 16 weeks
Active Comparator: focal laser photocoagulation group
• Focal laser photocoagulation performed at baseline (Day 0) with possible PRN laser retreatment at
week 16. Sham intravitreal injections will be performed at baseline (Day 0), 4 weeks, 8 weeks, 12 weeks, 16
weeks and 20 weeks
Outcomes Primary outcome measures:
• Change in OCT CSFT at Week 24 (time frame: 24 weeks)
• The primary efficacy outcome is OCT CSFT at Week 24 as compared to baseline
Secondary outcome measures:
• Change in BCVA at Week 24 (time frame: 24 weeks)
• Secondary efficacy outcome is BCVA changes at Week 24 as compared to baseline
Starting date October 2014
Estimated study completion date: March 2016
Estimated primary completion date: December 2015 (final data collection date for primary outcome measure)
Contact information Allegro Ophthalmics, LLC
Notes This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 Dec. 2016)
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NCT02645734
Trial name or title The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema
Methods Parallel group RCT
Participants DMO participants
Interventions Active comparator: injection intravitreous bevacizumab
Active comparator: injection ziv-aflibercept at dose of 1.25 mg
Active comparator: injection ziv-aflibercept at dose of 2.5 mg
Outcomes Primary outcome measures:
• VA (time frame: until 6 months)
Secondary outcome measures:
• CSFT (time frame: until 6 months)
Starting date Study first received: 2 January 2016
Last updated: 4 January 2016
Estimated primary completion date: February 2016 (final data collection date for primary outcome measure)
Contact information Zahra Rabbani Khah, Shahid Beheshti Medical University
Notes This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016)
NCT02699450
Trial name or title A Phase 2 Study of RO6867461 in Participants With Center-Involving Diabetic Macular Edema (CI-DME)
(BOULEVARD)
Methods Parallel group RCT
Participants DMO
Interventions Experimental: RO6867461 1.5 mg
• Participants will receive 1.5 milligrams (mg) RO6867461 intravitreal (IVT) every 4 weeks up to Week
20, followed by 1 sham administration at Week 24.
Experimental: RO6867461 6 mg
• Participants will receive 6 mg RO6867461 IVT every 4 weeks up to Week 20, followed by 1 sham
administration at Week 24.
Active Comparator: Ranibizumab 0.3 mg
• Participants will receive 0.3 mg ranibizumab IVT every 4 weeks up to Week 24
Outcomes Primary outcome measures:
• Mean change from baseline in BCVA at week 24 using ETDRS modified charts (time frame: baseline,
Week 24)
• Apparent plasma clearance of RO6867461 (time frame: pre-dose on Days 1, 28, 84, 140, and 168;
post-dose on Days 7, 182, and 196 or early termination)
• Apparent plasma volume of RO6867461 (time frame: pre-dose on Days 1, 28, 84, 140, and 168; post-
dose on Days 7, 182, and 196 or early termination)
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NCT02699450 (Continued)
Secondary Outcome Measures:
Percentage of participants gaining ≥ 15 letters from baseline BCVA at Week 24 (time frame: baseline, and
Week 24)
Percentage of participants with BCVA ≥ 69 letters (20/40 or better) at Week 24 (time frame: Week 24)
Percentage of participants with BCVA ≥ 84 letters (20/20 or better) at Week 24 (time frame: Week 24)
Mean change from baseline in BCVA at Week 28 (time frame: baseline, and Week 28)
Mean change from baseline in foveal centre point thickness at Week 24 and 28, as measures by spectral
domain OCT (SD-OCT) (time frame: baseline, Weeks 24 and 28)
Mean change frombaseline inmeanCSFT atWeek 24 and 28, as measures by SD-OCT (time frame: baseline,
Weeks 24 and 28)
Percentage of participants with resolution of subretinal and intraretinal fluid at Week 24 and 28, as measures
by SD-OCT (time frame: Weeks 24 and 28)
Percentage of participants with resolution of leakage at the macula at Week 24, as measures by FFA (time
frame: Week 24)
Change from baseline in the size of the foveal avascular zone at Week 24, as measures by FFA (time frame:
baseline and Week 24)
Change from baseline in plasma levels of vascular endothelial growth factor (VEGF) (time frame: baseline,
Weeks 1, 4, 12, 24, 26, and 28 or early termination)
Change from baseline in plasma levels of angiopoietin-2 (Ang-2) (time frame: baseline, Weeks 1, 4, 12, 24,
26, and 28 or early termination) (designated as safety issue: no)
Maximum observed plasma concentration (Cmax) of RO6867461 (time frame: pre-dose on Days 1, 28, 84,
140, and 168; post-dose on Days 7, 182, and 196 or early termination)
Area under the plasma concentration-time curve from time zero to extrapolated infinite time [AUC (0-inf )]
of RO6867461 (time frame: pre-dose on Days 1, 28, 84, 140, and 168; post-dose on Days 7, 182, and 196
or early termination)
Area under the plasma concentration-time curve from time zero to end of dosing interval [AUC (0-tau)] of
RO6867461 (time frame: pre-dose on Days 1, 28, 84, 140, and 168; post-dose on Days 7, 182, and 196 or
early termination)
Time to reach maximum observed plasma concentration (Tmax) of RO6867461 (time frame: pre-dose on
Days 1, 28, 84, 140, and 168; post-dose on Days 7, 182, and 196 or early termination)
Plasma decay half-life (t1/2) of RO6867461 (time frame: pre-dose on Days 1, 28, 84, 140, and 168; post-
dose on Days 7, 182, and 196 or early termination)
Number of participants with adverse events (time frame: baseline up to Week 28 or early termination)
Number of participants with anti-RO6867461 antibodies (time frame: baseline, Weeks 1, 4, 12, 20, 24, 26,
and 28 or early termination)
Starting date March 2016
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (final data collection date for primary outcome measure)
Contact information Hoffmann-La Roche
Notes This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016)
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NCT02712008
Trial name or title Anti-vasculaREndothelial Growth Factor plUsAnti-angiopoietin 2 in Fixed comBination therapY: Evaluation
for the Treatment of Diabetic Macular Edema (RUBY)
Methods Parallel group RCT
Participants participants with DMO
Interventions Experimental: Group 1
Participants in Group 1 will receive REGN910-3 dosing regimen 1
Experimental: Group 2
Participants in Group 2 will receive REGN910-3 dosing regimen 2
Active Comparator: Group 3
Participants in Group 3 will receive IAI
Outcomes Primary outcome measures:
• Change from baseline in BCVA measured by the ETDRS letter score at week 12 (time frame: baseline
to week 12)
Secondary outcome measures:
• Change from baseline in CSFT at week 12 (time frame: baseline to week 12)
• Change from baseline in CSFT at week 36 (time frame: baseline to week 36)
• Proportion of participants with a ≥2-step improvement in Diabetic Retinopathy Severity Scale from
baseline at week 12 (time frame: baseline to week 12)
• Proportion of participants with a ≥2-step improvement in Diabetic Retinopathy Severity Scale from
baseline at week 36 (time frame: baseline to week 36)
• Change from baseline in BCVA measured by the ETDRS letter score at week 36 (time frame: baseline
to week 36)
• Proportion of participants with no retinal and/or subretinal fluid at week 12 (time frame: baseline to
week 12)
• Proportion of participants with no retinal and/or subretinal fluid at week 36 (time frame: baseline to
week 36)
• Time to no retinal and/or subretinal fluid at week 12 (time frame: baseline to week 12)
• Time to no retinal and/or subretinal fluid at week 36 (time frame: baseline to week 36)
Starting date March 2016
Estimated study completion date: October 2017
Estimated primary completion date: April 2017 (final data collection date for primary outcome measure)
Contact information Regeneron Pharmaceuticals
Notes This study is on ongoing, but not recruiting participants; (status checked on ClinicalTrials.gov on 5December
2016)
Abbreviations
BCVA: best-corrected visual acuity
CSFT: central subfield thickness
CRT: central retinal thickness
CSMO: clinically significant macular oedema
DMO: diabetic macular oedema (DME: US spelling edema)
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ETDRS: Early Treatment Diabetic Retinopathy Study
FFA: fundus fluorescein angiography
IOP: intraocular pressure
NA: not available
OCT: optical coherence tomography
PDR: proliferative diabetic retinopathy
PRN: pro re nata (as required in the circumstances)
PRP: panretinal photocoagulation
RCT: randomised controlled trial
VA: visual acuity
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D A T A A N D A N A L Y S E S
Comparison 1. Ranibizumab versus laser photocoagulation at 6 to 12 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life: NEI-VFQ
composite score at 6 to 12
months
3 412 Mean Difference (Fixed, 95% CI) 5.14 [2.96, 7.32]
A D D I T I O N A L T A B L E S
Table 1. Reporting of all outcomes across studies
Study Gain 3+
VA lines
Mean VA
change
Mean CMT
change
QOL SSAE ATC Death
Fol-
low-
up
year
1 2 1 2 1 2 1 2 1 2 1 2 1 2
Ah-
madieh
2008
78 78
Azad
2012
40 40 40 40
BOLT
2010
80 65 80 65 80 65 80 80 80
DA
VINCI
2011
89 89 87 89 89 89
DR-
CR-
net
2010
668 486 668 486 617 483 240 505 505
DR-
CR-
net
2015
620 577 620 577 620 577 660 660 660
110Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Reporting of all outcomes across studies (Continued)
Ekinci
2014
100 100 100 100 100
Ishibashi
2014
233 233 233 233 233 233
Koro-
belnik
2014
573 573 573 865 865 865
LU-
CI-
DATE
2014
33 33 33 33 33 33
Macu-
gen
2005
86 86 86 86 86
Macu-
gen
2011
260 207 260 236 286 286 286
Nepo-
mu-
ceno
2013
60 60 60 60
READ2
2009
115 115 117 117
RE-
LA-
TION
2012
128 128 128 128
RE-
SOLVE
2010
151 151 151 151 151 151
RE-
SPOND
2013
203 203 202 237 237
RE-
STORE
2011
343 343 343 299 345 345 345
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Table 1. Reporting of all outcomes across studies (Continued)
RE-
VEAL
2015
390 390 268
RISE-
RIDE
509 504 500 500
So-
heil-
ian
2007
87 85 85 96
Turkoglu
2015
70 70 70
Wiley
2016
124 124
Total
stud-
ies
17 5 21 3 16 3 4 1 12 6 10 5 12 5
Total
par-
tici-
pants
4031 1844 4489 1128 3491 1125 838 504 1598 2631 1322 2396 1639 2816
Numbers in the table are the total number of eyes for each study,as available by follow-up year (1 or 2) and outcome measure.
Table 2. Network structure: efficacy at 12 months
Laser Aflibercept Beva-
cizumab
Pegap-
tanib RanibizumabRanibizumab
deferred-
laser
Ranibizumab
prompt
laser
Sham Overall
Gain 3+
lines
12 4 5 3 8 1 5 3 17
1074 539 344 410 713 188 545 218 4031
Mean VA
change
13 4 7 3 11 1 6 4 21
1131 539 476 410 861 188 629 255 4489
112Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Network structure: efficacy at 12 months (Continued)
Mean
CRT
change
11 4 7 10 1 4 2 16
986 538 476 779 175 451 86 3491
QOL 4 4
838 838
For each efficacy outcome, numbers in the table are the total number of studies (upper line for each outcome) and the total number
of eyes (lower line for each outcome), as available by treatment and measured at one year.
Table 3. Gain of 3 or more lines of visual acuity at 12 months: direct (upper-right triangle) and mixed (lower-left triangle)
estimates
LASER 3.82 (2.61 to
5.58)
2.74 (1.34 to
5.61)
2.82 (1.82 to
4.38)
1.88 (1.31 to
2.70)
2.30 (1.74 to
3.03)
3.66 (2.79 to
4.79)
AFLI 0.68 (0.52 to
0.90)
0.77 (0.59 to
0.99)
2.47 (1.81 to
3.37)
0.68 (0.53 to
0.86)
BEVA 1.14 (0.88 to
1.48)
1.70 (0.58 to
4.94)
0.46 (0.16 to
1.34)
0.69 (0.24 to
1.89)
PEGA 0.51 (0.30 to
0.89)
2.76 (2.12 to
3.59)
0.75 (0.60 to
0.94)
1.11 (0.87 to
1.43)
1.62 (0.58 to
4.57)
RANI 0.90 (0.67 to
1.21)
0.31 (0.13 to
0.76)
2.02 (1.46 to
2.81)
0.55 (0.37 to
0.82)
0.82 (0.54 to
1.24)
1.19 (0.40 to
3.58)
0.73 (0.51 to
1.06)
RANI-DL 1.10 (0.80 to
1.51)
2.33 (1.81 to
3.00)
0.64 (0.47 to
0.86)
0.94 (0.68 to
1.31)
1.37 (0.47 to
3.99)
0.85 (0.65 to
1.09)
1.15 (0.85 to
1.56)
RANI-PL
0.87 (0.35 to
2.17)
0.24 (0.10 to
0.59)
0.35 (0.14 to
0.87)
0.51 (0.30 to
0.89)
0.32 (0.13 to
0.76)
0.43 (0.17 to
1.11)
0.37 (0.15 to
0.93)
SHAM
P value for overall inconsistency = 0.883 in the network meta-analysis.
Values in the table are risk ratios and 95% confidence intervals. Values in bold are ones where the 95% confidence intervals does not
include 1 (null effect).
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Table 4. Mean visual acuity change at 12 months: direct (upper-right triangle) and mixed (lower-left triangle) estimates
LASER −0.20 (−0.
24 to −0.17)
−0.20 (−0.
28 to −0.12)
a
−0.11 (−0.
13 to −0.08)
−0.
12 (−0.16 to
−0.075)
−0.10 (−0.
13 to −0.08)
−0.20 (−0.
22 to −0.17)
AFLI 0.07 (0.03 to
0.11)
0.04 (0.00 to
0.08)
−0.12 (−0.
15 to −0.09)
a
0.08 (0.05 to
0.11)
BEVA −0.02 (−0.05
to 0.01)
0.01 (−0.09
to 0.07)
0.19 (0.11 to
0.27)
0.11 (0.04 to
0.19)
PEGA 0.08 (0.03 to
0.13)
−0.12 (−0.
14 to −0.10)
0.08 (0.05 to
0.11)
0.00 (−0.02
to 0.03)
−0.11 (−0.
19 to −0.04)
RANI 0.01 (−0.02
to 0.03)
0.23 (0.15 to
0.32)
−0.11 (−0.
13 to −0.09)
0.08 (0.04 to
0.13)
0.01 (−0.04
to 0.06)
−0.11 (−0.
19 to −0.02)
0.00 (−0.04
to 0.05)
RANI-DL 0.00 (−0.05
to 0.05)
−0.11 (−0.
14 to −0.08)
0.09 (0.06 to
0.12)
0.01 (−0.02
to 0.05)
−0.10 (−0.
18 to −0.02)
0.01 (−0.01
to 0.03)
0.01 (−0.04
to 0.05)
RANI-PL
0.08 (0.01 to
0.15)
0.28 (0.21 to
0.35)
0.20 (0.13 to
0.27)
0.09 (0.06 to
0.12)
0.20 (0.13 to
0.27)
0.20 (0.11 to
0.28)
0.19 (0.12 to
0.26)
SHAM
a P value for differences between direct and indirect estimates = 0.031 in the network meta-analysis.
P value for overall inconsistency = 0.665.
Table 5. Mean central retinal thickness change at 12 months: direct (upper-right triangle) and mixed (lower-left triangle)
estimates
LASER −119 (−143 to
−95)
−44 (−82 to
−5)
−71 (−120 to
−22)ˆ
−35 (−62 to
−8)
−64 (−103 to
−25)b∗
−114 (−147 to
−81)
AFLI 68 (43 to 94) 22 (−4 to 48)
−46 (−78 to
−14)
68 (29 to 108) BEVA −38 (−56 to
−20)
132 (72 to 187)
−75 (−100 to
−50)
39 (2 to 76) −29 (−58 to
−1)
RANI −19 (−39 to 2)
a
1470 (95 to
196)
−57 (−111 to
−2)
57 (−6 to 120) −11 (−73 to 51) 18 (−40 to 76) RANI-DL 6 (−22 to 34)
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Table 5. Mean central retinal thickness change at 12 months: direct (upper-right triangle) and mixed (lower-left triangle)
estimates (Continued)
−72.90 (−103
to −42)b
41 (−2 to 84) −27 (−68 to 13) 2 (−31 to 35)a −16 (−71 to 38) RANI-PL
77 (18 to 137) 191 (127 to
256)
123 (67 to 179) 153 (97 to 208) 134 (55 to 213) 150 (87 to 214) SHAM
a P value for differences between direct and indirect estimates = 0.003.
b P value for differences between direct and indirect estimates = 0.044.
∗ P value for heterogeneity = 0.002; I² = 80% in the direct meta-analysis.
ˆ P value for heterogeneity = 0.000; I² = 91% in the direct meta-analysis.
P value for overall inconsistency = 0.209 in the network meta-analysis.
Table 6. Network structure: safety at the longest available follow-up
Laser Aflibercept Bevacizumab Pegaptanib Ranibizumab Sham Overall
SSAE 9 3 6 2 10 5 18
1013 556 410 186 1303 528 4229
ATC* 10 3 4 2 8 2 15
824 846 330 188 1113 184 3718
Death 11 3 4 2 10 3 17
903 846 333 188 1521 434 4455
For each safety outcome, numbers in the table are the total number of studies (upper line for each outcome) and the total number of
eyes (lower line for each outcome), as available by treatment and measured at the longest available follow-up.
(*) combined incidence of (1) cardiovascular, hemorrhagic, and unknown death; (2) nonfatal MI; and (3) nonfatal stroke.
Table 7. All serious systemic adverse events (longest available follow-up)
CONTROL 0.95 (0.75 to 1.20) 1.29 (0.43 to 3.84) 1.02 (0.67 to 1.53) 0.98 (0.76 to 1.25)
0.98 (0.83 to 1.16) AFLI 0.95 (0.75 to 1.20) 1.04 (0.83 to 1.32)
0.93 (0.73 to 1.19) 0.95 (0.76 to 1.18) BEVA 0.96 (0.77 to 1.20)
1.02 (0.64 to 1.64) 1.04 (0.63 to 1.72) 1.09 (0.64 to 1.86) PEGA
0.97 (0.80 to 1.17) 0.98 (0.82 to 1.19) 1.04 (0.84 to 1.28) 0.95 (0.57 to 1.58) RANI
P value for overall inconsistency = 0.859.
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Table 8. Antiplatelet Trialists Collaboration arterial thromboembolic events at the longest available follow-up
CONTROL 1.50 (0.81 to 2.79) 0.92 (0.17 to 5.12) 0.78 (0.31 to 1.97) 0.64 (0.38 to 1.07)
0.88 (0.37 to 2.13) AFLI 1.46 (0.71 to 2.98) 2.26 (1.15 to 4.23)a
0.94 (0.33 to 2.66) 1.06 (0.36 to 3.11) BEVA 1.51 (0.85 to 2.69)
0.79 (0.20 to 3.02) 0.89 (0.18 to 4.43) 0.83 (0.15 to 4.61) PEGA
1.09 (0.52 to 2.29) 1.24 (0.48 to 3.19)a 1.17 (0.43 to 3.13) 1.17 (0.43 to 3.16) RANI
a P value for differences between direct and indirect estimates = 0.002.
P value for overall inconsistency = 0.274 in the network meta-analysis.
Table 9. All-cause mortality at the longest available follow-up
CONTROL 1.69 (0.30 to 9.42)a 0.95 (0.06 to 14.85) 0.82 (0.25 to 2.65) 0.64 (0.32 to 1.25)d
1.01 (0.34 to 3.03)a AFLI 2.67 (0.97 to 7.37)b 2.26 (0.80 to 6.40)c
1.61 (0.45 to 5.69) 1.59 (0.43 to 5.94)b BEVA 0.85 (0.40 to 1.83)
0.81 (0.16 to 4.03) 0.81 (0.12 to 5.62) 0.51(0.07 to 3.90) PEGA
0.90 (0.40 to 2.01) 1.16 (0.38 to 3.58)c 0.73 (0.22 to 2.37) 1.44 (0.24 to 8.48) RANI
a P value for differences between direct and indirect estimates = 0.011.
b P value for differences between direct and indirect estimates = 0.030.
c P value for differences between direct and indirect estimates = 0.015.
d P value for differences between direct and indirect estimates = 0.022.
P value for overall inconsistency = 0.087 in the network meta-analysis.
Table 10. Similarity among studies. baseline values and number of injections
Study Participants Interventions Mean n.
injections
Visual
acuity
(logMAR)
Retinal
thickness (µm)
Study
sponsor
Ahmadieh 2008 78 Bevacizumab
Sham
None reported
BOLT 2010 80 Bevacizumab
Laser
9*
3*
0.59
0.61
507
482
Public
DA VINCI
2011
89 Aflibercept
Laser
3.6 to 5.5
1.7
0.55 441 Industry
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Table 10. Similarity among studies. baseline values and number of injections (Continued)
DRCRnet 2010 668 Laser
Ranibizumab-
DL
Ranibizumab-PL
3*
9*
8*
0.38
0.39
0.38
Public
DRCRnet 2015 620 Aflibercept
Bevacizumab
Ranibizumab
9.2
9.4
9.7
0.40 412
414
407
Public
Ekinci 2014 100 Bevacizumab
Ranibizumab
5.1
6.5
0.22
0.24
484
490
Public
Ishibashi 2014 233 Pegaptanib
Sham
4 0.56 Industry
Korobelnik
2014
268 Aflibercept
Laser
8.5
2.4
0.50 Industry
Lopez-Galvez
2014
83 Ranibizumab
Laser
5.3
2.1
Industry
LUCIDATE
2014
33 Laser
Ranibizumab
2.6
9
0.42
0.30
489
455
No details
Macugen 2005 86 Pegaptanib
Sham
5
4.5
0.56
0.58
476
423
Industry
Macugen 2011 260 Pegaptanib
Sham
8.3
8.4
0.56
0.58
442
465
Industry
RELATION
2012
128 Laser
Ranibizumab-PL
Industry
Nepomuceno
2013
60 Bevacizumab
Ranibizumab
9.8
7.7
0.60
0.63
451
421
Public
READ2 2009 115 Laser
Ranibizumab
Ranibizumab-PL
4.4
5.3
2.9
0.60
0.54
0.60
228
190
263
Industry
RESOLVE 2010 151 Ranibizumab
Sham
10.2
8.9
0.50
0.48
455
449
Industry
RESPOND
2013
203 Laser
Ranibizumab
Ranibizumab-PL
9.2
8.8
0.46
0.44
0.40
458
448
422
Industry
RESTORE
2011
343 Laser
Ranibizumab
Ranibizumab-PL
7.3
7
6.8
0.46
0.40
0.42
412
427
416
Industry
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Table 10. Similarity among studies. baseline values and number of injections (Continued)
REVEAL 2015 390 Laser
Ranibizumab
Ranibizumab-PL
1.9
7.8
7
0.54
0.52
0.52
395
419
430
Industry
Soheilian 2007 85 Bevacizumab
Laser
0.71
0.55
352
319
Public
Turkoglu 2015 70 Laser
Ranibizumab
0.84
0.80
460
488
None reported
Wiley 2016 124 Bevacizumab
Ranibizumab
3
3
0.42 477 Public
DL: plus deferred laser
PL: plus prompt laser
(*): median, not mean, available and reported
F E E D B A C K
Feedback, 25 June 2013
Summary
Comments:1. In the electronic searches,did you not find the article: Lim JW, LeeHK, ShinMC.Comparison of intravitreal bevacizumab
alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: A randomized clinical trial. Ophthalmologica.
2012;227(2):100-6. The article was published online: October 12, 2011, so it should have been found in the last electronic search, June
2012. I understand this article would have been excluded because of the triamcinolone comparison (it compares bevacizumab 1.25 mg
versus bevacizumab 1.25 mg plus triamcinolone 2 mg versus triamcinolone 2 mg) but maybe It should appear in the ’Characteristics
of excluded studies’ section?
2. About the outcome results for ’Quality of life’: Quality of life results should be included from the RESTORE 2011 trial. In the
RESTORE 2011 trial (RESTORE 2011) data on quality of life have been reported using EQ-5D and NEI VFQ-25. It reported 12
months results, so it could also have been included. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R,
et al. The RESTORE 2011 Study ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular
edema. Ophthalmology. 2011;118(4):615-25.
3. In the section Effects of interventions/Anti-VEGF versus sham treatment/ Quality of the evidence: “READ2 2009 provided visual
gain, but not visual loss data”. This section evaluates anti-VEGF versus sham treatment and the READ trial is about ranibizumab versus
laser.
4. For the included study: DRCRnet 2010 {published data only} Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello
LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone
plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77. It seems that you have also considered results
from this trial, from the 2011 publication for 2 years results (Analysis 3.7-3.11): Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL
3rd, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt laser or deferred laser or triamcinolone plus prompt
laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614. The values of “N”, total population evaluated belong to 2011
publication; the numbers are higher than those belonging to the 2010 publication. So this reference should also be cited.
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5. For the included study: READ2 2009 {published data only} Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al.
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146-
51. The results that are considered in the review belong to the article by Nguyen 2009 (results and follow up at 6 months). Nguyen
QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the
mAcula in diabetes. Ophthalmology. 2009;116 (11):2175-81. All the analyses have been done with the 6 months follow up. Because
after six months all patients could be treated with ranibizumab, data were not collected beyond six months. So this reference should
also be cited.
6. In the ’Characteristics of included studies’ table for RISE-RIDE, the ’outcomes’ section should be completed.
7. In Tables 2, 5, 6, 7, 8 and 9 ’bevacacizumab’ should be corrected to ’bevacizumab’.
Reply
We thank Ruth Ubago Pérez for her comments submitted through the Feedback system in The Cochrane Library.
1. In the ’Characteristics of excluded studies’ table, we have added that not only Paccola 2008, but also Lim 2012 were excluded because
another Cochrane review focuses on the use of intravitreal steroids in people with diabetic macular oedema.
2. We will include quality of life data in the next review update.
3. We have removed this sentence.
4 and 5. We have added these references.
6. We have completed the ’Outcomes’ section.
7. We have corrected these typos.
Contributors
Comment from Ruth Ubago Pérez, Pharmacist Technician, Andalusian Agency for Health Technology Assessment, Spain
Reply from Gianni Virgili (lead author of review)
WH A T ’ S N E W
Last assessed as up-to-date: 26 April 2017.
Date Event Description
2 May 2017 New search has been performed Issue 6, 2017: Updated protocol: objectives revised as com-
paring different antiangiogenic drugs using network meta-
analysis technique
2 May 2017 New citation required and conclusions have changed Issue 6, 2017: Searches updated and six new studies added
(DRCRnet 2015, Ishibashi 2014, Lopez-Galvez 2014,
REVEAL2015, Turkoglu 2015,Wiley 2016) and conclusions
changed
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H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 4, 2009
Date Event Description
4 November 2014 Amended Plain language summary title has been amended
17 October 2014 New citation required but conclusions have not
changed
Issue 10, 2014: Five new studies (Azad 2012;
Ekinci 2014; Nepomuceno 2013; RELATION 2012;
RESPOND 2013) have been included in the update.
17 October 2014 New search has been performed Issue 10, 2014: Electronic searches updated.
4 November 2013 Feedback has been incorporated The authors have made some edits to the review in
response to feedback received. See ’Feedback 1’ for
further details.
14 March 2013 Amended The abstract has been amended to focus on the com-
parison with laser and presenting absolute effects
11 November 2012 New search has been performed Updated searches yielded seven new trials for inclu-
sion. One trial that had previously been included was
excluded. An economic section has been added. One
new author Massimo Brunetti has been added to the
review team
11 November 2012 New citation required and conclusions have changed Inclusion of seven new studies has changed the con-
clusions to this review from the previous version
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Data management for the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between protocol and review in the first published version of this review
We have added LILACS to the list of databases which have been searched for this review. We have used a sensitivity analysis for the
robustness of results in comparisons including only one trial according to a statistical technique derived from a recent publication
(Borm 2009).
Changes in update, 2012 compared to the protocol of the previous version
1. We have specified that studies comparing different anti-VEGF drugs will also be included in this review, but intravitreal steroids
will be excluded as they are the subject of another Cochrane Review. Moreover, we decided not to consider the comparison of
bevacizumab with bevacizumab plus triamcinolone, which included two studies; in fact this comparison investigates the additional
effect of triamcinolone rather than the benefit of anti-VEGF drugs.
2. We have computed indirect comparison odds ratios (OR) of a gain of 3+ and 2+ lines for bevacizumab and pegaptanib versus
ranibizumab as the reference drug using random-effects model logistic regression.
Changes in update, 2014 compared to the protocol of the previous version
1. We have included five more studies but the conclusions did not change.
2. We no longer consider economic evidence since antiangiogenic therapy is widely approved and reimbursed.
3. We eliminated the table on retinal detachment as an ocular adverse event since it proved to be extremely rare in all studies.
4. Units of analysis issue: in the update of this review we no longer performed a sensitivity analysis regarding the primary outcome
to determine the impact of excluding studies with eyes, rather than participants, as the unit of analysis. In fact, a significant amount of
evidence from studies with individuals as unit of analysis was achieved for the main comparisons.
5. Single trial issue: in the 2012 and 2014 updates of the review we did not use the sensitivity analysis on the robustness of single
trial results recommended by Borm 2009, as was originally planned. Instead, we calculated the ’Optimal Information Size’ to rate the
quality of evidence regarding imprecision as recommended by the GRADE study group in Guyatt 2011.
Changes in update, 2016 compared to the protocol of the previous version
1. The objective was now to compare different anti-VEGF drugs and a new protocol was developed.
2. We used network meta-analysis technique to augment direct evidence with indirect evidence.
3. We restricted the number of outcomes to three efficacy outcomes, three safety outcomes and quality of life.
4. We have included six more studies and conclusions are changed.
5. The sensitivity analysis restricted to low risk of bias studies was added to the protocol.
6. We included a cross-over study and treated it as a parallel arm study in efficacy analyses.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Angiogenesis Inhibitors [∗therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [thera-
peutic use]; Aptamers, Nucleotide [therapeutic use]; Bevacizumab; Diabetic Retinopathy [∗complications]; Laser Coagulation [meth-
ods]; Macular Edema [∗drug therapy; surgery]; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial
Growth Factor [therapeutic use]; Recombinant Fusion Proteins [therapeutic use]; Triamcinolone [therapeutic use]; Vascular Endothelial
Growth Factor A [∗antagonists & inhibitors]
MeSH check words
Humans
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